Updated on 2022/07/01

写真a

 
OHARA Toshiaki
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Assistant Professor
Position
Assistant Professor
External link

Research Areas

  • Life Science / Clinical pharmacy  / Cancer, Microenvironment, Iron, Artificial Intelligence, Medical Device

Research History

  • 岡山大学大学院医歯薬総合研究科   助教

    2014.5

      More details

  • Okayama University   Graduate School of Medicine , Dentistry and Pharmaceutical Sciences

    2012.4 - 2014.5

      More details

  • Okayama University   Medical School

    2002.4 - 2002.7

      More details

Professional Memberships

  • THE JAPAN ESOPHAGEAL SOCIETY

      More details

  • The Japanese BioIron society

      More details

  • American Association for Cancer Research

      More details

  • American Society of Clinical Oncology

      More details

  • Japanese Society for Gastroenterological Carcinogenesis

      More details

  • The Japanese Society of Pathology

      More details

  • Japan Surgical Society

      More details

  • The Japanese Society of Gastroenterological Surgery

      More details

  • The Japanese Cancer Association

      More details

  • Japanese Association for Medical Artificial Intelligence

      More details

▼display all

 

Papers

  • Modulation of p53 expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer. Reviewed International journal

    Toshihiro Ogawa, Satoru Kikuchi, Motoyasu Tabuchi, Ema Mitsui, Yuta Une, Hiroshi Tazawa, Shinji Kuroda, Kazuhiro Noma, Toshiaki Ohara, Shunsuke Kagawa, Yasuo Urata, Toshiyoshi Fujiwara

    Molecular therapy oncolytics   25   249 - 261   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are associated with the establishment and progression of peritoneal metastasis. This study investigated the efficacy of replicative oncolytic adenovirus-mediated p53 gene therapy (OBP-702) against CAFs and peritoneal metastasis of gastric cancer (GC). Higher CAF expression in the primary tumor was associated with poor prognosis of GC, and higher CAF expression was also observed with peritoneal metastasis in immunohistochemical analysis of clinical samples. And, we found transcriptional alteration of p53 in CAFs relative to normal gastric fibroblasts (NGFs). CAFs increased the secretion of cancer-promoting cytokines, including interleukin-6, and gained resistance to chemotherapy relative to NGFs. OBP-702 showed cytotoxicity to both GC cells and CAFs but not to NGFs. Overexpression of wild-type p53 by OBP-702 infection caused apoptosis and autophagy of CAFs and decreased the secretion of cancer-promoting cytokines by CAFs. Combination therapy using intraperitoneal administration of OBP-702 and paclitaxel synergistically inhibited the tumor growth of peritoneal metastases and decreased CAFs in peritoneal metastases. OBP-702, a replicative oncolytic adenovirus-mediated p53 gene therapy, offers a promising biological therapeutic strategy for peritoneal metastasis, modulating CAFs in addition to achieving tumor lysis.

    DOI: 10.1016/j.omto.2022.04.009

    PubMed

    researchmap

  • Thioredoxin interacting protein protects mice from fasting induced liver steatosis by activating ER stress and its downstream signaling pathways. Reviewed International journal

    Hiroyuki Miyahara, Kosei Hasegawa, Masato Yashiro, Toshiaki Ohara, Masayoshi Fujisawa, Teizo Yoshimura, Akihiro Matsukawa, Hirokazu Tsukahara

    Scientific reports   12 ( 1 )   4819 - 4819   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Under normal conditions, fasting results in decreased protein disulfide isomerase (PDI) activity and accumulation of unfolded proteins, leading to the subsequent activation of the unfolded protein response (UPR)/autophagy signaling pathway to eliminate damaged mitochondria. Fasting also induces upregulation of thioredoxin-interacting protein (TXNIP) expression and mice deficient of this protein (TXNIP-KO mice) was shown to develop severe hypoglycemia, hyperlipidemia and liver steatosis (LS). In the present study, we aimed to determine the role of TXNIP in fasting-induced LS by using male TXNIP-KO mice that developed LS without severe hypoglycemia. In TXNIP-KO mice, fasting induced severe microvesicular LS. Examinations by transmission electron microscopy revealed mitochondria with smaller size and deformities and the presence of few autophagosomes. The expression of β-oxidation-associated genes remained at the same level and the level of LC3-II was low. PDI activity level stayed at the original level and the levels of p-IRE1 and X-box binding protein 1 spliced form (sXBP1) were lower. Interestingly, treatment of TXNIP-KO mice with bacitracin, a PDI inhibitor, restored the level of LC3-II after fasting. These results suggest that TXNIP regulates PDI activity and subsequent activation of the UPR/autophagy pathway and plays a protective role in fasting-induced LS.

    DOI: 10.1038/s41598-022-08791-z

    PubMed

    researchmap

  • Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms. Reviewed International journal

    Kazuyuki Matsumoto, Toshiaki Ohara, Masayoshi Fujisawa, Akinobu Takaki, Masahiro Takahara, Hironari Kato, Ryuichi Yoshida, Yuzo Umeda, Takahito Yagi, Akihiro Matsukawa, Hiroyuki Okada

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Anti-programmed death 1/programmed death ligand 1 (PD1/PD-L1) antibodies have been successfully used as treatment agents for several solid tumors; however, it is difficult to predict their effectiveness. We evaluated whether biopsy specimens could predict the positive status of PD-L1 in surgically resected tissue. METHODS: Among 91 patients who underwent tissue sampling with endoscopic or liver biopsy before surgery for biliary tract neoplasms in an academic center, 45 (49%) patients were selected for retrospective analysis because the quality and quantity of their biopsy specimens were adequate for histologic evaluation. We performed immunohistochemical staining to investigate the PD-L1 expression in both resected and biopsy specimens. The percentage of the positively stained cells was calculated for subsequent use in the correlation investigation. RESULTS: The biopsy methods were endoscopic retrograde cholangiopancreatography (ERCP) in 28 cases, percutaneous liver biopsy in 10 cases, and endoscopic ultrasound fine-needle aspiration in 7 cases. Among the 45 patients, when patients with > 10% positive tumor cells in surgically resected tissues were regarded as truly positive PD-L1, the positive and negative concordance rates between surgically resected tissues and biopsy samples were 56% (5/9) and 100% (36/36), respectively. With regard to the use of preoperative biopsy as a diagnostic tool, all (5/5) PD-L1-positive patients had a positive resected specimen. The accuracy of each biopsy method was as follows: ERCP, 89% (25/28); fine-needle aspiration, 86% (6/7); and liver biopsy, 100% (10/10). CONCLUSIONS: Biopsy samples could be a surrogate material for the assessment of the PD-L1 expression with substantial positive and high negative concordance rates.

    DOI: 10.1007/s11605-021-05197-6

    PubMed

    researchmap

  • Different pancreatic cancer microenvironments convert iPSCs into cancer stem cells exhibiting distinct plasticity with altered gene expression of metabolic pathways. Reviewed International journal

    Ghmkin Hassan, Toshiaki Ohara, Said M Afify, Kazuki Kumon, Maram H Zahra, Xiaoying Fu, Mohamad Al Kadi, Akimasa Seno, David S Salomon, Masaharu Seno

    Journal of experimental & clinical cancer research : CR   41 ( 1 )   29 - 29   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cancer stem cells (CSCs) are generated under irregular microenvironment in vivo, of which mimic is quite difficult due to the lack of enough information of the factors responsible for cancer initiation. Here, we demonstrated that mouse induced pluripotent cells (miPSCs) reprogrammed from normal embryonic fibroblasts were susceptible to the microenvironment affected by cancer cells to convert into CSCs in vivo. METHODS: Three different pancreatic cancer line cells, BxPC3, PANC1, and PK8 cells were mixed with miPSCs and subcutaneously injected into immunodeficient mice. Tumors were evaluated by histological analysis and cells derived from iPSCs were isolated and selected from tumors. The isolated cells were characterized for cancer stem cell characters in vitro and in vivo as well as their responses to anticancer drugs. The impact of co-injection of iPSCs with cancer cells on transcriptome and signaling pathways of iPSCs was investigated. RESULTS: The injection of miPSCs mixed with human pancreatic cancer cells into immunodeficient mice maintained the stemness of miPSCs and changed their phenotype. The miPSCs acquired CSC characteristics of tumorigenicity and self-renewal. The drug responses and the metastatic ability of CSCs converted from miPSCs varied depending on the microenvironment of cancer cells. Interestingly, transcriptome profiles of these cells indicated that the pathways related with aggressiveness and energy production were upregulated from the levels of miPSCs. CONCLUSIONS: Our result suggests that cancer-inducing microenvironment in vivo could rewire the cell signaling and metabolic pathways to convert normal stem cells into CSCs.

    DOI: 10.1186/s13046-021-02167-3

    PubMed

    researchmap

  • Spred2 controls the severity of Concanavalin A-induced liver damage by limiting interferon-gamma production by CD4+ and CD8+ T cells. Reviewed International journal

    Cuiming Sun, Masayoshi Fujisawa, Toshiaki Ohara, Qiuying Liu, Chen Cao, Xu Yang, Teizo Yoshimura, Steven L Kunkel, Akihiro Matsukawa

    Journal of advanced research   35   71 - 86   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Introduction: Mitogen-activated protein kinases (MAPKs) are involved in T cell-mediated liver damage. However, the inhibitory mechanism(s) that controls T cell-mediated liver damage remains unknown. Objectives: We investigated whether Spred2 (Sprouty-related, EVH1 domain-containing protein 2) that negatively regulates ERK-MAPK pathway has a biological impact on T cell-mediated liver damage by using a murine model. Methods: We induced hepatotoxicity in genetically engineered mice by intravenously injecting Concanavalin A (Con A) and analyzed the mechanisms using serum chemistry, histology, ELISA, qRT-PCR, Western blotting and flow cytometry. Results: Spred2-deficient mice (Spred2-/-) developed more sever liver damage than wild-type (WT) mice with increased interferon-γ (IFNγ) production. Hepatic ERK phosphorylation was enhanced in Spred2-/- mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the liver damage and reduced IFNγ production. Neutralization of IFNγ abolished the damage with decreased hepatic Stat1 activation in Spred2-/- mice. IFNγ was mainly produced from CD4+ and CD8+ T cells, and their depletion decreased liver damage and IFNγ production. Transplantation of CD4+ and/or CD8+ T cells from Spred2-/- mice into RAG1-/- mice deficient in both T and B cells caused more severe liver damage than those from WT mice. Hepatic expression of T cell attractants, CXCL9 and CXCL10, was augmented in Spred2-/- mice as compared to WT mice. Conversely, liver damage, IFNγ production and the recruitment of CD4+ and CD8+ T cells in livers after Con A challenge were lower in Spred2 transgenic mice, and Spred2-overexpressing CD4+ and CD8+ T cells produced lower levels of IFNγ than WT cells upon stimulation with Con A in vitro. Conclusion: We demonstrated, for the first time, that Spred2 functions as an endogenous regulator of T cell IFNγ production and Spred2-mediated inhibition of ERK-MAPK pathway may be an effective remedy for T cell-dependent liver damage.

    DOI: 10.1016/j.jare.2021.03.014

    PubMed

    researchmap

  • Dialysis management by artificial intelligence Invited

    Toshiaki Ohara

    The Japanese Journal of Clinical Dialysis   37 ( 17 )   1502 - 1506   2021.12

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publishing type:Part of collection (book)  

    researchmap

  • Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment Reviewed

    May Wathone Oo, Hotaka Kawai, Kiyofumi Takabatake, Shuta Tomida, Takanori Eguchi, Kisho Ono, Qiusheng Shan, Toshiaki Ohara, Saori Yoshida, Haruka Omori, Shintaro Sukegawa, Keisuke Nakano, Kuniaki Okamoto, Akira Sasaki, Hitoshi Nagatsuka

    JCI Insight   e148960   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:American Society for Clinical Investigation  

    DOI: 10.1172/jci.insight.148960

    PubMed

    researchmap

  • Protective effects of anti-HMGB1 monoclonal antibody on lung ischemia reperfusion injury in mice Reviewed

    Kentaro Nakata, Mikio Okazaki, Dai Shimizu, Ken Suzawa, Kazuhiko Shien, Kentaroh Miyoshi, Shinji Otani, Hiromasa Yamamoto, Seiichiro Sugimoto, Masaomi Yamane, Daiki Ousaka, Toshiaki Ohara, Akihiro Matsukawa, Masahiro Nishibori, Shinichi Toyooka

    Biochemical and Biophysical Research Communications   573   164 - 170   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.bbrc.2021.08.015

    PubMed

    researchmap

  • PolyI:C suppresses TGF-β1-induced Akt phosphorylation and reduces the motility of A549 lung carcinoma cells Reviewed

    Takahiro Yamaguchi, Teizo Yoshimura, Toshiaki Ohara, Masayoshi Fujisawa, Gao Tong, Akihiro Matsukawa

    Molecular Biology Reports   48 ( 9 )   6313 - 6321   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s11033-021-06625-1

    PubMed

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s11033-021-06625-1/fulltext.html

  • Immuno-hyperthermia effected by antibody-conjugated nanoparticles selectively targets and eradicates individual cancer cells Reviewed

    Tetsuya Kagawa, Yuki Matsumi, Hiromichi Aono, Toshiaki Ohara, Hiroshi Tazawa, Kunitoshi Shigeyasu, Shuya Yano, Sho Takeda, Yasuhiro Komatsu, Robert M. Hoffman, Toshiyoshi Fujiwara, Hiroyuki Kishimoto

    Cell Cycle   20 ( 13 )   1221 - 1230   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Informa UK Limited  

    DOI: 10.1080/15384101.2021.1915604

    PubMed

    researchmap

  • Hyperthermia generated by magnetic nanoparticles for effective treatment of disseminated peritoneal cancer in an orthotopic nude-mouse model Reviewed

    Yuki Matsumi, Tetsuya Kagawa, Shuya Yano, Hiroshi Tazawa, Kunitoshi Shigeyasu, Sho Takeda, Toshiaki Ohara, Hiromichi Aono, Robert M. Hoffman, Toshiyoshi Fujiwara, Hiroyuki Kishimoto

    Cell Cycle   20 ( 12 )   1122 - 1133   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Informa UK Limited  

    DOI: 10.1080/15384101.2021.1919441

    PubMed

    researchmap

  • Nanog is a promising chemo-resistant stemness marker and therapeutic target by iron chelators for esophageal cancer. Reviewed International journal

    Toru Narusaka, Toshiaki Ohara, Kazuhiro Noma, Noriyuki Nishiwaki, Yuki Katsura, Takuya Kato, Hiroaki Sato, Yasuko Tomono, Satoru Kikuchi, Hiroshi Tazawa, Yasuhiro Shirakawa, Akihiro Matsukawa, Toshiyoshi Fujiwara

    International journal of cancer   149 ( 2 )   347 - 357   2021.3

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Esophageal cancer is a disease showing poor prognosis. Although combination chemotherapy using cisplatin and 5-fluorouracil is standard for unresectable esophageal cancer, the response rate is 35%. Cancer stem cells (CSCs) and inflammation are reportedly responsible for the poor prognosis of esophageal cancer. However, comprehensive analyses have not been conducted and proposals for progress remain lacking. Iron is known to be a key factor in the stemness of CSCs. This study focused on the therapeutic potential of iron control using iron chelators for CSCs in esophageal cancer. Among 134 immunohistochemically analyzed cases, Nanog expression was high in 98 cases and low in 36 cases. High Nanog expression correlated with low overall and disease-free survivals. The iron chelators deferasirox (DFX) and SP10 suppressed the proliferation and expression of stemness markers in TE8 and OE33 cells. DFX and SP10 did not induce compensatory interleukin (IL)-6 secretion, although cisplatin did result in high induction. Moreover, BBI608 and SSZ, as other CSC-targeting drugs, could not suppress the expression of stemness markers. Together, Nanog expression appears related to poor prognosis in esophageal cancer patients, and inhibition of stemness and compensatory IL-6 secretion by iron chelators may offer a novel therapeutic strategy for esophageal cancer.

    DOI: 10.1002/ijc.33544

    PubMed

    researchmap

  • Fibroblast activation protein targeted near infrared photoimmunotherapy (NIR PIT) overcomes therapeutic resistance in human esophageal cancer. Reviewed International journal

    Ryoichi Katsube, Kazuhiro Noma, Toshiaki Ohara, Noriyuki Nishiwaki, Teruki Kobayashi, Satoshi Komoto, Hiroaki Sato, Hajime Kashima, Takuya Kato, Satoru Kikuchi, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    Scientific reports   11 ( 1 )   1693 - 1693   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) have an important role in the tumor microenvironment. CAFs have the multifunctionality which strongly support cancer progression and the acquisition of therapeutic resistance by cancer cells. Near-infrared photoimmunotherapy (NIR-PIT) is a novel cancer treatment that uses a highly selective monoclonal antibody (mAb)-photosensitizer conjugate. We developed fibroblast activation protein (FAP)-targeted NIR-PIT, in which IR700 was conjugated to a FAP-specific antibody to target CAFs (CAFs-targeted NIR-PIT: CAFs-PIT). Thus, we hypothesized that the control of CAFs could overcome the resistance to conventional chemotherapy in esophageal cancer (EC). In this study, we evaluated whether EC cell acquisition of stronger malignant characteristics and refractoriness to chemoradiotherapy are mediated by CAFs. Next, we assessed whether the resistance could be rescued by eliminating CAF stimulation by CAFs-PIT in vitro and in vivo. Cancer cells acquired chemoradiotherapy resistance via CAF stimulation in vitro and 5-fluorouracil (FU) resistance in CAF-coinoculated tumor models in vivo. CAF stimulation promoted the migration/invasion of cancer cells and a stem-like phenotype in vitro, which were rescued by elimination of CAF stimulation. CAFs-PIT had a highly selective effect on CAFs in vitro. Finally, CAF elimination by CAFs-PIT in vivo demonstrated that the combination of 5-FU and NIR-PIT succeeded in producing 70.9% tumor reduction, while 5-FU alone achieved only 13.3% reduction, suggesting the recovery of 5-FU sensitivity in CAF-rich tumors. In conclusion, CAFs-PIT could overcome therapeutic resistance via CAF elimination. The combined use of novel targeted CAFs-PIT with conventional anticancer treatments can be expected to provide a more effective and sensible treatment strategy.

    DOI: 10.1038/s41598-021-81465-4

    Scopus

    PubMed

    researchmap

  • Artificial intelligence supported anemia control system (AISACS) to prevent anemia in maintenance hemodialysis patients. Reviewed International journal

    Toshiaki Ohara, Hiroshi Ikeda, Yoshiki Sugitani, Hiroshi Suito, Viet Quang Huy Huynh, Masaru Kinomura, Soichiro Haraguchi, Kazufumi Sakurama

    International journal of medical sciences   18 ( 8 )   1831 - 1839   2021

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Anemia, for which erythropoiesis-stimulating agents (ESAs) and iron supplements (ISs) are used as preventive measures, presents important difficulties for hemodialysis patients. Nevertheless, the number of physicians able to manage such medications appropriately is not keeping pace with the rapid increase of hemodialysis patients. Moreover, the high cost of ESAs imposes heavy burdens on medical insurance systems. An artificial-intelligence-supported anemia control system (AISACS) trained using administration direction data from experienced physicians has been developed by the authors. For the system, appropriate data selection and rectification techniques play important roles. Decision making related to ESAs poses a multi-class classification problem for which a two-step classification technique is introduced. Several validations have demonstrated that AISACS exhibits high performance with correct classification rates of 72%-87% and clinically appropriate classification rates of 92%-98%.

    DOI: 10.7150/ijms.53298

    PubMed

    researchmap

  • New Vascular-Access Intervention Assistance Plate Provides Good Operability and Safety by Preventing Accidental Falls: First Experience of 1,872 Cases. Reviewed International journal

    Toshiaki Ohara, Kazufumi Sakurama, Satoshi Hiramatsu

    Acta medica Okayama   74 ( 6 )   505 - 511   2020.12

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Vascular-access interventions are necessary for the continuation of hemodialysis, and they are performed under X-ray guidance. During interventions, patients' accidental falls from the bed are a serious problem, and spe-cialized fixation systems for hemodialysis patients to prevent their falls from the bed have been lacking. We developed a new fixation plate made of polypropylene homopolymer and tested its ability to prevent such falls retrospectively. This plate, which we named the 'vascular-access intervention assistance plate,' offers functional features such as the concurrent fixation of the body and either arm and an arm space with serrations for fixing a forearm strap. We performed computer simulations to examine the strength of the plate, and we evaluated the efficacy of fall prevention by reviewing patients' medical records. The results demonstrated that the functional design of the plate provides good operability via accurate concurrent fixations of the body and arm. The com-puter simulation analysis results indicated the plate's sufficient strength. The medical records analysis revealed three accidental falls before the plate's introduction (401 patients, 1,437 interventions), and none after plate introduction (683 patients, 1,872 interventions). Accidental falls were significantly prevented by use of the plate (p < 0.05). The dementia rate and type of procedure were not significantly different between the patients who fell and those who did not. This vascular-access intervention assisted plate provides good operability and safety by preventing accidental falls among hemodialysis patients.

    DOI: 10.18926/AMO/60880

    PubMed

    researchmap

  • Decreased miR-200b-3p in cancer cells leads to angiogenesis in HCC by enhancing endothelial ERG expression. Reviewed International journal

    Aye Moh-Moh-Aung, Masayoshi Fujisawa, Sachio Ito, Hiroshi Katayama, Toshiaki Ohara, Yoko Ota, Teizo Yoshimura, Akihiro Matsukawa

    Scientific reports   10 ( 1 )   10418 - 10418   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Transcription factor ERG (erythroblast transformation-specific (ETS)-related gene) is essential in endothelial differentiation and angiogenesis, in which microRNA (miR)-200b-3p targeting site is expected by miRNA target prediction database. miR-200b is known decreased in hepatocellular carcinoma (HCC), however, the functional relation between ERG and miR-200b-3p, originating from pre-miR-200b, in HCC angiogenesis remains unclear. We investigated whether hepatocyte-derived miR-200b-3p governs angiogenesis in HCC by targeting endothelial ERG. Levels of miR-200b-3p in HCC tissues were significantly lower than those in adjacent non-HCC tissues. Poorly differentiated HCC cell line expressed lower level of miR-200b-3p compared to well-differentiated HCC cell lines. The numbers of ERG-positive endothelial cells were higher in HCC tissues than in adjacent non-HCC tissues. There was a negative correlation between the number of ERG-positive cells and miR-200b-3p expression in HCC tissues. Culture supernatants of HCC cell lines with miR-200b-3p-overexpression reduced cell migration, proliferation and tube forming capacity in endothelial cells relative to the control, while those with miR-200b-3p-inhibition augmented the responses. Exosomes isolated from HCC culture supernatants with miR-200b-3p overexpression suppressed endothelial ERG expression. These results suggest that exosomal miR-200b-3p from hepatocytes suppresses endothelial ERG expression, and decreased miR-200b-3p in cancer cells promotes angiogenesis in HCC tissues by enhancing endothelial ERG expression.

    DOI: 10.1038/s41598-020-67425-4

    PubMed

    researchmap

  • Spred2欠損はコンカナバリンA誘発性肝傷害をCXCL9/10を介したT細胞の誘引により悪化させる(Spred2 deficiency exacerbated Concanavalin A-induced liver injury by attracting T cells via CXCL9/10)

    孫 翠明, 吉村 禎造, 藤澤 真義, 大原 利章, 松川 昭博

    日本病理学会会誌   109 ( 1 )   346 - 347   2020.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • Spred2は腫瘍幹細胞性の維持に関与しHepG2 HCCの悪性度を低下させる(Spred2 involved in tumor stemness maintenance down-regulates malignant potential of HepG2 HCC)

    高 桐, 吉村 禎造, 大原 利章, 藤澤 真義, 松川 昭博

    日本病理学会会誌   109 ( 1 )   348 - 348   2020.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 癌転移は,エキソソームの異なる細胞亜群からの放出によって調節される(Cancer metastasis is regulated via exosomes released from distinct cell subpopulation)

    李 春寧, 吉村 禎造, 田 ミョウ, 大原 利章, 藤澤 真義, 松川 昭博

    日本病理学会会誌   109 ( 1 )   358 - 358   2020.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 食道癌の幹細胞性を制御する鉄キレート療法の開発(Stemness control by iron chelator is a novel therapeutic strategy for esophageal cancer)

    大原 利章, 鳴坂 徹, Xing Boyi, Wang Yuze, 松川 昭博

    日本病理学会会誌   109 ( 1 )   338 - 339   2020.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • A Promising New Anti-Cancer Strategy: Iron Chelators Targeting CSCs. Reviewed

    Yuehua Chen, Toshiaki Ohara, Boyi Xing, Jiping Qi, Kazuhiro Noma, Akihiro Matsukawa

    Acta medica Okayama   74 ( 1 )   1 - 6   2020.2

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Iron is a trace but vital element in the human body and is necessary for a multitude of crucial processes in life. However, iron overload is known to induce carcinogenesis via oxidative stress. Cancer cells require large amounts of iron for their rapid division and cell growth. Iron was recently found to play a role in cancer stem cells (CSCs); it maintains stemness during development. Iron also plays an important role in stemness by moderating reactive oxygen species. Thus, iron metabolism in CSCs is a promising therapeutic target. In this review, we summarize the roles of iron in cancer cells and CSCs. We also summarize anti-cancer therapeutic studies with iron chelators and describe our expectation of a new therapeutic strategy for CSCs on the basis of our findings.

    DOI: 10.18926/AMO/57946

    PubMed

    researchmap

  • Prolonged warm ischemia exacerbated acute rejection after lung transplantation from donation after cardiac death in a mouse. Reviewed International journal

    Yutaka Hirano, Seiichiro Sugimoto, Sumiharu Yamamoto, Masanori Okada, Shinji Otani, Toshiaki Ohara, Masaomi Yamane, Akihiro Matsukawa, Takahiro Oto, Shinichi Toyooka

    General thoracic and cardiovascular surgery   68 ( 1 )   57 - 62   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: In lung transplantation (LTx) from donation after cardiac death (DCD), the donor lungs are inevitably exposed to warm ischemic time (WIT) between the cardiac arrest and the initiation of cold preservation. We conducted this study to examine the effect of prolonged WIT on lung allograft rejection in a murine model of LTx from DCD. METHODS: Allogeneic BALB/c → B6 LTx from DCD was performed with a WIT of 15 min (WIT15 group, n = 5) or 60 min (WIT60 group, n = 5). Recipients were immunosuppressed by perioperative costimulatory blockade. The lung allografts were analyzed by histology and flow cytometry on day 7 after the LTx. RESULTS: Histologically, the rejection grade in the WIT60 group was significantly higher than that in the WIT15 group (3.4 ± 0.4 vs. 2.2 ± 0.2, P = 0.0278). Moreover, the intragraft CD8+ to CD4+ T cell ratio in the WIT60 group was significantly higher than that in the WIT15 group (2.3 ± 0.12 vs. 1.2 ± 0.11, P < 0.0001). CONCLUSIONS: Prolonged WIT could exacerbate the severity of lung allograft rejection after LTx from DCD. Minimization of the WIT could improve the outcomes after LTx from DCD.

    DOI: 10.1007/s11748-019-01181-9

    PubMed

    researchmap

  • Negative impact of recipient SPRED2 deficiency on transplanted lung in a mouse model. Reviewed International journal

    Kohei Hashimoto, Masaomi Yamane, Seiichiro Sugimoto, Yutaka Hirano, Takeshi Kurosaki, Shinji Otani, Kentaroh Miyoshi, Toshiaki Ohara, Mikio Okazaki, Teizo Yoshimura, Takahiro Oto, Akihiro Matsukawa, Shinichi Toyooka

    Transplant immunology   57   101242 - 101242   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Ischemia-reperfusion injury (IRI) after lung transplantation mainly contributes to the development of primary graft dysfunction. The Sprouty-related EVH1-domain-containing (SPRED) protein family inhibits the mitogen activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway. Our study was aimed at examining the role of SPRED2 in IRI in mice that received orthotopic lung transplantation. Syngeneic mouse lung transplantation was performed in wild-type C57BL/6 J (WT) mice and Spred2 knockout (Spred2-/-) mice on the C57BL/6 J background from the WT donor. Four hours after reperfusion, blood gas analysis was performed, and lung grafts were sacrificed and analyzed. By using arterial oxygen tension measurements and histological evaluation using Lung Injury Score, we revealed more severe IRI in the grafts transplanted to Spred2-/- recipients, which manifested as exacerbated airway epithelial cell damage, interstitial edema with hemorrhage and neutrophil infiltration. Intragraft ERK1/2 activation and expression levels of proinflammatory cytokines and chemokines in Spred2-/- recipients were higher than those in WT recipients. SPRED2 plays an important role in protecting the lungs from IRI in lung transplantation recipients. We suggest that focused treatments suppressing the activity of the MAPK/ERK pathway in transplantation recipients could be the potential therapeutic option for the prevention of lung IRI.

    DOI: 10.1016/j.trim.2019.101242

    PubMed

    researchmap

  • Visualization of epithelial-mesenchymal transition in an inflammatory microenvironment-colorectal cancer network. Reviewed International journal

    Takeshi Ieda, Hiroshi Tazawa, Hiroki Okabayashi, Shuya Yano, Kunitoshi Shigeyasu, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Masahiko Nishizaki, Shunsuke Kagawa, Yasuhiro Shirakawa, Takashi Saitou, Takeshi Imamura, Toshiyoshi Fujiwara

    Scientific reports   9 ( 1 )   16378 - 16378   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Epithelial-mesenchymal transition (EMT) is a biological process by which epithelial cells acquire mesenchymal characteristics. In malignant tumors, EMT is crucial for acquisition of a mesenchymal phenotype with invasive and metastatic properties, leading to tumor progression. An inflammatory microenvironment is thought to be responsible for the development and progression of colorectal cancer (CRC); however, the precise role of inflammatory microenvironments in EMT-related CRC progression remains unclear. Here, we show the spatiotemporal visualization of CRC cells undergoing EMT using a fluorescence-guided EMT imaging system in which the mesenchymal vimentin promoter drives red fluorescent protein (RFP) expression. An inflammatory microenvironment including TNF-α, IL-1β, and cytokine-secreting inflammatory macrophages induced RFP expression in association with the EMT phenotype in CRC cells. In vivo experiments further demonstrated the distribution of RFP-positive CRC cells in rectal and metastatic tumors. Our data suggest that the EMT imaging system described here is a powerful tool for monitoring EMT in inflammatory microenvironment-CRC networks.

    DOI: 10.1038/s41598-019-52816-z

    PubMed

    researchmap

  • The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Reviewed International journal

    Kazuyuki Matsumoto, Toshiaki Ohara, Masayoshi Fujisawa, Akinobu Takaki, Masahiro Takahara, Noriyuki Tanaka, Hironari Kato, Shigeru Horiguchi, Ryuichi Yoshida, Yuzo Umeda, Soichiro Fushimi, Takahito Yagi, Akihiro Matsukawa, Hiroyuki Okada

    Journal of gastroenterology   54 ( 11 )   1019 - 1028   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Recently, therapeutic antibodies against programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) have shown promising clinical results for several solid tumors, including pancreatic cancer. In this study, we evaluated the relationship between the PD-L1 expression of surgical resected and fine-needle aspiration (FNA) specimens for patients with pancreatic cancer. METHODS: Of 121 patients who underwent endoscopic ultrasound-guided (EUS)-FNA before surgery for pancreatic cancer in an academic center, the 94 (78%) with adequate FNA specimens for a histological evaluation were retrospectively analyzed. All the patients had undergone upfront surgery without any chemotherapy or radiotherapy. We performed immunohistochemistry (IHC) staining to investigate the PD-L1 expression in both resected and FNA specimens. The positive-stained cells were counted, and their percentage was used for the investigation. RESULTS: Of the 94 patients, 16 (17%) and 11 (10%) were defined as positive on resected cancer specimens using cutoff points of 5% and 10% positively stained cancer cell counts, respectively. The concordance rates for the positive frequency of PD-L1 expression between resected and FNA specimens were 44% (7/16) and 55% (6/11) when the positivity was set to ≥ 5% and ≥ 10%, respectively. The concordance rates for the negative frequency of PD-L1 expression between two specimens were 97% (76/78) and 99% (82/83) when the positivity was set to ≥ 5% and ≥ 10%, respectively. CONCLUSIONS: Approximately, half of the patients with PD-L1 expression positive and almost all the patients with PD-L1 expression negative could be diagnosed on FNA specimens.

    DOI: 10.1007/s00535-019-01586-6

    PubMed

    researchmap

  • Cancer stem cell induction from mouse embryonic stem cells. Reviewed International journal

    Akimasa Seno, Chikae Murakami, Bishoy El-Aarag, Yoshiaki Iwasaki, Toshiaki Ohara, Masaharu Seno

    Oncology letters   18 ( 3 )   2756 - 2762   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Although cancers are often removed by surgery and treated by chemotherapy and/or radiation therapies, they often reoccur following treatment due to the presence of resistant residual cells such as cancer stem cells (CSCs). CSCs are characterized by their self-renewal, pluripotency, and tumorigenicity properties, and are promising therapeutic targets for the complete therapy of cancers; however, the number of CSCs in cancer tissue is typically too small to investigate fully. We have previously reported that CSCs could be established from induced pluripotent stem cells (iPSCs) using a conditioned medium during cancer cell culture. In the present study, mouse embryonic stem cells (mESCs) were observed to be converted to CSCs (mES-CSCs). This demonstrated that CSC induction does not exclusively occur following gene editing in somatic cells, and that conditioned medium from cancer cells may contain factors that can induce CSCs. Therefore, not only iPSCs but also mESCs, were demonstrated to be able to produce CSCs as one of the potentials of pluripotency of stem cells, suggesting that the conversion to CSCs is not specific to iPSCs. The resultant mES-CSCs would be also useful to generate tissue specific cancers and these naturally occurring cancers can contribute to drug screenings, but also undergo further investigation in order to reveal cancer mechanisms.

    DOI: 10.3892/ol.2019.10614

    PubMed

    researchmap

  • Cancer-associated fibroblasts (CAFs) promote the lymph node metastasis of esophageal squamous cell carcinoma. Reviewed International journal

    Hajime Kashima, Kazuhiro Noma, Toshiaki Ohara, Takuya Kato, Yuki Katsura, Satoshi Komoto, Hiroaki Sato, Ryoichi Katsube, Takayuki Ninomiya, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    International journal of cancer   144 ( 4 )   828 - 840   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Lymph node metastasis is a pathognomonic feature of spreading tumors, and overcoming metastasis is a challenge in attaining more favorable clinical outcomes. Esophageal cancer is an aggressive tumor for which lymph node metastasis is a strong poor prognostic factor, and the tumor microenvironment (TME), and cancer-associated fibroblasts (CAFs) in particular, has been implicated in esophageal cancer progression. CAFs play a central role in the TME and have been reported to provide suitable conditions for the progression of esophageal cancer, similar to their role in other malignancies. However, little is known concerning the relevance of CAFs to the lymph node metastasis of esophageal cancer. Here, we used clinical samples of esophageal cancer to reveal that CAFs promote lymph node metastasis and subsequently verified the intercellular relationships in vitro and in vivo using an orthotopic metastatic mouse model. In the analysis of clinical samples, FAP+ CAFs were strongly associated with lymph node metastasis rather than with other prognostic factors. Furthermore, CAFs affected the ability of esophageal cancer cells to acquire metastatic phenotypes in vitro; this finding was confirmed by data from an in vivo orthotopic metastatic mouse model showing that the number of lymph node metastases increased upon injection of cocultured cancer cells and CAFs. In summary, we verified in vitro and in vivo that the accumulation of CAFs enhances the lymph node metastasis of ESCC. Our data suggest that CAF targeted therapy can reduce lymph node metastasis and improve the prognosis of patients with esophageal cancer in the future.

    DOI: 10.1002/ijc.31953

    PubMed

    researchmap

  • A Novel Combination Cancer Therapy with Iron Chelator Targeting Cancer Stem Cells via Suppressing Stemness. Reviewed International journal

    Yuki Katsura, Toshiaki Ohara, Kazuhiro Noma, Takayuki Ninomiya, Hajime Kashima, Takuya Kato, Hiroaki Sato, Satoshi Komoto, Toru Narusaka, Yasuko Tomono, Boyi Xing, Yuehua Chen, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Tomonari Kasai, Masaharu Seno, Akihiro Matsukawa, Toshiyoshi Fujiwara

    Cancers   11 ( 2 )   177   2019.2

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Excess iron causes cancer and is thought to be related to carcinogenesis and cancer progression including stemness, but the details remain unclear. Here, we hypothesized that stemness in cancer is related to iron metabolism and that regulating iron metabolism in cancer stem cells (CSCs) may be a novel therapy. In this study, we used murine induced pluripotent stem cells that expressed specific stem cell genes such as Nanog, Oct3/4, Sox2, Klf4, and c-Myc, and two human cancer cell lines with similar stem cell gene expression. Deferasirox, an orally available iron chelator, suppressed expression of stemness markers and spherogenesis of cells with high stemness status in vitro. Combination therapy had a marked antitumor effect compared with deferasirox or cisplatin alone. Iron metabolism appears important for maintenance of stemness in CSCs. An iron chelator combined with chemotherapy may be a novel approach via suppressing stemness for CSC targeted therapy.

    DOI: 10.3390/cancers11020177

    PubMed

    researchmap

  • Spred2 Regulates High Fat Diet-Induced Adipose Tissue Inflammation, and Metabolic Abnormalities in Mice. Reviewed International journal

    Takahiro Ohkura, Teizo Yoshimura, Masayoshi Fujisawa, Toshiaki Ohara, Rie Marutani, Kaya Usami, Akihiro Matsukawa

    Frontiers in immunology   10   17 - 17   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Chronic low-grade inflammation in visceral adipose tissues triggers the development of obesity-related insulin resistance, leading to the metabolic syndrome, a serious health condition with higher risk of cardiovascular disease, diabetes, and stroke. In the present study, we investigated whether Sprouty-related EVH1-domain-containing protein 2 (Spred2), a negative regulator of the Ras/Raf/ERK/MAPK pathway, plays a role in the development of high fat diet (HFD)-induced obesity, adipose tissue inflammation, metabolic abnormalities, and insulin resistance. Spred2 knockout (KO) mice, fed with HFD, exhibited an augmented body weight gain, which was associated with enhanced adipocyte hypertrophy in mesenteric white adipose tissue (mWAT) and deteriorated dyslipidemia, compared with wild-type (WT) controls. The number of infiltrating macrophages with a M1 phenotype, and the crown-like structures, composed of macrophages surrounding dead or dying adipocytes, were more abundant in Spred2 KO-mWAT compared to in WT-mWAT. Exacerbated adipose tissue inflammation in Spred2 KO mice led to aggravated insulin resistance and fatty liver disease. To analyze the mechanism(s) that caused adipose tissue inflammation, cytokine response in mWAT was investigated. Stromal vascular fraction that contained macrophages from Spred2 KO-mWAT showed elevated levels of tumor necrosis factor α (TNFα) and monocyte chemoattractant protein-1 (MCP-1/CCL2) compared with those from WT-mWAT. Upon stimulation with palmitate acid (PA), bone marrow-derived macrophages (BMDMs) derived from Spred2 KO mice secreted higher levels of TNFα and MCP-1 than those from WT mice with enhanced ERK activation. U0126, a MEK inhibitor, reduced the PA-induced cytokine response. Taken together, these results suggested that Spred2, in macrophages, negatively regulates high fat diet-induced obesity, adipose tissue inflammation, metabolic abnormalities, and insulin resistance by inhibiting the ERK/MAPK pathway. Thus, Spred2 represents a potential therapeutic tool for the prevention of insulin resistance and resultant metabolic syndrome.

    DOI: 10.3389/fimmu.2019.00017

    PubMed

    researchmap

  • Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma. Reviewed International journal

    Shinichiro Watanabe, Kazuhiro Noma, Toshiaki Ohara, Hajime Kashima, Hiroaki Sato, Takuya Kato, Shinichi Urano, Ryoichi Katsube, Yuuri Hashimoto, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    Cancer biology & therapy   20 ( 9 )   1234 - 1248   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cancer-associated fibroblasts (CAFs) are strongly implicated in tumor progression, including in the processes of tumorigenesis, invasion, and metastasis. The targeting of CAFs using various therapeutic approaches is a novel treatment strategy; however, the efficacy of such therapies remains limited. Recently, near-infrared photoimmunotherapy (NIR-PIT), which is a novel targeted therapy employing a cell-specific mAb conjugated to a photosensitizer, has been introduced as a new type of phototherapy. In this study, we have developed a novel NIR-PIT technique to target CAFs, by focusing on fibroblast activation protein (FAP), and we evaluate the treatment efficacy in vitro and in vivo. Esophageal carcinoma cells exhibited enhanced activation of fibroblasts, with FAP over-expressed in the cytoplasm and on the cell surface. FAP-IR700-mediated PIT showed induced rapid cell death specifically for those cells in vitro and in vivo, without adverse effects. This novel therapy for CAFs, designed as local control phototherapy, was safe and showed a promising inhibitory effect on FAP+ CAFs. PIT targeting CAFs via the specific marker FAP may be a therapeutic option for CAFs in the tumor microenvironment in the future.

    DOI: 10.1080/15384047.2019.1617566

    PubMed

    researchmap

  • Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment. Reviewed International journal

    Takuya Kato, Kazuhiro Noma, Toshiaki Ohara, Hajime Kashima, Yuki Katsura, Hiroaki Sato, Satoshi Komoto, Ryoichi Katsube, Takayuki Ninomiya, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Clinical cancer research   24 ( 19 )   4820 - 4833   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Purpose: Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) play a central role in tumor progression. We investigated whether CAFs can regulate tumor-infiltrating lymphocytes (TILs) and their role in tumor immunosuppression.Experimental Design: A total of 140 cases of esophageal cancer were analyzed for CAFs and CD8+ or forkhead box protein 3 (FoxP3+) TILs by IHC. We analyzed cytokines using murine or human fibroblasts and cancer cells. Murine-derived fibroblasts and cancer cells were also inoculated into BALB/c or BALB/c-nu/nu mice and the tumors treated with recombinant IL6 or anti-IL6 antibody.Results: CD8+ TILs and CAFs were negatively correlated in intratumoral tissues (P < 0.001), whereas FoxP3+ TILs were positively correlated (P < 0.001) in esophageal cancers. Cocultured Colon26 cancer cells and fibroblasts resulted in accelerated tumor growth in BALB/c mice, along with decreased CD8+ and increased FoxP3+ TILs, compared with cancer cells alone. In vitro, IL6 was highly secreted in both murine and human cancer cell/fibroblast cocultures. IL6 significantly increased Colon26 tumor growth in immune-competent BALB/c (P < 0.001) with fewer CD8+ TILs than untreated tumors (P < 0.001), whereas no difference in BALB/c-nu/nu mice. In contrast, FoxP3+ TILs increased in IL6-treated tumors (P < 0.001). IL6 antibody blockade of tumors cocultured with fibroblasts resulted not only in regression of tumor growth but also in the accumulation of CD8+ TILs in intratumoral tissues.Conclusions: CAFs regulate immunosuppressive TIL populations in the TME via IL6. IL6 blockade, or targeting CAFs, may improve preexisting tumor immunity and enhance the efficacy of conventional immunotherapies. Clin Cancer Res; 24(19); 4820-33. ©2018 AACR.

    DOI: 10.1158/1078-0432.CCR-18-0205

    PubMed

    researchmap

  • New insertion support device assisted the accurate placement of tunneled cuffed catheter: First experience of 10 cases. Reviewed International journal

    Toshiaki Ohara, Kazufumi Sakurama, Satoshi Hiramatsu, Toshimasa Karai, Toshiaki Sato, Yuta Nishina

    The journal of vascular access   19 ( 5 )   501 - 505   2018.9

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: The tunneled cuffed catheter is used in hemodialysis patients for whom an arteriovenous fistula or arteriovenous graft is not suitable or for bridging usage of them. Accurate placement of a tunneled cuffed catheter is necessary for safe hemodialysis, but placement is sometimes difficult because of individual body differences. We developed a new device to support accurate placement of the tunneled cuffed catheter. In this study, we report our first clinical experience of the device. METHODS: We made the device by expanded polytetrafluoroethylene with some special processes. The processes enable it to maintain plasticity and temporary shape in the autoclaved condition. The device is laid on the surface of the patient's body to mark the root of the catheter with a felt-tipped marker before catheterization. That enables us to know the accurate catheter root and tunneled cuffed catheter exit site on the body surface. Ten patients underwent tunneled cuffed catheter insertion according to the marking. CASE DESCRIPTION: The mean age was 71.3 ± 12.8 years. The tunneled cuffed catheter was safely placed according to the marking in all patients, and all catheter tips were placed in the right atrium. The mean verification tip location difference before and after catheterization was 0.70 ± 0.48 cm. This result indicated that the device could assist in inserting a catheter accurately within an error of 1.18 cm. The tunneled cuffed catheters were patent in all the cases, without replacement and complications until the end of bridging use or during the observation period. CONCLUSION: Our newly developed insertion support device enhances safety and prevents catheter waste during replacement.

    DOI: 10.1177/1129729818771884

    PubMed

    researchmap

  • The Elucidation of Tumor Immunosuppression Affected by Cancer-Associated Fibroblasts Reviewed

    加藤卓也, 加藤卓也, 野間和広, 桂佑貴, 佐藤浩明, 河本慧, 二宮卓之, 大原利章, 田澤大, 香川俊輔, 白川靖博, 藤原俊義

    癌と化学療法   45 ( 9 )   1279 - 1281   2018.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Development of immunotherapy, especially checkpoint inhibitors, dramatically improved the prognosis of some malignancies. However, problems on the occurrence of severe adverse effects and limited responses to these checkpoint inhibitors remain. Recently, tumor infiltrating lymphocytes(TILs)are the predictive markers of immunotherapies based on clinical evidence. The proportion of cytotoxic T cells in the tumor has been reported to affect the antitumor effect. TILs in the tumor are thought to be controlled by the interaction between cancer and tumor microenvironment. As a cause of tumor immunosuppression, cancer-associated fibroblasts(CAFs)play the main role in the tumor microenvironment. We considered the strong involvement of tumor microenvironment, particularly the role of CAFs, and reported the interaction between CAFs and proliferation, invasion, angiogenesis, and resistance in the conventional therapy. The correlation between CAFs and tumor immunity and the immunosuppression promoted by CAFs were also evaluated. Their effects will be reported in our future studies.

    PubMed

    J-GLOBAL

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J00296&link_issn=&doc_id=20180920320008&doc_link_id=%2Fab8gtkrc%2F2018%2F004509%2F010%2F1279-1281%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2018%2F004509%2F010%2F1279-1281%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • A novel, nontoxic iron chelator, super-polyphenol, effectively induces apoptosis in human cancer cell lines. Reviewed International journal

    Toshiaki Ohara, Yasuko Tomono, Xing Boyi, Sun Yingfu, Kazuhiro Omori, Akihiro Matsukawa

    Oncotarget   9 ( 67 )   32751 - 32760   2018.8

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Iron chelation therapy is the main treatment for iron overload disease. Iron chelators were recently reported to be useful for cancer therapy; however, they cause side effects that make them difficult to use in some cancer patients. Thus, a novel oral iron chelator, super-polyphenol (SP), was developed for cancer therapy to decrease the side effects. SP is either water soluble or insoluble, and has different isoforms according to the number of side chains. Of these isoforms, water-soluble SP6 and SP10 appear to be the best candidates, as they have the strongest chelating abilities. In this study, we focused on the usefulness and safety of SP6 and SP10 as anti-cancer drugs, and examined their anti-cancer effects and toxicity. The results showed that SP6 and SP10 inhibited cancer cell proliferation by inducing apoptosis in HCT116, HSC-2, A549, and MCF-7 cancer cells. SP10 also inhibited tumor growth in an HCT116 xenograft model. SP6 and SP10 had no acute toxicities. An intravenous injection test revealed that SP6 and SP10 had better safety profiles than the iron chelator deferoxamine. In conclusion, SP is a novel oral iron chelator with anti-cancer effects and few adverse side effects. This is the first report of SP in the literature.

    DOI: 10.18632/oncotarget.25973

    PubMed

    researchmap

  • Spred2 Deficiency Exacerbates D-Galactosamine/Lipopolysaccharide -induced Acute Liver Injury in Mice via Increased Production of TNFα. Reviewed International journal

    Xu Yang, Masayoshi Fujisawa, Teizo Yoshimura, Toshiaki Ohara, Miwa Sato, Megumi Mino, Thar Htet San, Tong Gao, Steven L Kunkel, Akihiro Matsukawa

    Scientific reports   8 ( 1 )   188 - 188   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Acute liver injury (ALI) is characterized by hepatocyte damage and inflammation. In the present study, we examined whether the absence of Sprouty-related EVH1-domain-containing protein 2 (Spred2), a negative regulator of the Ras/Raf/ERK/MAPK pathway, influences ALI induced by D-galactosamine (D-GalN) and lipopolysaccharide (LPS). Compared to wild-type mice, Spred2-/- mice developed exacerbated liver injury represented by enhanced hepatocyte damage and inflammation. Enhanced ERK activation was observed in Spred2-/--livers, and the MEK/ERK inhibitor U0126 ameliorated ALI. Hepatic tumour necrosis factor α (TNFα) and interleukin (IL)-1β levels were increased in Spred-2-/--livers, and the neutralization of TNFα dramatically ameliorated ALI, which was associated with decreased levels of endogenous TNFα and IL-1β. When mice were challenged with D-GalN and TNFα, much severer ALI was observed in Spred2-/- mice with significant increases in endogenous TNFα and IL-1β in the livers. Immunohistochemically, Kupffer cells were found to produce TNFα, and isolated Kupffer cells from Spred2-/- mice produced significantly higher levels of TNFα than those from wild-type mice after LPS stimulation, which was significantly decreased by U0126. These results suggest that Spred2 negatively regulates D-GalN/LPS-induced ALI under the control of TNFα in Kupffer cells. Spred2 may present a therapeutic target for the treatment of ALI.

    DOI: 10.1038/s41598-017-18380-0

    PubMed

    researchmap

  • Iron depletion is a novel therapeutic strategy to target cancer stem cells. Reviewed International journal

    Takayuki Ninomiya, Toshiaki Ohara, Kazuhiro Noma, Yuki Katsura, Ryoichi Katsube, Hajime Kashima, Takuya Kato, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Ling Chen, Tomonari Kasai, Masaharu Seno, Akihiro Matsukawa, Toshiyoshi Fujiwara

    Oncotarget   8 ( 58 )   98405 - 98416   2017.11

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Adequate iron levels are essential for human health. However, iron overload can act as catalyst for the formation of free radicals, which may cause cancer. Cancer stem cells (CSCs), which maintain the hallmark stem cell characteristics of self-renewal and differentiation capacity, have been proposed as a driving force of tumorigenesis and metastases. In the present study, we investigated the role of iron in the proliferation and stemness of CSCs, using the miPS-LLCcm cell model. Although the anti-cancer agents fluorouracil and cisplatin suppressed the proliferation of miPS-LLCcm cells, these drugs did not alter the expression of stemness markers, including Nanog, SOX2, c-Myc, Oct3/4 and Klf4. In contrast, iron depletion by the iron chelators deferasirox and deferoxamine suppressed the proliferation of miPS-LLCcm cells and the expression of stemness markers. In an allograft model, deferasirox inhibited the growth of miPS-LLCcm implants, which was associated with decreased expression of Nanog and Sox2. Altogether, iron appears to be crucial for the proliferation and maintenance of stemness of CSCs, and iron depletion may be a novel therapeutic strategy to target CSCs.

    DOI: 10.18632/oncotarget.21846

    PubMed

    researchmap

  • Molecular Subtypes of Breast Cancers from Myanmar Women: A Study of 91 Cases at Two Pathology Centers Reviewed International journal

    Thar Htet San, Masayoshi Fujisawa, Soichiro Fushimi, Lamin Soe, Ngu Wah Min, Teizo Yoshimura, Toshiaki Ohara, Myint Myint Yee, Shinsuke Oda, Akihiro Matsukawa

    Asian Pacific journal of cancer prevention : APJCP   18 ( 6 )   1617 - 1621   2017.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: Breast cancer is the most common cancer in Myanmar women. Revealing the hormonal receptor
    status, human epidermal growth factor receptor 2 (HER2) and Ki-67 expression is useful for estimating patient
    prognosis as well as determination of treatment strategy. However, immunohistochemical features and classification of
    molecular subtypes in breast cancers from Myanmar remain unknown. Methods: The clinicopathological features of
    91 breast cancers from Myanmar women were examined. Immunohistochemistry was performed on tissue specimens
    with antibodies to estrogen receptor (ER), progesterone receptor (PgR), HER2, Ki-67, cytokeratin (CK)5/6 and CK14.
    Immunohistochemistry-based molecular subtyping was conducted. Results: Breast cancers in Myanmar women were
    relatively large, high grade with frequent metastatic lymph nodes. Of the 91 patients, tumors with ER positive, PgR
    positive, and HER2 positive were 57.1%, 37.4%, and 28.6%, respectively. The most prevalent subtype was luminal B
    (HER2-) (39.6%), followed by HER2 (22.0%), triple negative (TN)-basal-like (12.1%), luminal A (11.0%), TN-null
    (8.8%) and luminal B (HER2+) (6.6%). The mean Ki-67 expression of 91 cases was 33.9% (33.9% ± 19.2%) and the
    median was 28% (range; 4%-90%). The mean Ki-67 expression of luminal A, luminal B, HER2 and TN-basal-like/
    null was 7%, 30%, 40%, and 57%/43%, respectively. A higher Ki-67 expression significantly correlated with a higher
    grade, larger size and higher stage of malignancy. Conclusions: We, for the first time, investigated the histopathological
    features of breast cancers from Myanmar women. Myanmar breast cancers appeared to be aggressive in nature, as
    evidenced by high frequency of poor-prognosis subtypes with high level of Ki-67 expression.

    DOI: 10.22034/APJCP.2017.18.6.1617

    PubMed

    researchmap

  • Low prevalence of human mammary tumor virus (HMTV) in breast cancer patients from Myanmar. Reviewed International journal

    Thar Htet San, Masayoshi Fujisawa, Soichiro Fushimi, Teizo Yoshimura, Toshiaki Ohara, Lamin Soe, Ngu Wah Min, Ohnmar Kyaw, Xu Yang, Akihiro Matsukawa

    Infectious agents and cancer   12   20 - 20   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BIOMED CENTRAL LTD  

    BACKGROUND: Human mammary tumor virus (HMTV) is 90-95% homologous to mouse mammary tumor virus (MMTV), one of the causal agents of murine mammary tumors. HMTV (MMTV-like) sequences were reported to be present in human breast cancers from several populations with a prevalence range of 0-78%; however, the prevalence of HMTV in breast cancers from Myanmar remains unknown. METHODS: Fifty-eight breast cancer samples from Myanmar women were examined in this study. DNA was isolated from formalin-fixed paraffin-embedded specimens, and HMTV envelope sequences were detected by semi-nested PCR. The sequence of the PCR products was also confirmed. RESULTS: Only 1.7% (1 of 58) of the breast cancers were positive for HMTV, and the sequence of PCR products was 98.9% identical to the reference HMTV sequence (GenBank accession No. AF243039). The tumor with HMTV was grade III invasive ductal carcinoma, 7.0 cm in size with lymph node metastasis (T3, N1, M0). CONCLUSIONS: We, for the first time, investigated the presence of HMTV in Myanmar breast cancer patients. In accordance with other Asian studies, the prevalence of HMTV in Myanmar was quite low, supporting the hypothesis that Asian breast cancers have different etiologies than in Western countries, where HMTV is more prevalent.

    DOI: 10.1186/s13027-017-0130-0

    Web of Science

    PubMed

    researchmap

  • Iron depletion-induced downregulation of N-cadherin expression inhibits invasive malignant phenotypes in human esophageal cancer. Reviewed International journal

    Seishi Nishitani, Kazuhiro Noma, Toshiaki Ohara, Yasuko Tomono, Shinichiro Watanabe, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    International journal of oncology   49 ( 4 )   1351 - 9   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPANDIDOS PUBL LTD  

    Esophageal carcinomas often have a poor prognosis due to early lymph node metastasis. Epithelial-mesenchymal transition (EMT) is strongly associated with the acquisition of cancer metastasis and invasion. However, there is no established treatment to eliminate the EMT of cancer cells. Iron is an essential element for both normal and cancer cells in humans. Recently, iron depletion has been discovered to suppress tumor growth. Therefore, we hypothesized that decreased iron conditions would regulate EMT phenotypes, as well as suppressing tumor growth. The human TE esophageal cancer cell lines and OE19 were used in our study. Decreased iron conditions were made using an iron-depletion diet in mice and the iron chelator deferasirox for cell studies. Migration and invasion abilities of cells were measured using migration, invasion, and sphere-formation assays. Esophageal subcutaneous tumor growth was suppressed in decreased iron conditions. In vitro study showed that decreased iron conditions inhibited esophageal cancer cell proliferation as well as migration and invasion abilities, with downregulation of N-cadherin expression. Also, migration and invasion abilities were suppressed by inhibiting expression of N-cadherin. In conclusion, decreased iron conditions revealed a profound anticancer effect by the suppression of tumor growth and the inhibition of migration and invasion abilities via N-cadherin.

    DOI: 10.3892/ijo.2016.3640

    Web of Science

    PubMed

    researchmap

  • Iron depletion enhances the effect of sorafenib in hepatocarcinoma. Reviewed International journal

    Shinichi Urano, Toshiaki Ohara, Kazuhiro Noma, Ryoichi Katsube, Takayuki Ninomiya, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Kazuhiro Nouso, Akihiro Matsukawa, Kazuhide Yamamoto, Toshiyoshi Fujiwara

    Cancer biology & therapy   17 ( 6 )   648 - 56   2016.6

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:TAYLOR & FRANCIS INC  

    ABSTACT Human hepatocellular carcinoma (HCC) is known to have a poor prognosis. Sorafenib, a molecular targeted drug, is most commonly used for HCC treatment. However, its effect on HCC is limited in clinical use and therefore new strategies regarding sorafenib treatment are required. Iron overload is known to be associated with progression of chronic hepatitis and increased risk of HCC. We previously reported that iron depletion inhibited cancer cell proliferation and conversely induced angiogenesis. Indeed iron depletion therapy including iron chelator needs to be combined with anti-angiogenic drug for its anti-cancer effect. Since sorafenib has an anti-angiogenic effect by its inhibitory targeting VEGFR, we hypothesized that sorafenib could complement the anti-cancer effect of iron depletion. We retrospectively analyzed the relationship between the efficacy of sorafenib and serum iron-related markers in clinical HCC patients. In clinical cases, overall survival was prolonged in total iron binding capacity (TIBC) high- and ferritin low-patients. This result suggested that the low iron-pooled patients, who could have a potential of more angiogenic properties in/around HCC tumors, could be adequate for sorafenib treatment. We determined the effect of sorafenib (Nexavar®) and/or deferasirox (EXJADE®) on cancer cell viability, and on cell signaling of human hepatocarcinoma HepG2 and HLE cells. Both iron depletion by deferasirox and sorafenib revealed insufficient cytotoxic effect by each monotherapy, however, on the basis of increased angiogenesis by iron depletion, the addition of deferasirox enhanced anti-proliferative effect of sorafenib. Deferasirox was confirmed to increase vascular endothelial growth factor (VEGF) secretion into cellular supernatants by ELISA analysis. In in vivo study sorafenib combined with deferasirox also enhanced sorafenib-induced apoptosis. These results suggested that sorafenib combined with deferasirox could be a novel combination chemotherapy for HCC.

    DOI: 10.1080/15384047.2016.1177677

    Web of Science

    PubMed

    researchmap

  • Recurrence after Endoscopic Curative Resection of Mucosal Gastric Cancer Associated with an Adjacent Neoplastic Precursor Lesion. Reviewed International journal

    Satoru Kikuchi, Shunsuke Kagawa, Toshiaki Ohara, Tetsushi Kubota, Kazuya Kuwada, Tetsuya Kagawa, Shinji Kuroda, Yasuhiro Shirakawa, Masahiko Nishizaki, Toshiyoshi Fujiwara

    Acta medica Okayama   70 ( 3 )   213 - 216   2016.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:OKAYAMA UNIV MED SCHOOL  

    A 69-year-old man underwent endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) at the lesser curvature in the angle of stomach. Histological examination revealed tub1, pM, ly0, v0, pLM(-), pVM(-), and the resection was considered curative. The scar after ESD was followed by esophagogastroduodenoscopy (EGD) and biopsy. Twenty months later, EGD showed an ulcerative lesion in the vicinity of the ESD scar, and histological examination of the biopsy specimen showed adenocarcinoma. A distal gastrectomy with lymph node dissection was then performed. Postoperative pathology showed tub1, pM, pN0, ly0, v0, and Stage 1A. Skip lesions were seen in the specimen resected by ESD, and the histological review confirmed so-called "dysplasia-like atypia" (DLA) between the lesions. It has been reported recently that in DLA, the dysplasia-like change involves only the bases of the pits, without upper pit or surface epithelium involvement, and it is said that the rate of DLA is higher in gastric cancer patients. We speculated that a precancerous lesion close to the resected cancer developed into a local recurrence.

    DOI: 10.18926/AMO/54421

    Web of Science

    PubMed

    researchmap

  • Therapeutic Potential of Targeting Cancer-Associated Fibroblasts in Esophageal Cancer Reviewed

    野間和広, 賀島肇, 二宮卓之, 勝部亮一, 渡邉伸一郎, 大原利章, 田澤大, 香川俊輔, 白川靖博, 藤原俊義

    癌と化学療法   42 ( 10 )   1228 - 1230   2015.10

     More details

    Language:Japanese  

    Advances in molecular and cellular biochemistry, such as the development of targeted cancer therapy, have dramatically improved the prognosis of cancer patients. Emerging data have suggested that bevacizumab treatment may act by controlling the cancer microenvironment. Many reports have examined the interaction of cancer cells with the tumor microenvironment, and cancer-associated fibroblasts (CAFs) are thought to play a central role in this process. We speculated that the cancer microenvironment and in particular, CAFs, strongly influence the development of esophageal cancer. We have analyzed the signaling pathways of molecular targets. However, inhibition of a single signaling pathway is insufficient to treat cancer effectively. Photoimmunotherapy is a molecular-targeted specific cancer therapy using near-infrared radiation, which was introduced by Mitsunaga et al. in 2011. We are using its specific method of killing cells to target CAFs. We will report the results of its effect on cancer cells in the future.

    PubMed

    J-GLOBAL

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J00296&link_issn=&doc_id=20151027380020&doc_link_id=%2Fab8gtkrc%2F2015%2F004210%2F021%2F1228-1230%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2015%2F004210%2F021%2F1228-1230%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Prone-position thoracoscopic resection of posterior mediastinal lymph node metastasis from rectal cancer Reviewed International journal

    Yasuhiro Shirakawa, Kazuhiro Noma, Takeshi Koujima, Naoaki Maeda, Shunsuke Tanabe, Toshiaki Ohara, Toshiyoshi Fujiwara

    WORLD JOURNAL OF SURGICAL ONCOLOGY   13   45 - 45   2015.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BIOMED CENTRAL LTD  

    Mediastinal lymph node metastasis from colorectal cancer is rare, and barely any reports have described resection of this pathology. We report herein a successful thoracoscopic resection of mediastinal lymph node metastasis in a prone position. A 65-year-old man presented with posterior mediastinal lymph node metastasis after resection of the primary rectal cancer and metachronous hepatic metastasis. Metastatic lymph nodes were resected completely using thoracoscopic surgery in the prone position, which provided advantages of minimal invasiveness, good surgical field, and reduced ergonomic burden on the surgeon. Thoracoscopic resection in the prone position was thought to have the potential to become the standard procedure of posterior mediastinal tumors.

    DOI: 10.1186/s12957-015-0466-0

    Web of Science

    PubMed

    researchmap

  • Operative technique of antethoracic esophageal reconstruction with pedicled jejunal flap Reviewed International journal

    Yasuhiro Shirakawa, Kazuhiro Noma, Takeshi Koujima, Naoaki Maeda, Shunsuke Tanabe, Toshiaki Ohara, Kazufumi Sakurama, Toshiyoshi Fujiwara

    Esophagus   12 ( 1 )   57 - 64   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    Esophageal reconstruction using intestine is often performed for esophageal cancer patients in cases where the stomach cannot be used. We have previously performed reconstruction using ileocolon with supercharge and drainage as our first choice in those cases. However, a less invasive, simpler, and safer reconstructive technique using jejunum without vascular anastomosis has recently become popular at our facility. This study describes the technique of esophageal reconstruction with jejunum, compares the surgical outcomes to those of standard reconstruction using ileocolon, and discusses the clinical significance of this new concept.Subjects comprised 53 patients (52 males, 1 female) who underwent esophageal reconstruction using jejunum between January 2008 and July 2013. Patient characteristics, technical details, and outcomes were compared with those of 51 subjects who had undergone esophageal reconstruction using ileocolon. When making the pedicled jejunal flap, the first jejunal vascular arcade was preserved, which in most cases allowed it to be pulled up to the cervical region by processing and transection up to the second jejunal vascular branch.The vascular anastomosis techniques were used in 80.4 % (41/51) of esophageal reconstructions using colon, compared with only 24.5 % (13/53) of reconstructions using jejunum. No difference in the frequency of postoperative adverse effects was seen between groups, but the frequency of diarrhea was significantly lower with reconstruction using jejunum.Esophageal reconstruction using jejunum with the blood vessel processing technique results in both simpler and safer pulling up. Thus the need to perform supercharge and superdrainage is reduced.

    DOI: 10.1007/s10388-014-0455-3

    Web of Science

    researchmap

  • Prone-Position Thoracoscopic Ligation of the Thoracic Duct for Chyle Leak Following Radical Neck Dissection in a Patient with a Right Aortic Arch. Reviewed International journal

    Yasuhiro Shirakawa, Kazuhiro Noma, Toshiaki Ohara, Hajime Kashima, Naoaki Maeda, Shunsuke Tanabe, Shunsuke Kagawa, Toshiyoshi Fujiwara

    Acta medica Okayama   69 ( 3 )   173 - 6   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A chyle leak can occur as a complication after neck or chest surgery. Such a leak prolongs the hospital stay and is sometimes life-threatening. The treatment options are conservative management, interventional radiologic embolization, and surgery. Thoracoscopic ligation of the thoracic duct has emerged as a promising and definitive treatment. The case of a 65-year-old Japanese male patient with a rare congenital right aortic arch (typeⅢB1 of Edward's classification) and a severe chyle leak that occurred after a total pharyngolaryngo-esophagectomy (TPLE) is described. The chyle leak was successfully managed by thoracoscopic ligation of the thoracic duct via a left-side approach with the patient in the prone position.

    DOI: 10.18926/AMO/53524

    PubMed

    researchmap

  • 腫瘍血管新生抑制療法に対する鉄欠乏の新規の相乗効果(A novel synergistic effect of iron depletion on antiangiogenic cancer therapy)

    大原 利章

    岡山医学会雑誌   126 ( 2 )   182 - 183   2014.8

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Part of collection (book)   Publisher:岡山医学会  

    researchmap

  • 手術手技 食道癌手術における用手補助的腹腔鏡下胃管作成の工夫

    白川 靖博, 前田 直見, 田辺 俊介, 大原 利章, 野間 和広, 藤原 俊義

    手術   68 ( 7 )   951 - 954   2014.6

     More details

    Language:Japanese   Publishing type:Part of collection (book)   Publisher:金原出版(株)  

    researchmap

  • 術前DCF療法が著効した食道原発内分泌細胞癌の1切除例

    前田 直見, 白川 靖博, 國府島 健, 大原 利章, 田邊 俊輔, 野間 和広, 櫻間 教文, 藤原 俊義

    岡山医学会雑誌   126 ( 1 )   39 - 43   2014.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:岡山医学会  

    66歳男。心窩部痛を主訴とした。上部消化管造影検査所見で胸部中部食道(Mt)左-前壁に70mm大の周堤隆起明瞭な2型病変が認められた。上部消化管内視鏡検査所見で切歯より25cm〜33cmの食道左-前壁に半周性の2型病変を認められた。同部位の生検を施行し、内分泌細胞癌(小細胞型)と診断された。造影CT検査所見およびPET/CT検査より、胸部食道内分泌細胞癌(小細胞型)cT3cN1cM0:cStage IIIと診断し、術前補助化学療法2コースの後、手術の方針とした。化学療法は、docetaxel、cisplatin、5-fluorouracilの三剤を併用した。手術は腹臥位胸腔鏡下食道亜全摘、用手補助的腹腔鏡下胃管作製、3領域リンパ節郭清、胸骨後経路再建、頸部吻合を施行した。組織所見にて潰瘍部では加療による影響と考えられる線維化とヘモジデリンの沈着を認め、Grade 3と判定した。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J00175&link_issn=&doc_id=20140415220008&doc_link_id=10.4044%2Fjoma.126.39&url=https%3A%2F%2Fdoi.org%2F10.4044%2Fjoma.126.39&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 食道原発悪性黒色腫の1切除例

    前田 直見, 白川 靖博, 國府島 健, 大原 利章, 田邊 俊輔, 野間 和広, 櫻間 教文, 藤原 俊義

    岡山医学会雑誌   126 ( 1 )   45 - 48   2014.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:岡山医学会  

    61歳男。食物つかえ感を主訴とした。上部消化管造影検査所見にて胸部中部下部食道(MtLt)前から右壁に、60mm大の周堤隆起明瞭な2型病変が認められた。上部消化管内視鏡検査所見で切歯より30cm〜36cmの食道前〜右壁に半周性の2型病変が認められた。口側には1型隆起部分も認めた。2型部分は黒紫色であったが、1型部分はピンクから白色調で一部血腫を形成していた。以上より、胸部食道原発悪性黒色腫cT3cN0 cM0:cStage IIと診断した。手術は腹臥位胸腔鏡下食道亜全摘、用手補助的腹腔鏡下胃管作製、2領域リンパ節郭清(胸部、腹部)、胸骨後経路再建、頸部吻合を施行した。組織所見よりpT2N0M0 pStage IIと診断し、術後補助化学療法として高用量DTIC療法を6コース行った。術後1年5ヵ月経過しているが無再発生存中である。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J00175&link_issn=&doc_id=20140415220009&doc_link_id=10.4044%2Fjoma.126.45&url=https%3A%2F%2Fdoi.org%2F10.4044%2Fjoma.126.45&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • Assistant-based standardization of prone position thoracoscopic esophagectomy. Reviewed

    Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Ryoichi Katsube, Shunsuke Tanabe, Toshiaki Ohara, Kazufumi Sakurama, Toshiyoshi Fujiwara

    Acta medica Okayama   68 ( 2 )   111 - 7   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:OKAYAMA UNIV MED SCHOOL  

    Thoracoscopic esophagectomy in the prone position (TEPP) might enable solo-surgery in cases requiring resection of the esophagus and the surrounding lymph nodes due to the associated advantages of good exposure of the surgical field and ergonomic considerations for the surgeon. However, no one approach can be for all patients requiring extensive lymphadenectomy. We recently developed an assistant-based procedure to standardize exposure of the surgical field. Patients were divided into 1 of 2 groups:a pre-standardization group (n=37) and a post-standardization group (n=28). The thoracoscopic operative time was significantly shorter (p=0.0037) in the post-standardization group (n=28; 267 ± 31 min) than in the pre-standardization group (n=37;301 ± 53 min). Further, learning curve analysis using the moving average method showed stabilization of the thoracoscopic operative time after the standardization. No significant differences were found in the number of mediastinal lymph nodes dissected or intraoperative blood loss between the 2 groups. There were also no significant differences in the complication rate. Assistant-based surgery and standardization of the procedure resulted in a well-exposed and safe surgical field. TEPP decreased the operative time, even in patients requiring extensive lymphadenectomy.

    DOI: 10.18926/AMO/52407

    Web of Science

    PubMed

    researchmap

  • 次世代ライフイノベーションへの挑戦 除鉄を応用した新規がん治療法の開発

    大原利章

    化学工業   65 ( 7 )   2014

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Part of collection (book)  

    J-GLOBAL

    researchmap

  • The 2013 Incentive Award of the Okayama Medical Association in Cancer Research (2013 Hayashibara Prize and Yamada Prize) Invited

    Ohara Toshiaki

    Okayama Igakkai Zasshi (Journal of Okayama Medical Association)   126 ( 2 )   93 - 94   2014

     More details

    Language:Japanese   Publisher:Okayama Medical Association  

    DOI: 10.4044/joma.126.93

    CiNii Article

    researchmap

  • Advanced hepatocellular carcinoma with lymph node metastases showing epithelial to mesenchymal transition effectively treated with systemic chemotherapy: Report of a case. Reviewed International journal

    Hiroshi Sadamori, Takahito Yagi, Kunitoshi Shigeyasu, Yuzo Umeda, Masahiro Sugihara, Naosuke Yokomichi, Toshiaki Ohara, Naoshi Nishida, Takeshi Nagasaka, Ajay Goel, Toshiyoshi Fujiwara

    Hepatology research : the official journal of the Japan Society of Hepatology   43 ( 12 )   1368 - 73   2013.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We present a case in which combination chemotherapy was used to successfully treat hepatocellular carcinoma (HCC) with rapid progression of lymph node (LN) metastases after liver resection. In addition, epithelial to mesenchymal transition (EMT) markers were examined immunohistochemically. A 43-year-old man who had been diagnosed with HCC showed an enlarged LN near the hepatic artery proper. After extended left lobectomy with lymphadenectomy in the hepatoduodenal ligament, he experienced rapid progression of metastases to the para-aortic and mediastinal LN. Partial remission was achieved after induction and maintenance of combination chemotherapy using etoposide, carboplatin, epirubicin and 5-fluorouracil. As a consequence of this treatment, the patient survived 10 months. Immunohistochemical studies demonstrated that HCC cells in the metastatic LN showed low expression of E-cadherin and high expression of N-cadherin and vimentin, indicating EMT. Combination chemotherapy may prove effective for patients with HCC accompanied by LN metastases that show features of EMT.

    DOI: 10.1111/hepr.12080

    PubMed

    researchmap

  • Direct observation diverticulectomy for Zenker’s diverticulum carcinoma

    Toshiaki Ohara, Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Ryouichi Katsube, Shunsuke Tanabe, Toshiyoshi Fujiwara

    Esophagus   10 ( 4 )   235 - 238   2013.12

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s10388-013-0376-6

    researchmap

    Other Link: http://link.springer.com/article/10.1007/s10388-013-0376-6/fulltext.html

  • Current Status of Neoadjuvant Chemotherapy for Advanced Esophageal Cancer Reviewed

    田辺俊介, 白川靖博, 前田直見, 勝部亮一, 大原利章, 櫻間教文, 野間和広, 藤原俊義

    癌と化学療法   40 ( 12 )   1612 - 1614   2013.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Since reported in the JCOG9907 trial, neoadjuvant chemotherapy prior to surgery has become the standard treatment for advanced (Stage II/III) esophageal cancers. However, more powerful neoadjuvant chemotherapy is required for the treatment of locally advanced cases or cases involving multiple lymph node metastases. At our institute, DCF therapy (docetaxel, cisplatin, and 5-fluorouracil) is administered selectively for the treatment of patients with far-advanced esophageal cancer. We treated 53 thoracic esophageal cancer patients who underwent surgery following neoadjuvant chemotherapy between January 2010 and December 2012. FP therapy (cisplatin and 5-fluorouracil) was administered to 43 patients, and DCF therapy to 7 patients who had far-advanced esophageal cancer. All patients treated with DCF therapy experienced grade 3 and 4 adverse events. With the exception of 1 patient, all patients who received DCF therapy could undergo curative surgery. DCF therapy could become an effective preoperative chemotherapy.

    PubMed

    J-GLOBAL

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2013&ichushi_jid=J00296&link_issn=&doc_id=20131212480013&doc_link_id=%2Fab8gtkrc%2F2013%2F004012%2F013%2F1612-1614%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2013%2F004012%2F013%2F1612-1614%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • A novel synergistic effect of iron depletion on antiangiogenic cancer therapy. Reviewed International journal

    Toshiaki Ohara, Kazuhiro Noma, Shinichi Urano, Shinichiro Watanabe, Seishi Nishitani, Yasuko Tomono, Fumiaki Kimura, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    International journal of cancer   132 ( 11 )   2705 - 13   2013.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Iron is an essential element for both normal and cancer cells in humans. Treatment to reduce iron levels has been shown to suppress tumor growth in vivo. However, iron depletion monotherapy by iron decreased treatment has not been thought to be superior to ordinary chemotherapy and is not part of the standard therapeutic strategy for the treatment of cancer. Iron depletion is also known to reduce serum hemoglobin and oxygen supply to the tissue, which indicates that iron depletion may induce angiogenesis. Therefore, we hypothesized that iron depletion with antiangiogenic therapy can have a novel therapeutic effect in the treatment of cancer. Human nonsmall cell carcinoma cell lines A549 and H1299 were used in our study. An iron-deficient diet and an iron chelator were used to simulate an iron-depleted condition. The antitumor effects of iron depletion and antiangiogenic therapy were determined on A549 xenograft mice. The iron-depleted condition produced by an iron-deficient diet suppressed tumor growth. Tumor tissue from the iron-deficient diet group showed that cancer cell proliferation was suppressed and hypoxia was induced. Microvessel density of this group was increased which suggested that the iron-depleted condition induced angiogenesis. Bevacizumab administration had a synergetic effect on inhibiting the tumor growth on Day 39. An iron-depleted condition inhibited cancer cell proliferation and reciprocally induced angiogenesis. Bevacizumab synergistically enhanced the iron-depleted antitumor effect. Treatment to deplete iron levels combined with anti-angiogenic therapy could induce a novel therapeutic effect in the treatment of cancer.

    DOI: 10.1002/ijc.27943

    Web of Science

    PubMed

    researchmap

  • Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. Reviewed International journal

    Toshio Nishikawa, Munenori Takaoka, Toshiaki Ohara, Yasuko Tomono, Huifang Hao, Xiaohong Bao, Takuya Fukazawa, Zhigang Wang, Kazufumi Sakurama, Yasuhiro Fujiwara, Takayuki Motoki, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Toshiyoshi Fujiwara, Yoshio Naomoto

    Cancer biology & therapy   14 ( 3 )   230 - 6   2013.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I α (HIF-1α), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 ± 722.0; temsirolimus, 599.2 ± 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024). These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome.

    DOI: 10.4161/cbt.23294

    PubMed

    researchmap

  • Successfully treated pneumatosis cystoides intestinalis with pneumoperitoneum onset in a patient administered α-glucosidase inhibitor. Reviewed

    Shunsuke Tanabe, Yasuhiro Shirakawa, Yuko Takehara, Naoaki Maeda, Ryoichi Katsube, Toshiaki Ohara, Kazufumi Sakurama, Kazuhiro Noma, Toshiyoshi Fujiwara

    Acta medica Okayama   67 ( 2 )   123 - 8   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:OKAYAMA UNIV MED SCHOOL  

    An 80-year-old woman, who had been administered α-glucosidase inhibitor for diabetes, was brought to the hospital with the sensation of abdominal fullness and pain. Abdominal computed tomography indicated pneumatosis cystoides intestinalis (PCI) in the small intestinal wall, with free air within the abdomen. A blood examination showed no increases in white blood cells or C-reactive protein level. The patient's condition improved with conservative therapy. PCI with pneumoperitoneum induced by α-glucosidase inhibitor is rare, with only 27 cases (excluding the present case) reported in Japan to date. In PCI with pneumoperitoneum, differentiation from gastrointestinal perforation is important and following the clinical symptoms over time is vital.

    DOI: 10.18926/AMO/49672

    Web of Science

    PubMed

    researchmap

  • 頭頸部表在癌のESDにおける工夫

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    耳鼻咽喉科展望   55 ( 4 )   262 - 263   2012.8

     More details

    Language:Japanese   Publishing type:Part of collection (book)   Publisher:耳鼻咽喉科展望会  

    researchmap

  • 小細胞癌成分を含む食道癌肉腫の1切除例

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 野間 和広, 櫻間 教文, 柳井 広之, 山辻 知樹, 猶本 良夫, 藤原 俊義

    岡山医学会雑誌   124 ( 2 )   145 - 148   2012.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:岡山医学会  

    73歳男。58歳時、早期胃癌にて幽門側胃切除・Billroth I法再建を施行した。食餌摂取時のつかえ感を自覚し、上部消化管内視鏡検査で胸部食道に隆起性病変を認めた。上部消化管内視鏡検査では、上切歯列より33cmに後壁主体の5cm大の1型病変を認めた。腫瘍は食道内腔をほぼ占拠していた。原発巣の生検で、小細胞癌成分を伴った食道癌肉腫と診断した。肺小細胞癌に準じて、CDDP+VP-16を施行し、原発巣は著明に縮小した。化学療法を繰り返す治療のみでは、副作用にて治療の継続が困難になると判断し、初回治療開始後から約2ヵ月後に手術を施行した。切除術、再建術と二期的に分割して手術を施行後、術後療養ののち、退院した。さらなる術後助化学療法として術前と同様の化学療法を1コース施行したが、肺炎を発症し、1コースのみにて補助療法終了し、その後外来通院中である。現在のところ術後3年が経過しているが無再発生存中である。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J00175&link_issn=&doc_id=20120802150010&doc_link_id=10.4044%2Fjoma.124.145&url=https%3A%2F%2Fdoi.org%2F10.4044%2Fjoma.124.145&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer. Reviewed International journal

    Hui-fang Hao, Munenori Takaoka, Xiao-hong Bao, Zhi-gang Wang, Yasuko Tomono, Kazufumi Sakurama, Toshiaki Ohara, Takuya Fukazawa, Tomoki Yamatsuji, Toshiyoshi Fujiwara, Yoshio Naomoto

    Biochemical and biophysical research communications   423 ( 4 )   744 - 9   2012.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Peritoneal dissemination is one of the most terrible types of colorectal cancer progression. Focal adhesion kinase (FAK) plays a crucial role in the biological processes of cancer, such as cell attachment, migration, proliferation and survival, all of which are essential for the progression of peritoneal dissemination. Since we and other groups have reported that the inhibition of FAK activity exhibited a potent anticancer effect in several cancer models, we hypothesized that TAE226, a novel ATP-competitive tyrosine kinase inhibitor designed to target FAK, can prevent the occurrence and progression of peritoneal dissemination. In vitro, TAE226 greatly inhibited the proliferation and migration of HCT116 colon cancer cells, while their adhesion on the matrix surface was minimally inhibited when FAK activity and expression was suppressed by TAE226 and siRNA. In vivo, when HCT116 cells were intraperitoneally inoculated in mice, the cells could attach to the peritoneum and begin to grow within 24 h regardless of the pretreatment of cells with TAE226 or FAK-siRNA, suggesting that FAK is not essential, at least for the initial integrin-matrix contact. Interestingly, the treatment of mice before and after inoculation significantly suppressed cell attachment to the peritoneum. Furthermore, oral administration of TAE226 greatly reduced the size of disseminated tumors and prolonged survival in tumor-bearing mice. Taken together, a possible strategy for inhibiting peritoneal dissemination by targeting FAK with TAE226 appears to be applicable through anti-proliferative and anti-invasion/anti-migration mechanisms.

    DOI: 10.1016/j.bbrc.2012.06.030

    Web of Science

    PubMed

    researchmap

  • A Case of Adenosquamous Carcinoma of Lower Extrahepatic Bile Duct Reviewed

    青木秀樹, 金澤卓, 藤原裕子, 森廣俊昭, 竹原清人, 清田正之, 大原利章, 荒田尚, 中川仁志, 田中屋宏爾, 竹内仁司

    癌と化学療法   39 ( 1 )   131 - 133   2012.1

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    We report a 83-year-old female with bile duct cancer who underwent subtotal stomach preserving pancreatoduodenectomy. Pathologically, her tumor was diagnosed as adenosquamous carcinoma of the lower extrahepatic bile duct with final stage IVb[pT3pN3M(-)].The prognosis of patients with adenosquamous carcinoma of the bile duct is very poor, and the reason is thought to be its tendency to invade the pancreas.Although she was an aged patient, we performed adjuvant chemotherapy using gemcitabine.No recurrence has occurred until this day, 30 months after the operation.This is thought to be an effect of the adjuvant chemotherapy, considering its poor prognosis.

    PubMed

    J-GLOBAL

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2012&ichushi_jid=J00296&link_issn=&doc_id=20120125290028&doc_link_id=%2Fab8gtkrc%2F2012%2F003901%2F029%2F0131-0133%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fab8gtkrc%2F2012%2F003901%2F029%2F0131-0133%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 冠動脈バイパス術後横隔膜ヘルニアの1例 Reviewed

    大原 利章, 竹原 清人, 中西 将元, 田中屋 宏爾, 青木 秀樹, 竹内 仁司

    日本臨床外科学会雑誌   72 ( 9 )   2257 - 2260   2011.9

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本臨床外科学会  

    症例は81歳,男性.2日前から続く発熱,心窩部痛を主訴に近医より紹介受診となった.既往歴として8ヵ月前にオフポンプ冠動脈バイパス手術(3枝)を受けていた.胸部レントゲン検査では心陰影に重なり,ニボー像が認められた.CT検査では胸骨右背側の横隔膜を穿破して心嚢内に腸管の脱出が認められた.横隔膜ヘルニアと考えられ,手術目的に入院となった.開腹すると肝前面に横行結腸を認め,大網と合わせて横隔膜内への陥入が認められた.横行結腸を用手的に引き戻し,大網は心嚢内で心臓と癒着していたため切離し,半吸収性メッシュにてヘルニア門を修復した.半吸収性メッシュは臓器癒着を予防し,収縮率が低いとされ,腹壁瘢痕ヘルニアでは有用性が報告されている.横隔膜ヘルニアの修復に半吸収性メッシュを用いた本邦報告例はない.冠動脈バイパス手術後の横隔膜ヘルニアは,胃大網動脈をグラフト血管として用いた場合は報告されているが,その他のグラフト血管での報告は極めて稀である.冠動脈バイパス手術後には,グラフトの種類に関わらず横隔膜ヘルニアが起こる可能性を念頭に置くことが肝要と考えられた.(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J03156&link_issn=&doc_id=20111004220014&doc_link_id=10.3919%2Fjjsa.72.2257&url=https%3A%2F%2Fdoi.org%2F10.3919%2Fjjsa.72.2257&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells. Reviewed International journal

    Toshiaki Ohara, Munenori Takaoka, Shinichi Toyooka, Yasuko Tomono, Toshio Nishikawa, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Toshiyoshi Fujiwara, Yoshio Naomoto

    Cancer science   102 ( 7 )   1344 - 9   2011.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Temsirolimus (CCI-779), a recently synthesized analogue of rapamycin, specifically inhibits mTOR and has been approved for clinical use in renal cell carcinoma. Recent reports have indicated the growth inhibitory effect of temsirolimus in some cancers including non-small-cell lung carcinoma (NSCLC). In this study, we aimed to explore the potential therapeutic use of temsirolimus as a treatment for NSCLC. Using cultured NSCLC cells (A549, H1299, and H358), we determined the effect of temsirolimus on cell proliferation and its antitumor effects on subcutaneous tumors, as well as its contribution to the survival of mice having pleural dissemination of cancer cells, mimicking advanced NSCLC. Temsirolimus suppressed proliferation of NSCLC cells in a dose-dependent manner, with an IC(50) of <1 nM. Western blot analysis revealed that temsirolimus treatment specifically inhibited the phosphorylation of mTOR and its downstream effectors in 1 h, accompanied by an increased cell population in the G(0) /G(1) phase, but according to flow cytometry, the cell population did not increase in the sub-G(0) phase. When NSCLC subcutaneous tumor-bearing mice were treated with temsirolimus, tumor volume was significantly reduced (tumor volume on day 35: vehicle vs temsirolimus = 1239 vs 698 cm(3) ; P < 0.05). Furthermore, prolonged survival was observed in pleural disseminated tumor-bearing mice with temsirolimus treatment (median survival: vehicle vs temsirolimus = 53.5 vs 72.5 days; P < 0.05). These results suggest that temsirolimus could be useful for NSCLC treatment, due to its antiproliferative effect, and could be a potential treatment for advanced NSCLC, giving prolonged survival.

    DOI: 10.1111/j.1349-7006.2011.01967.x

    Web of Science

    PubMed

    researchmap

  • 魚骨肝穿破による胃壁,肝,横隔膜下膿瘍の1例 Reviewed

    大原 利章, 青木 秀樹, 中西 将元, 清田 正之, 田中屋 宏爾, 竹内 仁司

    日本臨床外科学会雑誌   72 ( 6 )   1611 - 1615   2011.6

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:日本臨床外科学会  

    症例は81歳,男性.食欲不振,39.3度の発熱を認めたため当院救急外来を受診した.CT検査にて胃壁,肝,横隔膜下に膿瘍と考えられる低吸収域と内部を貫通して魚骨と考えられる線状の石灰化陰影が認められた.上部消化管内視鏡検査では,胃角部小彎側に粘膜下病変を認め,魚骨の刺入部と考えられたため,生検用鉗子にて粘膜を開窓したところ,内部より膿汁の流出が認められた.入院後第3病日に再度,上部消化管内視鏡検査を施行し,魚骨の摘出を試みたが見当たらず,内視鏡的な摘出を断念し,第5病日手術を施行した.横隔膜下の膿瘍を開窓すると,内部に肝臓を穿破した魚骨を認めた.魚骨を摘出し,肝内異物除去術および腹腔内洗浄ドレナージ術を施行した.摘出された魚骨は長さが5.2cmであり,鯖の骨と考えられた.魚骨が肝臓を穿破して横隔膜下に膿瘍を作った報告はわれわれが検索した範囲では,文献的に英文も含め自験例のみであった.(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2011&ichushi_jid=J03156&link_issn=&doc_id=20110706200055&doc_link_id=10.3919%2Fjjsa.72.1611&url=https%3A%2F%2Fdoi.org%2F10.3919%2Fjjsa.72.1611&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • The establishment of a new mouse model with orthotopic esophageal cancer showing the esophageal stricture. Reviewed International journal

    Toshiaki Ohara, Munenori Takaoka, Kazufumi Sakurama, Kaori Nagaishi, Haruo Takeda, Yasuhiro Shirakawa, Tomoki Yamatsuji, Takeshi Nagasaka, Junji Matsuoka, Noriaki Tanaka, Yoshio Naomoto

    Cancer letters   293 ( 2 )   207 - 12   2010.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER IRELAND LTD  

    We established a promising new experimental animal model with an orthotopic xenograft of esophageal cancer that successfully represents poor oral intake, a major clinical feature of esophageal cancer. The advantage of this model is that no surgical technique is required, only the injection of a cell suspension by a needle and syringe via the esophageal lumen from the mouth, which provides a high reproducibility of tumor implantation and a rapid progress of outcome. We propose that this model is useful to study cancer-related outcomes and for developing new therapies for esophageal cancer, and we expect it to make a contribution to clinical practice.

    DOI: 10.1016/j.canlet.2010.01.017

    Web of Science

    PubMed

    researchmap

  • 手術回数を反映したバスキュラーアクセス開存の指標 平均無手術期間について Reviewed

    宮崎 雅史, 岡 良成, 高津 成子, 宇野 太, 大原 利章, 近藤 喜太, 丸山 昌伸, 松田 浩明

    腎と透析   69 ( 別冊 アクセス2010 )   158 - 160   2010.7

     More details

    Language:Japanese   Publisher:(株)東京医学社  

    20年間に透析治療を行った609例を対象に、バスキュラーアクセス開存の指標として無手術期間を検討した。無手術期間は、観察期間内の全アクセス関連手術施行回数に1を加えた数字で観察期間を除した値とした。609例中477例は何らかのアクセス関連手術を行っており、手術総数は905件であった。内訳は内シャント造設術540件、人工血管移植術154件、シャント修復術211件(自家血管51件・人工血管160件)、PTA 14件で、手術回数10回以上は8例であった。現在透析中の患者199例のうち、観察期間5年以上の102例は平均観察期間13.42年、手術回数2.70回、無手術期間7.95年、観察期間5年未満の97例はそれぞれ2.62年、1.14回、2.04年であった。また、観察期間20年の32例では平均手術回数2.91回、無手術期間9.05年で、5年以上観察を行った275例の最終5年間での平均手術回数は0.81回、無手術期間3.80年であった。5年累積二次開存率は自家血管56.9%、人工血管45.6%であった。

    researchmap

  • RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Reviewed International journal

    Zhi Gang Wang, Takuya Fukazawa, Toshio Nishikawa, Nobuyuki Watanabe, Kazufumi Sakurama, Takayuki Motoki, Shinji Hatakeyama, Osamu Omori, Toshiaki Ohara, Shunsuke Tanabe, Yasuhiro Fujiwara, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Yoshio Naomoto

    Oncology reports   23 ( 4 )   1167 - 72   2010.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPANDIDOS PUBL LTD  

    Esophageal cancer is one of the most frequently occurring cancers in the world. Targeting therapy strategy of cancer with specific inhibitors is developing and has showed promising antitumor efficacy. It is known that mTOR is an important controller of cell growth. RAD001 (everolimus) is a specific inhibitor of mTOR that can block the mTOR signaling pathway. The purposes of this study was to explore the inhibitory effects of RAD001 on mTOR signaling and the mechanism of cell growth suppression by RAD001. We examined both the expression of mTOR, p70S6K and S6 in SEG-1 esophageal cancer cells and KOB-13 normal esophageal epithelial cells and the efficacy of RAD001 against SEG-1 esophageal cancer cells. mTOR, p70S6K and S6 were overexpressed in SEG-1 esophageal cancer cells compared with KOB-13 normal esophageal epithelial cells. SEG-1 esophageal cancer cells were sensitive to RAD001. The survival rate of the cells treated with RAD001 over 0.33 microM was significantly different compared with that of control (P<0.01). RAD001 inhibited the phosphorylation of mTOR (Ser2448) and S6 (Ser240/244) in different grades and the expressions of mTOR, p70S6K and S6. As a result, RAD001 induced a dose-dependent decrease in cell proliferation, G1/S arrest and damage of cell shape. Taken together, these data showed that RAD001 can inhibit mTOR signaling and proliferation in SEG-1 esophageal cancer cells in vitro. It offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.

    DOI: 10.3892/or_00000747

    Web of Science

    PubMed

    researchmap

  • Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor (TAE226) leads to apoptosis in esophageal cancer by inhibiting AKT-mTOR survival signaling Reviewed

    Huifang Hao, Zhigang Wang, Xiaohong Bao, Nobuyuki Watanabe, Kazufumi Sakurama, Yasuko Tomono, Takuya Fukazawa, Shinji Hatakeyama, Osamu Omori, Seishi Nishitani, Toshiaki Ohara, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Masakiyo Sakaguchi, Noriaki Tanaka, Yoshio Naomoto

    CANCER RESEARCH   69   2009.5

     More details

    Language:English   Publisher:AMER ASSOC CANCER RESEARCH  

    Web of Science

    researchmap

  • 活動性SLEを伴う進行食道癌の一例 根治切除後4年間無再発生存例の検討 Invited

    元木 崇之, 猶本 良夫, 藤原 康宏, 白川 靖博, 山辻 知樹, 高岡 宗徳, 田邊 俊介, 大原 利章, 松岡 順治, 田中 紀章

    外科治療   100 ( 3 )   315 - 318   2009.3

     More details

    Language:Japanese   Publishing type:Part of collection (book)   Publisher:(株)永井書店  

    42歳女。下腿の浮腫、全身倦怠感、嚥下困難、38℃をこえる発熱で近医を受診し、Systemic lupus Erythematosus(SLE)と診断された。上部消化管内視鏡で下部食道から胃噴門部に2型病変を認め、生検より食道扁平上皮癌と診断され当院入院となった。貧血、血小板数低下と低アルブミン血症を認め、上部消化管内視鏡で右壁中心に胃噴門部へ浸潤する高い隆起性病変を認め、腹部造影CTで#7リンパ節の腫大、胸腹水、脾腫を認めた。以上よりEsophageal cancer、AeG Type2、T3N2M0 StageIIIと術前診断した。SLEは強い活動性を示したためSLEの治療を先行し、ステロイドパルス療法とPSL維持療法により術前準備を行った。縫合不全の合併症のリスクを考慮して分割手術として開腹・頸部・経横隔膜操作による食道・胃噴門部切除、胃管皮下経路再建(未吻合)・胆嚢摘出術を行い、術後10ヵ月目に食道・胃管吻合を施行した。初回術後の大量の胸水に対して、胸腔腹腔間にデンバーシャントを留置して胸水の減量と胸水に含まれ漏出した蛋白の腹腔内での再吸収により血中の蛋白濃度が改善できた。I期目手術後4年経過した現在、再発もなく社会復帰した。

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2009&ichushi_jid=J00396&link_issn=&doc_id=20090309180019&doc_link_id=%2Faf2gktye%2F2009%2F010003%2F019%2F0315-0318%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Faf2gktye%2F2009%2F010003%2F019%2F0315-0318%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • Establishment of a lymph node metastasis model from subcutaneous tumors of gastrointestinal stromal tumor model cells. Reviewed International journal

    Kazufumi Sakurama, Yoshio Naomoto, Toshiaki Ohara, Nobuyuki Watanabe, Munenori Takaoka, Hitoshi Nagatsuka, Yasuko Tomono, Toru Tanida, Kazuhiro Noma, Shunsuke Tanabe, Yasuhiro Fujiwara, Takayuki Motoki, Yasuhiro Shirakawa, Tomoki Yamatsuji, Seiichi Hirota, Takahiro Taguchi, Noriaki Tanaka

    Oncology reports   21 ( 2 )   407 - 11   2009.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    There is currently no suitable animal model of metastasis using cultured human gastrointestinal stromal tumor cells even though the molecular mechanisms of c-KIT-mediated progression and metastasis should be clarified. Ba/F3 murine lymphocyte cells transduced with mutant c-KIT have been utilized to analyze some molecular mechanisms related to a constitutively activated c-KIT signaling and to assess the efficacy of molecular-targeted inhibitors. Using this cellular system, we coincidentally discovered the development of axillary and inguinal lymph node swelling three weeks after subcutaneous injection of Ba/F3 cells with c-KIT mutation into nude mice. Mutation-specific PCR detected c-KIT mutation in the swollen lymph nodes but not in unmetastasized normal lymph nodes, indicating that the lymph nodes contain tumor cells which should come from a primary subcutaneous tumor. Microscopic observation revealed tumor cells infiltrating through lymphatic follicles with Ki-67-positive staining to distinguish them from lymphocytes. The significance of this model is helpful to understand the molecular mechanisms of c-KIT-mediated metastasis and is useful for assessments of molecular therapeutics and in vivo imaging.

    PubMed

    researchmap

  • Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Reviewed International journal

    Toshiaki Ohara, Takahiro Oto, Kentaro Miyoshi, Hiroyuki Tao, Masaomi Yamane, Shinichi Toyooka, Megumi Okazaki, Hiroshi Date, Yoshifumi Sano

    The Annals of thoracic surgery   86 ( 6 )   e7-8 - 8   2008.12

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    We report a successful case of sirolimus treatment for chylous pleural and peritoneal effusions of lymphangioleiomyomatosis after lung transplantation. A 32-year-old woman underwent living donor lung transplantation. Persistent chylous pleural and peritoneal effusions were seen postoperatively. Pleurodesis by intrathoracic injection of OK-432, minomycin, and somatostatine analog failed to control chylous effusions. However, sirolimus treatment reduced the amount of chylous drainage and improved both chylous pleural and peritoneal effusions.

    DOI: 10.1016/j.athoracsur.2008.07.062

    PubMed

    researchmap

  • TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells. Reviewed International journal

    Zhi Gang Wang, Takuya Fukazawa, Toshio Nishikawa, Nobuyuki Watanabe, Kazufumi Sakurama, Takayuki Motoki, Munenori Takaoka, Shinji Hatakeyama, Osamu Omori, Toshiaki Ohara, Shunsuke Tanabe, Yasuhiro Fujiwara, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Yoshio Naomoto

    Oncology reports   20 ( 6 )   1473 - 7   2008.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Esophageal cancer is one of the most aggressive cancers in the world. Novel preventive and therapeutic strategies tend to target the key molecules involved in the signaling transduction pathways for cell growth. It is known that FAK and mTOR are important controllers of cell growth. TAE226, a novel small molecule compound, is a potent ATP competitive inhibitor of FAK and IGF-IR. TAE226 can block FAK and IGF-IR signaling pathways. The purpose of this study was to explore the inhibitory effects on mTOR signaling and the mechanism of cell growth suppression by TAE226. We examined the expression of mTOR and S6 in esophageal cancer cells (SEG-1) and normal esophageal epithelial cells (KOB-13) and the efficacy of TAE226 against SEG-1 cells. mTOR and S6 were overexpressed in SEG-1 cells compared with KOB-13 cells. TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244). As a result, TAE226 induced a dose-dependent decrease in cell growth (number) and damage in the cell shape. Together, these data show that TAE226 has potent inhibitory effects on mTOR signaling and esophageal cancer cell growth indicating that TAE226 has potential application in esophageal cancer treatment.

    PubMed

    researchmap

  • 骨シンチグラフィーで腫瘍に骨外集積を認めた肺原発多形癌の1例 Reviewed

    大原 利章, 木村 幸男

    肺癌   47 ( 4 )   333 - 336   2007.8

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(NPO)日本肺癌学会  

    背景。肺原発多形癌は稀な腫瘍であり、術前診断は困難なことが多い。症例。67歳女性。左下胸部痛あり近医受診し、翌日精査加療目的にて当院へ紹介となった。胸部CTにて左下葉に径5.5cm大の腫瘤を認め、左下葉肺癌cT2N0M0の疑いにて手術を施行した。術中針生検による迅速病理診断では腺癌の診断であり、左下葉切除とリンパ節郭清を施行した。術後病理診断にて多形癌と診断された。なお、本症例では術前骨シンチグラフィーにて、腫瘍に一致して骨外集積が認められた。結論。骨シンチグラフィーにて腫瘍に一致した骨外集積を伴う肺多形癌の1例を経験した。肺多形癌と骨シンチグラフィー骨外集積との関係を解明していくことが必要と考えられた。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2007&ichushi_jid=J01244&link_issn=&doc_id=20070913160005&doc_link_id=%2Fec7jaluc%2F2007%2F004704%2F005%2F0333-0336%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fec7jaluc%2F2007%2F004704%2F005%2F0333-0336%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • A Case of Perforated Refractory Ulcer in the Gastric Tube after Esophageal Cancer Reviewed

    39 ( 3 )   289 - 293   2006.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A 66-year-old man who had undergone esophagectomy for intrathoracic esophageal cancer developed a peptic epithelial ulcer and edema on the anterior aspect of the reconstructed gastric tube while undergoing regular follow-up examinations. On admission, he received ulcer therapy, but the ulcer didn’t heal and the gastric
    tube was partialy resectioned under local anesthesia. The ulcer recurred twice, and we conducted a thorough
    investigation. A detailed history revealed that he had been treated of the shoulder with NSAIDS and longterm steroid therapy, and they were thought to be factors contributing to formation of the ulcers. A secretin
    test was performed to rule out the Zollinger-Ellison syndrome, but it was negative because the patients’
    plasma gastrin level was continuously high(1,210~1,620pgml )and there was no paradoxical response. The
    plasma gastrin level was much higher than in other cases reported in Japan, and we attempted to find the
    cause. Parietal cell antibody(PCA)was negative. The patient was positive for urophanic and serum antibodies to Helicobacter pylori, but the gastric tube resection specimens were negative, and the cause remained unclear. Because of the generally long-term survival after esophageal cancer surgery, patient education is necessary to prevent the development of gastric tube ulcers.

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2006&ichushi_jid=J01117&link_issn=&doc_id=20060314040003&doc_link_id=10.5833%2Fjjgs.39.289&url=https%3A%2F%2Fdoi.org%2F10.5833%2Fjjgs.39.289&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 腸膀胱瘻の臨床病理学的検討 Reviewed

    大原 利章, 田中屋 宏爾, 小山 裕, 黒田 新士, 谷口 信將, 大橋 勝久, 荒田 尚, 武田 晃, 安井 義政, 竹内 仁司

    日本消化器外科学会雑誌   38 ( 7 )   1241 - 1241   2005.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 虫垂原発悪性腫瘍におけるカルチノイドの臨床的特徴 Reviewed

    田中屋 宏爾, 竹内 仁司, 安井 義政, 武田 晃, 荒田 尚, 大橋 勝久, 大原 利章, 黒田 新士, 谷口 信将, 小山 裕, 徳田 貴則

    日本大腸肛門病学会雑誌   58 ( 6 )   374 - 374   2005.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(一社)日本大腸肛門病学会  

    researchmap

  • 当院における肝癌に対する肝切除術症例の検討

    國土 泰孝, 香川 茂雄, 渡辺 信之, 内海 方嗣, 大原 利章, 村岡 篤, 立本 昭彦, 曽根 良幸, 津村 眞, 鶴野 正基, 吉永 浩明, 影山 淳一, 児島 完治

    香川労災病院雑誌   ( 9 )   15 - 19   2003.10

     More details

    Language:Japanese   Publishing type:Research paper (bulletin of university, research institution)   Publisher:香川労災病院  

    10年間に肝切除を施行した肝癌症例89例(肝細胞癌59例,胆管細胞癌3例,混合型肝癌1例,転移性肝癌26例)について検討した.手術時間342±116分,出血量320±ml,胃管抜去日2.3±2.3日,胸腔ドレーン抜去日5.0±2.3日,腹腔ドレーン抜去日10±5.5日,経口摂取開始日5.7±2.8日,点滴終了日18.6±6.5日,ガーゼ交換終了日23.9±8.6日,術後在院日数34.8±13.8日であった.術後合併症は89例中38例に認められ,創感染,難治性腹水,術後腎機能障害,黄疸等であった.術後死亡,在院死は0例であった.肝細胞癌の術後5年生存率は64%,無再発生存率は53%であった.また,肝炎マーカー別5年生存率は,肝炎マーカー陰性例では80%,HBs抗原陽性例では70%,HCV抗体陽性例では56%であった.転移性肝癌の術後5年生存率は,同時性では21%,異時性では66%で,有意に異時肝転移の生存率が良好であった

    researchmap

  • 術前診断し得た腸石を有するメッケル憩室炎の一例 Reviewed

    國土 泰孝, 大原 利章, 渡辺 信之, 池田 義博, 村岡 篤, 曽根 良幸, 立本 昭彦, 香川 茂雄, 津村 眞, 鶴野 正基

    日本消化器外科学会雑誌   36 ( 7 )   1020 - 1020   2003.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

▼display all

MISC

  • Drug repositioningによる新規がん治療の開発に向けて がん関連線維芽細胞由来IL-6の作用と制御

    國友 知義, 野間 和広, 西脇 紀之, 河崎 健人, 小林 照貴, 菊地 覚次, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   80回   [J13 - 3]   2021.9

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • これからのハイパーサーミアに向けた研究のトピックス 同所性ヌードマウスモデルにおける腹膜播種に対する磁性体ナノ粒子を用いた温熱療法

    松三 雄騎, 香川 哲也, 矢野 修也, 田澤 大, 重安 邦俊, 武田 正, 大原 利章, 青野 宏通, Hoffman Robert M., 藤原 俊義, 岸本 浩行

    Thermal Medicine   37 ( Suppl. )   S7 - 2   2021.9

     More details

    Language:Japanese   Publisher:(一社)日本ハイパーサーミア学会  

    researchmap

  • 透析医療とartificial intelligence 専門医の思考を学ぶAI投薬支援システムの開発 Reviewed

    大原 利章

    日本透析医学会雑誌   54 ( Suppl.1 )   268 - 268   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    researchmap

  • 腫瘍環境のSpred2欠損は4T1乳がん細胞の増殖と転移を抑制する(Spred2 deficiency in cancer microenvironment inhibits progression of 4T1 breast cancer cells in mice)

    Tian Miao, 吉村 禎造, 李 春寧, 大原 利章, 藤澤 真義, 松川 昭博

    日本病理学会会誌   110 ( 1 )   324 - 324   2021.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • Spred2はHCCで幹細胞性をmiR-506-3pによって一部負に抑制する(Spred2 down-regulates stemness in HCC partly through targeting miR-506-3p)

    高 桐, 藤澤 真義, Aye Moh Moh Aung, 大原 利章, 吉村 禎造, 王 天一, 伊藤 佐智夫, 松川 昭博

    日本病理学会会誌   110 ( 1 )   225 - 225   2021.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • HCC細胞のオートファジーにおけるSpred2の役割とERK活性化との関係(Role of Spred2 in autophagy in HCC cells and its relation to ERK activation)

    王 天一, 藤澤 真義, 大原 利章, 吉村 禎造, 高 桐, 松川 昭博

    日本病理学会会誌   110 ( 1 )   314 - 314   2021.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 癌関連線維芽細胞に対する鉄キレート剤の効果(Effects of Iron Chelators on Cancer-associated Fibroblasts)

    王 宇沢, 大原 利章, 李 春寧, 田 ミャオ, 小槙 志保, 吉村 禎造, 藤澤 真義, 松川 昭博

    日本病理学会会誌   110 ( 1 )   324 - 324   2021.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 異なる亜集団の腫瘍細胞から放出されたエクソソームWnt7aによリ4T1細胞の転移は促進される(4T1 cells promote tumor metastasis by exosomal Wnt7a released from distinct subpopulations)

    李 春寧, 大原 利章, 藤澤 真義, 阪口 政清, 山本 健一, 田 ミャオ, 王 宇沢, 吉村 禎造, 松川 昭博

    日本病理学会会誌   110 ( 1 )   231 - 231   2021.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • Development of novel photoimmunotherapy targeting cancer associated fibroblasts.

    Teruki Kobayashi, Kazuhiro Noma, Kento Kawasaki, Masaaki Akai, Noriyuki Nishiwaki, Toshiaki Ohara, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   112   414 - 414   2021.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • RNA editing activated by chemoradiation therapy artificially generates neoantigen in colorectal cancer

    Yasuhiro Komatsu, Kunitoshi Shigeyasu, Sho Takeda, Kazutaka Takahashi, Nanako Hata, Kazuhiro Yoshida, Shuya Yano, Toshiaki Ohara, Kazuhiro Noma, Yuzo Umeda, Shinji Kuroda, Yoshitaka Kondo, Fuminori Teraishi, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   112   336 - 336   2021.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Interplay between gastric cancer subtypes and cancer-associated fibroblasts

    Yuncheng Li, Hiroshi Tazawa, Kazuhiro Noma, Toshiaki Ohara, Shinji Kuroda, Satoru Kikuchi, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   112   425 - 425   2021.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Overcoming cancer-associated fibroblasts induced immunosuppression by blocking IL-6-Exploring for Drug Repositioning-

    Noriyuki Nishiwaki, Kazuhiro Noma, Toshiaki Ohara, Teruki Kobayashi, Satoru Kikuchi, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   112   391 - 391   2021.2

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • がん関連線維芽細胞由来IL-6制御による免疫応答の効率化バイオマーカーとしてのIL-6の可能性

    西脇 紀之, 野間 和広, 大原 利章, 河崎 健人, 赤井 正明, 小林 照貴, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本分子腫瘍マーカー研究会誌   36   32 - 33   2021

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • 血管造影室での転落事故防止するにはどうすればよいか~転落防止機能付きレントゲン透過手術板開発を通して考える~

    櫻間教文, 平松聡, 大原利章

    医工学治療   33 ( Supplement )   2021

  • 病理解剖にて判明した肛門管部原発の悪性黒色腫の1例

    杉原悟, 藤井江利子, 中井友美, 野村隼人, 山崎修, 森実真, 大原利章, 眞部恵子, 守山喬史

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集   37th   2021

  • フェルカルボトランを用いた胃癌腹膜播種に対する磁気温熱療法

    松三 雄騎, 岸本 浩行, 香川 哲也, 矢野 修也, 重安 邦俊, 岡林 弘樹, 大原 利章, 田澤 大, 藤原 俊義

    日本消化器外科学会総会   75回   P077 - 3   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • フェルカルボトランを用いた胃癌腹膜播種に対する磁気温熱療法

    松三 雄騎, 岸本 浩行, 香川 哲也, 矢野 修也, 重安 邦俊, 岡林 弘樹, 大原 利章, 田澤 大, 藤原 俊義

    日本消化器外科学会総会   75回   P077 - 3   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 癌関連線維芽細胞を標的とした光免疫療法の新たな開発

    小林 照貴, 野間 和広, 河崎 健人, 赤井 正明, 西脇 紀之, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   79回   OJ12 - 3   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 胃癌サブタイプと癌関連線維芽細胞の相互作用

    李 云成, 田澤 大, 野間 和広, 大原 利章, 黒田 新士, 菊地 覚次, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   79回   OE14 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 大腸癌化学放射線療法で活性化されるRNA編集によるネオアンチゲンの人工的生成

    小松 泰浩, 重安 邦俊, 武田 正, 高橋 一剛, 畑 七々子, 吉田 一博, 矢野 修也, 大原 利章, 野間 和広, 楳田 祐三, 黒田 新士, 近藤 喜太, 寺石 文則, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   79回   OE9 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 癌関連線維芽細胞由来IL-6制御による免疫応答の効率化 "Drug repositioning"による癌治療の可能性

    西脇 紀之, 野間 和広, 大原 利章, 小林 照貴, 菊地 覚次, 田澤 大, 藤原 俊義

    日本癌学会総会記事   79回   OE12 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    researchmap

  • 胃癌サブタイプと癌関連線維芽細胞の相互作用

    李 云成, 田澤 大, 野間 和広, 大原 利章, 黒田 新士, 菊地 覚次, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   79回   OE14 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    J-GLOBAL

    researchmap

  • 癌関連線維芽細胞由来IL-6制御による免疫応答の効率化 "Drug repositioning"による癌治療の可能性

    西脇 紀之, 野間 和広, 大原 利章, 小林 照貴, 菊地 覚次, 田澤 大, 藤原 俊義

    日本癌学会総会記事   79回   OE12 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    J-GLOBAL

    researchmap

  • 癌関連線維芽細胞を標的とした光免疫療法の新たな開発

    小林 照貴, 野間 和広, 河崎 健人, 赤井 正明, 西脇 紀之, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   79回   OJ12 - 3   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    J-GLOBAL

    researchmap

  • 大腸癌化学放射線療法で活性化されるRNA編集によるネオアンチゲンの人工的生成

    小松 泰浩, 重安 邦俊, 武田 正, 高橋 一剛, 畑 七々子, 吉田 一博, 矢野 修也, 大原 利章, 野間 和広, 楳田 祐三, 黒田 新士, 近藤 喜太, 寺石 文則, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   79回   OE9 - 7   2020.10

     More details

    Language:English   Publisher:(一社)日本癌学会  

    J-GLOBAL

    researchmap

  • がん関連線維芽細胞由来IL-6制御による免疫応答の効率化バイオマーカーとしてのIL-6の可能性

    西脇 紀之, 野間 和広, 大原 利章, 河崎 健人, 赤井 正明, 小林 照貴, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本分子腫瘍マーカー研究会プログラム・講演抄録   40回   72 - 73   2020.9

     More details

    Language:Japanese   Publisher:日本分子腫瘍マーカー研究会  

    researchmap

  • 癌微小環境が引き起こす腫瘍免疫抑制の解明 "Drug repositioning"による免疫応答賦活化の可能性

    西脇 紀之, 野間 和広, 赤井 正明, 小林 照貴, 鳴坂 徹, 河本 慧, 加藤 卓也, 前田 直見, 田辺 俊介, 大原 利章, 田澤 大, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 4   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • Fibroblast activation protein-α(FAP)を標的とした癌関連線維芽細胞(CAFs)に対する光免疫療法 Sunrise of targeting tumor microenvironment therapy

    小林 照貴, 野間 和広, 赤井 正明, 西脇 紀之, 鳴坂 徹, 河本 慧, 前田 直見, 大原 利章, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   120回   SF - 8   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 新世代の外科医の苦悩と挑戦

    西脇紀之, 野間和広, 赤井正明, 小林照貴, 鳴坂徹, 河本慧, 大原利章, 田澤大, 藤原俊義

    日本外科学会定期学術集会(Web)   120th   2020

  • A novel photoimmunotherapy for cancer cells and cancer-associated-fibroblasts

    小林照貴, 野間和広, 大原利章, 河崎健人, 赤井正明, 西脇紀之, 前田直見, 菊地覚次, 矢野修也, 田辺俊介, 田澤大, 白川靖博, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   31st   2020

  • 膵癌におけるFNA検体と切除検体とのPD-L1発現の検討

    松本 和幸, 高木 章乃夫, 大原 利章, 藤澤 真義, 高原 政宏, 加藤 博也, 吉田 龍一, 楳田 祐三, 八木 孝仁, 松川 昭博, 岡田 裕之

    日本消化器病学会雑誌   116 ( 臨増大会 )   A826 - A826   2019.11

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  • 膵癌におけるFNA検体と切除検体とのPD-L1発現の検討

    松本 和幸, 高木 章乃夫, 大原 利章, 藤澤 真義, 高原 政宏, 加藤 博也, 吉田 龍一, 楳田 祐三, 八木 孝仁, 松川 昭博, 岡田 裕之

    日本消化器病学会雑誌   116 ( 臨増大会 )   A826 - A826   2019.11

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    researchmap

  • がん関連線維芽細胞(CAFs)による腫瘍免疫抑制のメカニズムについて(Exploring the mechanism of cancer-associated fibroblasts(CAFs) induced immunosuppression in tumor microenvironment)

    西脇 紀之, 野間 和広, 小林 照貴, 鳴坂 徹, 河本 慧, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   78回   P - 3083   2019.9

     More details

    Language:English   Publisher:日本癌学会  

    J-GLOBAL

    researchmap

  • 化学放射線療法は線維芽細胞の活性化を介して食道癌細胞の悪性度を向上させる(Chemoradiotherapy promotes malignancy of cancer cells via activating fibroblasts in esophageal squamous cell carcinomas)

    河本 慧, 野間 和広, 小林 照貴, 西脇 紀之, 鳴坂 徹, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   78回   E - 1038   2019.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 鉄キレート剤による幹細胞性制御による新規食道癌治療法(Stemness control by iron chelator is a novel therapeutic strategy for esophageal cancer treatment)

    鳴坂 徹, 大原 利章, 桂 佑貴, 野間 和広, 西脇 紀之, 河本 慧, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   78回   P - 1077   2019.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • Sternness control by iron chelator is a novel therapeutic strategy for esophageal cancer

    Toru Narusaka, Toshiaki Ohara, Kazuhiro Noma, Yuki Katsura, Noriyuki Nishiwaki, Motoyasu Tabuchi, Takuro Fushimi, Toshihiro Ogawa, Sho Takeda, Satoshi Komoto, Hiroaki Sato, Satoru Kikuchi, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   79 ( 13 )   2019.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2019-1155

    Web of Science

    researchmap

  • Overcoming resistance of conventional therapies by targeting cancer-associated fibroblasts (CAFs) with near-infrared photoimmunotherapy (NIR-PIT)

    Satoshi Komoto, Kazuhiro Noma, Ryoichi Katsube, Takuya Kato, Toshiaki Ohara, Hiroaki Sato, Toru Narusaka, Noriyuki Nisiwaki, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   79 ( 13 )   2019.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2019-LB-310

    Web of Science

    researchmap

  • 食道癌の幹細胞性を制御する鉄キレート療法の開発(Stemness control by iron chelator can be a novel therapeutic strategy for esophageal cancer)

    大原 利章, 鳴坂 徹, Xing Boyi, Chen Yuehua, 松川 昭博

    日本病理学会会誌   108 ( 1 )   318 - 318   2019.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • HepG2細胞におけるSpred2遺伝子の不活化はERK経路を活性化して細胞増殖、移動および浸潤を促進する(Spred2 deletion accelerates growth, migration and invasion in HepG2 cells by activating ERK pathway)

    高 桐, 楊 旭, 藤澤 真義, 大原 利章, 吉村 禎造, 松川 昭博

    日本病理学会会誌   108 ( 1 )   382 - 382   2019.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • Spred2はINF gamma生産を調節することによりマウスのConA誘発肝障害を予防する(Spred2 protects mice from ConA-induced liver injury by regulating IFN gamma production)

    孫 翠明, 藤澤 真義, 大原 利章, 吉村 禎造, 松川 昭博

    日本病理学会会誌   108 ( 1 )   382 - 382   2019.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 異なる細胞亜集団に由来するエキソソームによって癌の進行が制御される可能性(Cancer progression can be regulated by exosomes from distinct cell subpopulation)

    李 春寧, 田 ミョウ, 大原 利章, 藤澤 真義, 吉村 禎造, 松川 昭博

    日本病理学会会誌   108 ( 1 )   394 - 394   2019.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • Exploring the mechanism of cancer-associated fibroblasts (CAFs) induced immunosuppression in tumor microenvironment

    西脇紀之, 野間和広, 小林照貴, 鳴坂徹, 河本慧, 大原利章, 田澤大, 藤原俊義

    日本癌学会学術総会抄録集(Web)   78th   P - 3083   2019

     More details

    Language:English   Publisher:日本癌学会  

    J-GLOBAL

    researchmap

  • Chemoradiotherapy promotes malignancy of cancer cells via activating fibroblasts in esophageal squamous cell carcinomas

    河本慧, 野間和広, 小林照貴, 西脇紀之, 鳴坂徹, 大原利章, 田澤大, 藤原俊義

    日本癌学会学術総会抄録集(Web)   78th   E - 1038   2019

     More details

    Language:English   Publisher:日本癌学会  

    J-GLOBAL

    researchmap

  • Stemness control by iron chelator is a novel therapeutic strategy for esophageal cancer treatment

    鳴坂徹, 大原利章, 桂佑貴, 野間和広, 西脇紀之, 河本慧, 田澤大, 香川俊輔, 藤原俊義

    日本癌学会学術総会抄録集(Web)   78th   P - 1077   2019

     More details

    Language:English   Publisher:日本癌学会  

    J-GLOBAL

    researchmap

  • 膵癌におけるFNA検体と切除検体とのPD-L1発現の検討

    松本和幸, 高木章乃夫, 大原利章, 藤澤真義, 高原政宏, 加藤博也, 吉田龍一, 楳田祐三, 八木孝仁, 松川昭博, 岡田裕之

    日本消化器病学会雑誌(Web)   116   2019

  • Visualization of epithelial-mesenchymal transition in inflammatory microenvironment-colorectal cancer crosstalk

    Hiroshi Tazawa, Takeshi Ieda, Shuya Yano, Kunitoshi Shigeyasu, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Masahiko Nishizaki, Shunsuke Kagawa, Takashi Saitou, Takeshi Imamura, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   669 - 669   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Cancer-associated fibroblasts affect the intra-tumoral infiltration of CD8+and FoxP3+T cells via IL-6

    Takuya Kato, Kazuhiro Noma, Hiroaki Sato, Satoshi Komoto, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   1120 - 1120   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Stemness control by iron chelator is a novel strategy for cancer treatment

    Toshiaki Ohara, Yuki Katsura, Kazuhiro Noma, Toru Narusaka, Hiroaki Sato, Satoshi Komoto, Takuya Kato, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   1309 - 1309   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Dual-targeting Photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in tumor microenvironment

    Hiroaki Sato, Kazuhiro Noma, Toru Narusaka, Satoshi Komoto, Toshiaki Ohara, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   371 - 371   2018.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • 鉄キレート剤の幹細胞性制御による新規癌治療法(Stemness control by iron chelator is a novel strategy for cancer treatment)

    大原 利章, 桂 佑貴, 野間 和広, 鳴坂 徹, 佐藤 浩明, 河本 慧, 加藤 卓也, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   77回   2318 - 2318   2018.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 消化管がん治療の新展開 食道癌におけるがん細胞及びがん関連線維芽細胞に対するDual-targeting Photoimmunotherapy(Developments in gastrointestinal cancer treatments Dual-targeting Photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in tumor microenvironment)

    佐藤 浩明, 野間 和広, 鳴坂 徹, 河本 慧, 大原 利章, 田澤 大, 藤原 俊義

    日本癌学会総会記事   77回   96 - 96   2018.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 炎症性微小環境-大腸がんクロストークにおけるEMTイメージング(Visualization of epithelial-mesenchymal transition in inflammatory microenvironment-colorectal cancer crosstalk)

    田澤 大, 家田 偉史, 矢野 修也, 重安 邦俊, 黒田 新士, 大原 利章, 野間 和広, 岸本 浩行, 西崎 正彦, 香川 俊輔, 斎藤 卓, 今村 健志, 藤原 俊義

    日本癌学会総会記事   77回   1204 - 1204   2018.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 癌関連線維芽細胞が放出するIL-6が腫瘍内に浸潤するCD8+ならびにFoxP3+T細胞に影響を与える(Cancer-associated fibroblasts affect the intra-tumoral infiltration of CD8+ and FoxP3+ T cells via IL-6)

    加藤 卓也, 野間 和広, 佐藤 浩明, 河本 慧, 大原 利章, 田澤 大, 白川 靖博, 藤原 俊義

    日本癌学会総会記事   77回   1860 - 1860   2018.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 癌関連線維芽細胞が引き起こす腫瘍免疫抑制の解明 腫瘍浸潤リンパ球とIL-6と代謝の観点から

    加藤 卓也, 野間 和広, 賀島 肇, 桂 佑貴, 佐藤 浩明, 河本 慧, 二宮 卓之, 大原 利章, 田澤 大, 白川 靖博, 稲垣 優, 岩垣 博巳, 藤原 俊義

    日本がん免疫学会総会プログラム・抄録集   22回   95 - 95   2018.7

     More details

    Language:Japanese   Publisher:日本がん免疫学会  

    researchmap

  • Visualization of epithelial-mesenchymal transition in inflammatory microenvironment-colorectal cancer network in vitro and in vivo

    Hiroshi Tazawa, Takeshi Ieda, Shuya Yano, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Masahiko Nishizaki, Shunsuke Kagawa, Takashi Saitou, Takeshi Imamura, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-1101

    Web of Science

    researchmap

  • Novel theranostic strategy against peritoneal metastasis of scirrhous gastric cancer: Combination with fluorescence oncolytic adenovirus and chemotherapy

    Wataru Ishikawa, Satoru Kikuchi, Hiroshi Tazawa, Toshiaki Ohara, Shinji Kuroda, Kazuhiro Noma, Hiroyuki Kishimoto, Masahiko Nishizaki, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-4807

    Web of Science

    researchmap

  • Cancer-associated fibroblasts regulate intratumoral CD8(+)/FoxP3(+) T cells via interleukin 6 in the tumor immune microenvironment

    Takuya Kato, Kazuhiro Noma, Yuki Katsura, Hiroaki Sato, Satoshi Kohmoto, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Masaru Inagaki, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-1741

    Web of Science

    researchmap

  • Iron depletion suppress the stemness markers and functions of cancer stem cells

    Toshiaki Ohara, Yuki Katsura, Kazuhiro Noma, Toru Narusaka, Takuya Kato, Hiroaki Sato, Satoshi Komoto, Yasuko Tomono, Takayuki Ninomiya, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-LB-045

    Web of Science

    researchmap

  • Dual-targeting photoimmunotherapy (NIR-PIT) for esophageal cancer cells and cancer-associated fibroblasts (CAFs)

    Hiroaki Sato, Kazuhiro Noma, Toru Narusaka, Satoshi Komoto, Yuki Katsura, Takuya Kato, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    CANCER RESEARCH   78 ( 13 )   2018.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2018-5066

    Web of Science

    researchmap

  • 除鉄による癌幹細胞の幹細胞性マーカーと機能は制御される(Iron depletion suppress the stemness markers and functions of cancer stem cells)

    大原 利章, Sun Yingfu, 友野 靖子, 松川 昭博

    日本病理学会会誌   107 ( 1 )   299 - 299   2018.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • Spred2欠損は内臓脂肪織炎、インスリン抵抗性を増悪させる

    大倉 隆宏, 丸谷 梨栄, 吉村 禎造, 藤澤 真義, 大原 利章, 松川 昭博

    日本病理学会会誌   107 ( 1 )   347 - 347   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    researchmap

  • spred-2は肝傷害を保護する(Spred-2 protects mice from ConA-induced liver injury)

    孫 翠明, 吉村 禎造, 藤澤 真義, 大原 利章, 楊 旭

    日本病理学会会誌   107 ( 1 )   368 - 368   2018.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 除鉄による癌幹細胞の幹細胞性マーカーと機能は制御される(Iron depletion suppress the stemness markers and functions of cancer stem cells)

    大原 利章, Sun Yingfu, 友野 靖子, 松川 昭博

    日本病理学会会誌   107 ( 1 )   299 - 299   2018.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • spred-2は肝傷害を保護する(Spred-2 protects mice from ConA-induced liver injury)

    孫 翠明, 吉村 禎造, 藤澤 真義, 大原 利章, 楊 旭

    日本病理学会会誌   107 ( 1 )   368 - 368   2018.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • Cancer-associated fibroblasts (CAFs) promote to tumor immunosuppression via IL-6 secretion.

    Takuya Kato, Kazuhiro Noma, Hajime Kashima, Yuki Katsura, Hiroaki Sato, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   299 - 299   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Focusing on the antitumor effect of iron chelator, specifically suppressing the stemness of cancer stem cell.

    Yuki Katsura, Toshiaki Ohara, Hajime Kashima, Hiroaki Sato, Takuya Kato, Takayuki Ninomiya, Kazuhiro Noma, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   87 - 87   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Fluorescence-guided live cell imaging system of EMT-tumor microenvironment network in gastrointestinal cancer

    Takeshi Ieda, Hiroshi Tazawa, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Takeshi Imamura, Toshiyoshi Fujiwara

    CANCER SCIENCE   109   557 - 557   2018.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:WILEY  

    Web of Science

    researchmap

  • Spred2欠損は内臓脂肪織炎、インスリン抵抗性を増悪させる

    大倉 隆宏, 丸谷 梨栄, 吉村 禎造, 藤澤 真義, 大原 利章, 松川 昭博

    日本病理学会会誌   107 ( 1 )   347 - 347   2018

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    J-GLOBAL

    researchmap

  • 鉄キレート剤の幹細胞性制御による新規癌治療法の確立

    大原利章, 大原利章, 桂佑貴, 野間和広, 鳴坂徹, 二宮卓之, 友野靖子, 田澤大, 香川俊輔, 白川靖博, 松川昭博, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   29th   2018

  • 正確なカフ型カテーテル留置を可能にした血液透析カテーテル挿入補助器具Dot Marker開発

    櫻間教文, 平松聡, 大原利章

    日本アクセス研究会学術集会・総会プログラム・抄録集   22nd   2018

  • 除鉄による幹細胞性制御による新規食道癌治療法の開発

    鳴坂徹, 桂佑貴, 木村文昭, 大原利章, 大原利章

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   42nd   2018

  • 食道癌におけるがん細胞及びがん関連線維芽細胞に対するDual-targeting Photoimmunotherapy

    佐藤浩明, 野間和宏, 鳴坂徹, 河本慧, 大原利章, 田澤大, 白川靖博, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   29th   2018

  • Spred-2 protects mice from ConA-induced liver injury

    Cuiming Sun, Teizo Yoshimura, Masatoshi Fujisawa, Toshiaki Ohara, Xu Yang, Akihiro Matsukawa

    CYTOKINE   100   120 - 120   2017.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD  

    Web of Science

    researchmap

  • Spred-2 deficiency exacerbates lipopolysaccharide (LPS)/D-galactosamine (D-GalN) induced acute liver injury

    Yang Xu, Teizo Yoshimura, Masayoshi Fujisawa, Toshiaki Ohara, Cuiming Sun, Akihiro Matsukawa

    CYTOKINE   100   137 - 137   2017.12

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD  

    Web of Science

    researchmap

  • 抗体結合磁性ナノ粒子による温熱療法 癌播種病変への治療応用へ向けて

    香川 哲也, 岸本 浩行, 松三 雄騎, 田澤 大, 大原 利章, 永坂 岳司, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   76回   P - 2368   2017.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 鉄キレート剤特異的な腫瘍幹細胞性抑制効果の検討

    桂 佑貴, 大原 利章, 賀島 肇, 佐藤 浩明, 加藤 卓也, 二宮 卓之, 野間 和広, 友野 靖子, 田澤 大, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本癌学会総会記事   76回   E - 1014   2017.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 癌関連線維芽細胞(CAFs)により放出されるIL-6が腫瘍免疫抑制を引き起こす

    加藤 卓也, 野間 和広, 賀島 肇, 桂 佑貴, 佐藤 浩明, 二宮 卓之, 大原 利章, 田澤 大, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   76回   P - 1260   2017.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • バイオイメージングの創薬、診断、治療への展開 EMT-がん微小環境ネットワークの蛍光生細胞イメージングシステム

    家田 偉史, 田澤 大, 菊地 覚次, 黒田 新士, 大原 利章, 野間 和広, 岸本 浩行, 永坂 岳司, 西崎 正彦, 香川 俊輔, 今村 健志, 藤原 俊義

    日本癌学会総会記事   76回   S15 - 7   2017.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • Cancer associated fibroblasts promote tumor metastasis coexisting with cancer cells in blood circulation

    Hajime Kashima, Kazuhiro Noma, Hiroaki Sato, Yuki Katsura, Takuya Kato, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-5905

    Web of Science

    researchmap

  • Cancer-associated fibroblasts contribute to tumor immunosuppression by regulating tumor-infiltrating lymphocytes

    Takuya Kato, Kazuhiro Noma, Hajime Kashima, Yuki Katsura, Hiroaki Sato, Takayuki Ninomiya, Toshiaki Ohara, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-5934

    Web of Science

    researchmap

  • Tumorigenesis of murine iPS cell is prevented by iron depletion with downregulation of stemness markers

    Yuki Katsura, Toshiaki Ohara, Hajime Kashima, Hiroaki Sato, Takuya Kato, Takayuki Ninomiya, Kazuhiro Noma, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-925

    Web of Science

    researchmap

  • Fluorescence-guided spatiotemporal dynamics of epithelial-mesenchymal transition under inflammatory microenvironment during colorectal cancer progression

    Takeshi Ieda, Hiroshi Tazawa, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Takeshi Imamura, Toshiyoshi Fujiwara

    CANCER RESEARCH   77   2017.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2017-5809

    Web of Science

    researchmap

  • ePTFEを用いた新規カテーテル挿入補助デバイスの開発

    大原 利章, 櫻間 教文, 平松 聡, 野間 和広, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   117回   SF - 7   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • Spred-2欠損はGalN/LPS誘導性の急性肝障害を悪化させる(Spred-2 deficiency exacerbated GalN/LPS induced acute liver injury)

    楊 旭, 吉村 禎造, 藤澤 真義, 大原 利章, 佐藤 美和, 美野 愛, 松川 昭博

    日本病理学会会誌   106 ( 1 )   446 - 446   2017.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • polyI:CによるAktリン酸化抑制を介した腫瘍細胞の転移抑制機構(Poly I:C suppress migration of carcinoma cells by inhibiting Akt phosphorylation)

    山口 隆廣, 吉村 禎造, 大原 利章, 藤澤 真義, 松川 昭博

    日本病理学会会誌   106 ( 1 )   282 - 282   2017.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 除鉄はマウスiPS細胞の腫瘍化を未分化マーカーの発現制御を介して抑制する(Tumorigenesis of miPS cells is prevented from suppressing the stemness by iron depletion treatment)

    大原 利章, Xing Boyi, 桂 佑貴, 松川 昭博

    日本病理学会会誌   106 ( 1 )   405 - 405   2017.3

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 膀胱腫瘍におけるRas-ERK経路とその制御因子Spred-2の解析

    小田 晋輔, 藤澤 真義, 吉村 禎造, 大原 利章, 河原 明奈, 山口 隆廣, 太田 陽子, 松川 昭博

    日本病理学会会誌   106 ( 1 )   326 - 326   2017

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    J-GLOBAL

    researchmap

  • 鉄キレート剤による幹細胞性制御を介した新規癌幹細胞の治療法の開発

    桂佑貴, 友野靖子, 木村文昭, 大原利章, 大原利章

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   41st   2017

  • 癌関連線維芽細胞はIL-6を分泌しリンパ球の遊走を制御することで腫瘍免疫抑制を誘導する

    加藤卓也, 野間和広, 賀島肇, 桂佑貴, 佐藤浩明, 二宮卓之, 大原利章, 藤原俊義

    日本がん転移学会学術集会・総会プログラム抄録集   26th   2017

  • 医療現場から鉄を中心に癌および磁気的治療を考える

    大原利章

    日本磁気学会研究会資料   211th   2017

  • 癌関連線維芽細胞は食道癌のリンパ節転移を促進するか~臨床検体の解析と同所移植モデルを用いた検証~

    賀島肇, 野間和広, 佐藤浩明, 桂佑貴, 加藤卓也, 大原利章, 田澤大, 白川靖博, 藤原俊義

    日本がん転移学会学術集会・総会プログラム抄録集   26th   2017

  • 抗体結合磁性ナノ粒子による腫瘍選択的な細胞内温熱療法の開発

    香川 哲也, 岸本 浩行, 田澤 大, 大原 利章, 永坂 岳司, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   75回   P - 3307   2016.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 癌関連線維芽細胞(CAFs)が及ぼす腫瘍免疫逃避の解明 CAFsと腫瘍浸潤リンパ球の検討

    加藤 卓也, 野間 和広, 賀島 肇, 桂 佑貴, 二宮 卓之, 大原 利章, 田澤 大, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本癌学会総会記事   75回   E - 1068   2016.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 鉄代謝は癌幹細胞の新規治療ターゲットとなり得る

    大原 利章, 二宮 卓之, 桂 佑貴, 賀島 肇, 加藤 卓也, 野間 和広, 田澤 大, 藤原 俊義

    日本癌学会総会記事   75回   E - 1109   2016.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 炎症性微小環境によって誘導されるEMTの蛍光生細胞イメージングシステム

    家田 偉史, 田澤 大, 菊地 覚次, 黒田 新士, 大原 利章, 野間 和広, 岸本 浩行, 永坂 岳司, 西崎 正彦, 香川 俊輔, 今村 健志, 藤原 俊義

    日本癌学会総会記事   75回   J - 3053   2016.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 食道癌において癌関連繊維芽細胞が腫瘍転移に及ぼす影響の検証

    賀島 肇, 野間 和広, 桂 佑貴, 加藤 卓也, 勝部 亮一, 二宮 卓之, 大原 利章, 田澤 大, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本癌学会総会記事   75回   P - 3151   2016.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 外科における基礎的研究 セレンディピティーを求めて 鉄コントロールによる新規癌幹細胞治療

    二宮 卓之, 大原 利章, 桂 佑貴, 賀島 肇, 加藤 卓也, 野間 和広, 田辺 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会   71回 ( Supplement1 )   WS7 - 2   2016.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • A novel live imaging system for inflammation-induced epithelial-mesenchymal transition in colorectal cancers

    Takeshi Ieda, Hiroshi Tazawa, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-1613

    Web of Science

    researchmap

  • Prognostic correlation of tumor-infiltrating lymphocytes (TILs) and cancer associated fibroblasts (CAFs) in patients with human esophageal carcinoma

    Takuya Kato, Kazuhiro Noma, Yuki Katsura, Hajime Kashima, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-4160

    Web of Science

    researchmap

  • Iron control is a novel therapeutic target of cancer stem cells

    Toshiaki Ohara, Takayuki Ninomiya, Kazuhiro Noma, Hajime Kashima, Yuki Katsura, Takuya Kato, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-2510

    Web of Science

    researchmap

  • Correlation of FAP(fibroblast activation protein)-expressing cancer associated fibroblasts (CAFs) and tumor metastasis in esophageal carcinoma

    Hajime Kashima, Kazuhiro Noma, Yuki Katsura, Takuya Kato, Ryoichi Katsube, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   76   2016.7

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2016-1560

    Web of Science

    researchmap

  • 滅菌可能なカフ型カテーテル事前設定装置の有用性の検討(第1報)

    櫻間 教文, 平松 聡, 大原 利章

    日本透析医学会雑誌   49 ( Suppl.1 )   544 - 544   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    J-GLOBAL

    researchmap

  • 膀胱腫瘍におけるRas-Raf-ERK経路とその制御因子Spred-2の解析

    小田 晋輔, 藤澤 真義, 吉村 禎造, 大原 利章, 河原 明奈, 山口 隆廣, 太田 陽子, 松川 昭博

    日本病理学会会誌   105 ( 1 )   464 - 464   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    J-GLOBAL

    researchmap

  • 臨床病態に近い不均一性とがん幹細胞性を備えた新規腫瘍モデルの開発

    大原 利章, 友野 靖子, 吉村 禎造, 藤澤 真義, 松川 昭博

    日本病理学会会誌   105 ( 1 )   365 - 365   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    J-GLOBAL

    researchmap

  • Spred-2欠損はGalN/LPS誘導性の急性腎障害を悪化させる(Spred-2 deficiency exacerbates D-Galactosamine/lipopolysaccharide -induced acute liver injury)

    楊 旭, 吉村 禎造, 藤澤 真義, 大原 利章, 山口 隆廣, サン・タ・テ, 小田 晋輔, 佐藤 美和, 美野 愛, 松川 昭博

    日本病理学会会誌   105 ( 1 )   449 - 450   2016.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 鉄コントロールによる新規がん幹細胞治療

    二宮 卓之, 大原 利章, 加藤 卓也, 賀島 肇, 野間 和広, 田澤 大, 田辺 俊介, 香川 俊輔, 白川 靖博, 藤原 俊義

    日本外科学会定期学術集会抄録集   116回   PS - 8   2016.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • ミャンマーの乳がんの組織学的側面(Histologic Profile of Breast Cancer in Myanmar)

    サン・タ・テ, 藤澤 真義, 伏見 聡一郎, イー・ミント・ミント, Yang Xu, Aye Moh Moh Aung, 渡邉 治之, 荒嶋 康晴, 大原 利章, 松川 昭博

    日本病理学会会誌   105 ( 1 )   566 - 566   2016.4

     More details

    Language:English   Publisher:(一社)日本病理学会  

    researchmap

  • 低分子化合物および未利用資源によるプラントアクティベーターの開発研究

    鳴坂義弘, 山次康幸, 大原利章, 鳴坂真理

    日本植物病理学会大会プログラム・講演要旨予稿集   2016   2016

  • 癌関連線維芽細胞が食道癌の浸潤と転移に及ぼす影響の検証

    賀島肇, 野間和広, 桂佑貴, 加藤卓也, 大原利章, 田澤大, 白川靖博, 香川俊輔, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   27th   2016

  • 環境にやさしい病害防除剤プラントアクティベーターの開発研究

    鳴坂義弘, 山次康幸, 大原利章, 吉岡博文, 鳴坂真理

    日本植物細胞分子生物学会大会・シンポジウム講演要旨集   34th   2016

  • 肝臓がんへ分化するがん幹細胞モデルの作成

    堤 愛姫, 竹尻 崇人, 水谷 昭文, Vaidyanath Arun, 大原 利章, 岩崎 良章, 笠井 智成, 妹尾 昌治

    日本生化学会大会・日本分子生物学会年会合同大会講演要旨集   88回・38回   [2P1127] - [2P1127]   2015.12

     More details

    Language:Japanese   Publisher:(公社)日本生化学会  

    researchmap

  • 日本外科学会禁煙宣言作成に携わって

    大原 利章

    日本禁煙学会学術総会プログラム・抄録集   9回   165 - 165   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本禁煙学会  

    researchmap

  • ヒト癌細胞におけるEMT可視化生体イメージング技術の開発

    家田 偉史, 田澤 大, 菊池 覚次, 黒田 新士, 大原 利章, 野間 和広, 岸本 浩行, 永坂 岳司, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   74回   P - 2028   2015.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 鉄コントロールによる新規がん幹細胞治療

    二宮 卓之, 大原 利章, 勝部 亮一, 賀島 肇, 加藤 卓也, 野間 和広, 田澤 大, 香川 俊輔, 水谷 昭文, 笠井 智成, 妹尾 昌治, 藤原 俊義

    日本癌学会総会記事   74回   IS4 - 6   2015.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • A novel photoimmunotherapy targeting cancer-associated fibroblasts (CAFs) overcomes therapeutic resistance in human esophageal cancer

    Ryoichi Katsube, Kazuhiro Noma, Shinichiro Watanabe, Shinichi Urano, Takayuki Ninomiya, Toshiaki Ohara, Hiroshi Tazawa, Shunsuke Kagawa, Hisataka Kobayashi, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-401

    Web of Science

    researchmap

  • Iron control is a novel therapeutic target of cancer stem cells

    Takayuki Ninomiya, Toshiaki Ohara, Hajime Kashima, Ryoichi Katsube, Kazuhiro Noma, Yasuko Tomono, Akifumi Mizutani, Tomonari Kasai, Masaharu Seno, Shinji Kuroda, Hiroyuki Kishimoto, Hiroshi Tazawa, Yasuhiro Shirakawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   75   2015.8

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2015-4243

    Web of Science

    researchmap

  • 当科における食道憩室手術症例の検討

    賀島 肇, 白川 靖博, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   70回 ( Supplement1 )   P - 5   2015.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • その他 鉄コントロールによるがん幹細胞に対する新規治療

    二宮 卓之, 大原 利章, 浦野 真一, 勝部 亮一, 野間 和広, 田澤 大, 白川 靖博, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   OP - 7   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 上部消化管 超高齢者食道癌手術への取り組みと放射線併用ウイルス療法の可能性

    田辺 俊介, 白川 靖博, 賀島 肇, 国府島 健, 前田 直見, 大原 利章, 黒田 新士, 櫻間 教文, 野間 和広, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会定期学術集会抄録集   115回   OP - 2   2015.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 鉄コントロールを用いた新規がん幹細胞治療法の基礎的検討

    大原 利章, 伏見 総一郎, 松川 昭博

    日本病理学会会誌   104 ( 1 )   283 - 283   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    J-GLOBAL

    researchmap

  • 限局性皮質異形成と皮質結節(結節性硬化症)との鑑別が問題になった一例

    太田陽子, 山口隆廣, 小田晋輔, 河原明奈, 板倉淳哉, 伏見聡一郎, 大原利章, 平麻美, 宮田元, 松川昭博

    日本病理学会会誌   104 ( 1 )   2015

  • 鉄制御を用いた新しい癌の浸潤・転移抑制治療法の開発

    大原利章, 大原利章, 二宮卓之, 野間和広, 賀島肇, 加藤卓也, 勝部亮一, 白川靖博, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   26th   2015

  • 肝細胞癌に対する除鉄剤の臨床投与経験

    大原利章, 二宮卓之, 友野靖子, 木村文昭

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   39th   2015

  • 癌関連線維芽細胞を標的とした新規食道癌治療法の開発

    勝部亮一, 野間和広, 賀島肇, 加藤卓也, 二宮卓之, 大原利章, 田澤大, 白川靖博, 香川俊輔, 小林久隆, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   26th   2015

  • 食道癌におけるFAP(fibroblast activation protein)陽性癌関連線維芽細胞の発現と癌転移の関係

    賀島肇, 野間和広, 加藤卓也, 勝部亮一, 二宮卓之, 大原利章, 田澤大, 白川靖博, 香川俊輔, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   26th   2015

  • 新規鉄キレート剤スーパーポリフェノールの抗腫瘍効果についての基礎的検討

    友野靖子, 二宮卓之, 木村文昭, 大原利章, 大原利章

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   39th   2015

  • 鉄コントロールによるがん幹細胞治療

    二宮卓之, 友野靖子, 木村文昭, 大原利章

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   39th   2015

  • Iron chelation therapy increased the anticancer effect of sorafenib in hepatocarcinoma

    Shinichi Urano, Toshiaki Ohara, Ryoichi Katsube, Shinichiro Watanabe, Kazuhiro Noma, Yasuko Tomono, Hiroshi Tazawa, Kazuhiro Nouso, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   74 ( 19 )   2014.10

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2014-1681

    Web of Science

    researchmap

  • 鉄キレート療法は肝癌におけるソラフェニブの抗腫瘍効果を増強する(Iron chelation therapy enhances the anticancer effect of sorafenib in hepatocarcinoma)

    浦野 真一, 大原 利章, 勝部 亮一, 野間 和広, 友野 靖子, 田澤 大, 能祖 一裕, 白川 靖博, 藤原 俊義

    日本癌学会総会記事   73回   P - 2328   2014.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 鉄コントロールによるがん幹細胞の新規治療法(Iron control is a potent novel therapeutic for cancer stem cells)

    二宮 卓之, 大原 利章, 浦野 真一, 勝部 亮一, 野間 和広, 田澤 大, 香川 俊輔, 水谷 昭文, 笠井 智成, 妹尾 昌治, 藤原 俊義

    日本癌学会総会記事   73回   P - 1187   2014.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 食道癌の悪性化に対するCAF標的光免疫療法の開発(Development of novel strategy of targeting cancer associated fibroblast (CAFs) for resistant esophageal cancer)

    勝部 亮一, 野間 和広, 渡邉 伸一郎, 浦野 真一, 二宮 卓之, 大原 利章, 白川 靖博, 田澤 大, 香川 俊輔, 小林 久隆, 藤原 俊義

    日本癌学会総会記事   73回   P - 3157   2014.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 鏡視下手術及び多職種による周術期管理による80歳以上超高齢者食道癌症例に対する手術成績向上の取り組み

    田邊 俊介, 白川 靖博, 国府島 健, 前田 直見, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   69回 ( Supplement1 )   O - 1   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 食道切除・再建術におけるリスク評価と治療成績向上に向けた対策 食食道癌術前の呼吸機能管理目標設定とチーム介入の成果

    大原 利章, 白川 靖博, 國府島 健, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   69回 ( Supplement1 )   PD - 12   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 進行食道癌による食道狭窄に起因した経口摂取困難症例に対して、PEGを用いた術前栄養療法の有用性

    國府島 健, 白川 靖博, 前田 直見, 田邊 俊介, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   69回 ( Supplement1 )   P - 3   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 小児領域における噴門形成術の検討

    尾山 貴徳, 野田 卓男, 木村 圭佑, 前田 直見, 大原 利章, 田邊 俊輔, 野間 和広, 西崎 正彦, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   48 - 48   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 鏡視下手術導入と多職種組織横断的周術期管理による高齢者食道癌手術への取り組み

    田辺 俊介, 白川 靖博, 國府島 健, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   78 - 78   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • cT1bN0M0 cStage I食道癌に対する外科治療についての検討

    白川 靖博, 國府島 健, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   83 - 83   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 食道癌手術患者の術前胸郭拡張差についての基礎的検討

    大原 利章, 白川 靖博, 國府島 健, 前田 直見, 田辺 俊介, 野間 和広, 岩井 賢司, 伊藤 真理, 足羽 孝子, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   99 - 99   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 食道がん手術患者の集中治療体験とその後の心理状態<第二報>

    足羽 孝子, 伊藤 真理, 岩谷 美貴子, 國府島 健, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   131 - 131   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 食道癌手術における歯科の役割

    山中 玲子, 曽我 賢彦, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 白川 靖博, 森松 博史, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   145 - 145   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 局所進行食道癌に対する治療戦略

    前田 直見, 白川 靖博, 國府島 健, 大原 利章, 田邊 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   155 - 155   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 当科におけるバレット食道表在癌の治療経験

    野間 和広, 白川 靖博, 国府島 健, 前田 直見, 大原 利章, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   176 - 176   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 頸部食道癌の治療戦略 喉頭温存を目指して

    國府島 健, 白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   68回   188 - 188   2014.7

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 当科における食道胃接合部癌の経験および治療戦略

    野間 和広, 白川 靖博, 国府島 健, 前田 直見, 大原 利章, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   69回 ( Supplement1 )   O - 2   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 食道癌手術における安全な吻合法 空腸を用いた食道再建及び吻合の工夫 全例に血管吻合が必要か?

    白川 靖博, 國府島 健, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   69回 ( Supplement1 )   VSY - 8   2014.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 消化器外科領域におけるマイクロサージェリー 空腸を用いた食道再建おけるマイクロサージェリーの適応とその工夫

    白川 靖博, 國府島 健, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科系連合学会誌   39 ( 3 )   506 - 506   2014.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    J-GLOBAL

    researchmap

  • 食道癌の狭窄による経口摂取困難症例に対するPEGを用いた術前管理の利点

    田辺 俊介, 白川 靖博, 國府島 健, 前田 直見, 勝部 亮一, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    Gastroenterological Endoscopy   56 ( Suppl.1 )   1220 - 1220   2014.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    J-GLOBAL

    researchmap

  • OP-036-7 食道癌周術期における外科医の負担軽減に対しチーム医療が果たした役割(OP-036 周術期管理 術後合併症・その他,一般演題,第114回日本外科学会定期学術集会)

    白川 靖博, 二宮 卓之, 前田 直見, 大原 利章, 田辺 俊助, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   379 - 379   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-099-2 肝臓癌における除鉄併用分子標的薬治療の可能性(OP-099 肝 肝細胞癌-1,一般演題,第114回日本外科学会定期学術集会)

    浦野 真一, 大原 利章, 白川 靖博, 勝部 亮一, 前田 直見, 田辺 俊介, 友野 靖子, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   489 - 489   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-052-4 がん関連線維芽細胞(Cancer Associated Fibroblasts)を標的とした新規癌治療法の開発(PS-052 食道 基礎-2,ポスターセッション,第114回日本外科学会定期学術集会)

    野間 和広, 白川 靖博, 二宮 卓之, 勝部 亮一, 前田 直見, 田辺 俊介, 大原 利章, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   678 - 678   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • OP-084-4 高度狭窄を伴う進行食道癌患者におけるPEGを用いた術前栄養管理の効果 : 術前後筋肉量変化に着目して(OP-084 食道 周術期管理,一般演題,第114回日本外科学会定期学術集会)

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 2 )   464 - 464   2014.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • がん関連線維芽細胞(Cancer Associated Fibroblasts)を標的とした新規癌治療法の開発

    野間 和広, 白川 靖博, 二宮 卓之, 勝部 亮一, 前田 直見, 田辺 俊介, 大原 利章, 田澤 大, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   678 - 678   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 肝臓癌における除鉄併用分子標的薬治療の可能性

    浦野 真一, 大原 利章, 白川 靖博, 勝部 亮一, 前田 直見, 田辺 俊介, 友野 靖子, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   489 - 489   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 食道癌周術期における外科医の負担軽減に対しチーム医療が果たした役割

    白川 靖博, 二宮 卓之, 前田 直見, 大原 利章, 田辺 俊助, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   379 - 379   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 高度狭窄を伴う進行食道癌患者におけるPEGを用いた術前栄養管理の効果 術前後筋肉量変化に着目して

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科学会雑誌   115 ( 臨増2 )   464 - 464   2014.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • A Case of Advanced Esophageal Cancer with Pulmonary Hypertention due to Atrial Septal Defect

    FUJITA Toshihiko, OHARA Toshiaki, TANABE Shunsuke, NOMA Kazuhiro, SHIRAKAWA Yasuhiro, FUJIWARA Toshiyoshi

    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)   75 ( 2 )   384 - 387   2014.2

     More details

    Language:Japanese   Publisher:Japan Surgical Association  

    A 62-year-old man was detected to have advanced esophageal cancer with pulmonary hypertension (PH) due to atrial septal defect (ASD). We planned to perform radical repair of ASD and neoadjuvant chemotherapy before esophagectomy. However, he went into shock with melena by using an anticoagulant before cardiac catheterization. Endoscopic examination showed hemorrhage from the esophageal tumor, which suggested that ASD repair should be preceded by esophagectomy to remove the hemorrhage source. After esophagectomy, circulatory dynamics was unstable. Pulmonary arterial pressure (PAP) temporarily exceeded arterial pressure (AP) with coughing on the second day after the operation. Strict management with infusion and administration of vasopressin led to stable circulatory dynamics. However, unstable dynamics seemed to recur and we decided to repair ASD. Amplatzer Septal Occluder was inserted with intra cardiac echocardiography (ICE) because trans-esophageal echocardiography could not be used. After amplazter insertion, he became in good condition and was transferred to POD another hospital on 20.

    DOI: 10.3919/jjsa.75.384

    CiNii Article

    CiNii Books

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J03156&link_issn=&doc_id=20140306070009&doc_link_id=10.3919%2Fjjsa.75.384&url=https%3A%2F%2Fdoi.org%2F10.3919%2Fjjsa.75.384&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 進行食道癌狭窄症例に対する術前栄養管理 経鼻胃管からPEGへの変遷

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 長谷川 祐子, 平 健太郎, 名和 秀起, 岡田 恵子, 坂本 八千代, 藤原 俊義

    静脈経腸栄養   29 ( 1 )   552 - 552   2014.1

     More details

    Language:Japanese   Publisher:(株)ジェフコーポレーション  

    J-GLOBAL

    researchmap

  • 癌関連線維芽細胞を標的とした光線免疫療法の開発

    野間和広, 勝部亮一, 浦野真一, 大原利章, 白川靖博, 藤原俊義

    日本がん転移学会学術集会・総会プログラム抄録集   23rd   2014

  • 固形癌に対する除鉄誘導による血管新生阻害薬併用療法の確立

    大原利章, 木村文昭, 浦野真一, 二宮卓之, 勝部亮一, 野間和広, 友野靖子, 藤原俊義, 松川昭博

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   38th   2014

  • 腹臥位胸腔鏡下食道亜全摘のための新しい解剖教材の開発 多視点3D解剖システム

    前田 直見, 白川 靖博, 二宮 卓之, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   508 - 508   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 当科における進行食道癌における合理的胸腔鏡下手術の試み

    野間 和広, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   549 - 549   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 胸部食道癌に対する合理的縦隔郭清 腹臥位胸腔鏡下食道切除術における縦隔リンパ節郭清での助手による積極的術野展開とその定型化

    白川 靖博, 二宮 卓之, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   339 - 339   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 80歳以上の超高齢者食道癌症例に対する胸腔鏡下手術の現況

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   18 ( 7 )   502 - 502   2013.11

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 鉄欠乏状態は肝細胞癌におけるソラフェニブの感受性を改善しうる(Iron depletion status has a possibility to improve the sensitivity of sorafenib in HCC)

    浦野 真一, 大原 利章, 勝部 亮一, 渡邉 伸一郎, 野間 和広, 友野 靖子, 田澤 大, 能祖 一裕, 白川 靖博, 貞森 裕, 藤原 俊義

    日本癌学会総会記事   72回   345 - 345   2013.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 吻合、再建の手術手技(食道) 当科における食道胃管吻合の変遷とその工夫

    白川 靖博, 二宮 卓之, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   360 - 360   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 食道癌に対するESDの適応と限界 食道癌ESD後再発症例から考えるESDの適応と補助治療のあり方について

    田辺 俊介, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   369 - 369   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • がん関連線維芽細胞を標的とした新たな癌治療法の可能性 光線免疫療法を用いて(Novel cancer therapy targeting cancer-associated fibroblasts(CAFs) by targeted infrared photoimmunotherapy(PIT))

    勝部 亮一, 野間 和広, 渡邉 伸一郎, 浦野 真一, 大原 利章, 白川 靖博, 田澤 大, 香川 俊輔, 小林 久隆, 藤原 俊義

    日本癌学会総会記事   72回   349 - 350   2013.10

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 周術期管理におけるチーム医療の現状と展望 食道癌低肺機能患者に対する術前呼吸器チーム医療

    大原 利章, 白川 靖博, 前田 直見, 二宮 卓之, 田辺 俊介, 櫻間 教史, 野間 和広, 藤原 俊儀

    日本臨床外科学会雑誌   74 ( 増刊 )   405 - 405   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 食道癌のサルベージ手術(適応と手技と成績と) 当科における食道癌サルベージ手術の検討

    前田 直見, 白川 靖博, 二宮 卓之, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   413 - 413   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 食道胃接合部癌の手術 当科における食道胃接合部癌の治療経験 郭清範囲と再建法について

    野間 和広, 白川 靖博, 前田 直見, 二宮 卓之, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊介, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   467 - 467   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 食道癌患者のより良い周術期医療のために歯科はどのような貢献ができるのか? 周術期管理センター(PERIO)

    山中 玲子, 曽我 賢彦, 前田 直見, 田辺 俊介, 大原 利章, 野間 和広, 白川 靖博, 森田 学, 佐藤 健治, 森松 博史, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   478 - 478   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • Zenker憩室症の8例

    二宮 卓之, 田辺 俊介, 前田 直見, 大原 利章, 野間 和広, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌   74 ( 増刊 )   842 - 842   2013.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 除鉄を用いた新たな肝細胞癌治療

    大原 利章, 野間 和広, 浦野 真一, 前田 直見, 二宮 卓之, 田辺 俊介, 友野 靖子, 能祖 一裕, 白川 靖博, 貞森 裕, 木村 文昭, 藤原 俊儀

    日本癌治療学会誌   48 ( 3 )   1949 - 1949   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    J-GLOBAL

    researchmap

  • Iron-controlled cancer therapy: A new concept for anti-angiogenic drug (bevacizumab and sorafenib)

    T. Ohara, K. Noma, S. Urano, R. Katsube, T. Ninomiya, S. Tanabe, Y. Tomono, H. Tazawa, Y. Shirakawa, T. Fujiwara

    EUROPEAN JOURNAL OF CANCER   49   S639 - S639   2013.9

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:ELSEVIER SCI LTD  

    Web of Science

    researchmap

  • 透視を用いず位置確認が可能な内視鏡的バルーン拡張術の工夫

    田辺 俊介, 白川 靖博, 前田 直見, 勝部 亮一, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    Gastroenterological Endoscopy   55 ( Suppl.2 )   2890 - 2890   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    J-GLOBAL

    researchmap

  • 当科における腹臥位胸腔鏡下食道切除術定型化の工夫

    青山 克幸, 白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   68回 ( Supplement1 )   O - 6   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 胸部食道癌のよりよい周術期管理を目指して PERIOと鏡視下手術の融合

    白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   68回 ( Supplement1 )   O - 1   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 患者負担軽減のためのPEGを用いた食道癌術前補助栄養療法の現状について

    勝部 亮一, 白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和宏, 藤原 俊義

    日本消化器外科学会総会   68回 ( Supplement1 )   RS - 1   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 除鉄効果を利用した新たな消化器癌治療

    大原 利章, 白川 靖博, 浦野 真一, 前田 直見, 勝部 亮一, 渡辺 伸一郎, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊儀

    日本消化器外科学会総会   68回 ( Supplement1 )   P - 8   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 当科における低侵襲再建術の試み 用手補助的腹腔鏡下胃管作製の60例の検討

    前田 直見, 白川 靖博, 勝部 亮一, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   68回 ( Supplement1 )   RV - 3   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 胃が使用できない食道癌症例における空腸による食道再建術の工夫 血管吻合は全例に必要か?

    渡邊 伸一郎, 白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本消化器外科学会総会   68回 ( Supplement1 )   RV - 5   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 食道胃接合部癌の外科治療戦略 当科における食道胃接合部癌の治療経験 下縦隔リンパ節転移症例の検討

    野間 和広, 白川 靖博, 前田 直見, 勝部 亮一, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本消化器外科学会総会   68回 ( Supplement1 )   PD - 5   2013.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 食道癌における予後延長効果を目指した治療戦略新規としてのmTOR阻害剤(テムシロリムス)の可能性

    高岡 宗徳, 西川 敏雄, 大原 利章, 深澤 拓也, 林 次郎, 繁光 薫, 浦上 淳, 吉田 和弘, 山辻 知樹, 猶本 良夫

    日本消化器外科学会総会   68回 ( Supplement1 )   RS - 2   2013.7

     More details

    Language:English   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 食道原発小細胞癌及び食道原発悪性黒色腫の治療における手術療法の位置付け

    前田 直見, 白川 靖博, 勝部 亮一, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   240 - 240   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 当科での腹臥位胸腔鏡下食道切除術における助手操作定型化の工夫

    白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   186 - 186   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 当科における空腸を用いた食道再建術の工夫

    白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   190 - 190   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 進行食道癌に対する術前化学療法の現況 DCFの位置づけを中心に

    田辺 俊介, 白川 靖博, 前田 直見, 勝部 亮一, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   193 - 193   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 当科における食道胃接合部がんの治療経験 下縦隔廓清と再建法について

    野間 和広, 白川 靖博, 前田 直見, 勝部 亮一, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   200 - 200   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 食道がん手術患者の集中治療体験とその後の心理状態(第一報)

    伊藤 真理, 足羽 孝子, 岩谷 美貴子, 前田 直見, 勝部 亮一, 大原 利章, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   223 - 223   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 地域一体型NSTの取り組みと効果について

    西川 みか, 櫻間 教文, 多田 仁美, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   224 - 224   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    researchmap

  • 食道癌手術患者の術前禁煙に対する医療連携による包括的取り組みとその効果

    大原 利章, 白川 靖博, 前田 直見, 勝部 亮一, 田辺 俊介, 野間 和広, 櫻間 教文, 伊藤 真理, 足羽 孝子, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   67回   229 - 229   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 食道癌手術の周術期管理におけるチーム医療 当院での胸部食道癌周術期管理におけるPERIO導入についての検討

    白川 靖博, 勝部 亮一, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本外科系連合学会誌   38 ( 3 )   605 - 605   2013.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    J-GLOBAL

    researchmap

  • Novel photoimmunotherapy (PIT) targeting cancer-associated fibroblasts (CAFs) for esophageal cancer.

    Shinichiro Watanabe, Kazuhiro Noma, Shinichi Urano, Toshiaki Ohara, Yuuri Hashimoto, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   73 ( 8 )   2013.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2013-4946

    Web of Science

    researchmap

  • Iron depletion by deferasirox have a synergistic effect on sorafenib in hepatocellular carcinoma.

    Shinichi Urano, Toshiaki Ohara, Shinichiro Watanabe, Kazuhiro Noma, Yasuko Tomono, Hiroshi Tazawa, Masafumi Kataoka, Nouso Kazuhiro, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   73 ( 8 )   2013.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2013-5608

    Web of Science

    researchmap

  • PS-164-4 血清鉄コントロールによる食道癌細胞の浸潤・転移能制御の可能性(PS ポスターセッション,第113回日本外科学会定期学術集会)

    浦野 真一, 野間 和広, 大原 利章, 西谷 正史, 前田 直見, 渡邉 伸一郎, 田辺 俊介, 櫻間 教文, 友野 靖子, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   747 - 747   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-265-5 高リスクGIST症例の検討 : 無作為化比較試験SSGX VIII/AIOの報告をうけて(PS ポスターセッション,第113回日本外科学会定期学術集会)

    宇野 太, 永坂 岳司, 香川 俊輔, 西崎 正彦, 岸本 浩行, 黒田 新士, 石田 道拡, 青山 克幸, 稲田 涼, 前田 直見, 大原 利章, 近藤 喜太, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   891 - 891   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-082-3 血清鉄コントロールを用いた新たな肝細胞癌治療戦略(PS ポスターセッション,第113回日本外科学会定期学術集会)

    大原 利章, 白川 靖博, 浦野 真一, 前田 直見, 渡邊 伸一郎, 田辺 俊介, 野間 和広, 能祖 一裕, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   634 - 634   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • VF-034-1 腹臥位胸腔鏡下食道亜全摘術においてEndoCAMeleonがもたらした新たな視野展開(VF ビデオフォーラム,第113回日本外科学会定期学術集会)

    野間 和広, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   451 - 451   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • WS-12-1-2 当科における80歳以上の超高齢者食道癌症例に対する外科治療の変遷(WS ワークショップ,第113回日本外科学会定期学術集会)

    田辺 俊介, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   114 ( 2 )   317 - 317   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-285-5 パラチノースを主糖質源とした流動食MHN-01を用いた食道癌周術期管理の意義(PS ポスターセッション,第113回日本外科学会定期学術集会)

    山辻 知樹, 田村 卓也, 小池 良和, 平林 葉子, 高岡 宗徳, 深澤 拓也, 林 次郎, 繁光 薫, 浦上 淳, 吉田 和弘, 大原 利章, 田辺 俊介, 藤原 康宏, 櫻間 教文, 野間 和広, 白川 靖博, 羽井 佐実, 中島 一毅, 森田 一郎, 藤原 俊義, 猶本 良夫

    日本外科学会雑誌   114 ( 2 )   919 - 919   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • PS-069-1 腹膜播種転移の形成過程におけるfocal adhesion kinase(FAK)の関与とFAK分子標的による治療戦略の可能性(PS ポスターセッション,第113回日本外科学会定期学術集会)

    高岡 宗徳, 桜間 教文, 大原 利章, 深澤 拓也, 山辻 知樹, 平林 葉子, 林 次郎, 繁光 薫, 浦上 淳, 吉田 和弘, 中島 一毅, 森田 一郎, 猶本 良夫

    日本外科学会雑誌   114 ( 2 )   614 - 614   2013.3

     More details

    Language:Japanese   Publisher:一般社団法人日本外科学会  

    CiNii Article

    CiNii Books

    researchmap

  • パラチノースを主糖質源とした流動食MHN-01を用いた食道癌周術期管理の意義

    山辻 知樹, 田村 卓也, 小池 良和, 平林 葉子, 高岡 宗徳, 深澤 拓也, 林 次郎, 繁光 薫, 浦上 淳, 吉田 和弘, 大原 利章, 田辺 俊介, 藤原 康宏, 櫻間 教文, 野間 和広, 白川 靖博, 羽井佐 実, 中島 一毅, 森田 一郎, 藤原 俊義, 猶本 良夫

    日本外科学会雑誌   114 ( 臨増2 )   919 - 919   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 超高齢者に対する外科治療の問題点 消化管外科、術式の選択 当科における80歳以上の超高齢者食道癌症例に対する外科治療の変遷

    田辺 俊介, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   317 - 317   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 腹臥位胸腔鏡下食道亜全摘術においてEndoCAMeleonがもたらした新たな視野展開

    野間 和広, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   451 - 451   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 腹膜播種転移の形成過程におけるfocal adhesion kinase(FAK)の関与とFAK分子標的による治療戦略の可能性

    高岡 宗徳, 桜間 教文, 大原 利章, 深澤 拓也, 山辻 知樹, 平林 葉子, 林 次郎, 繁光 薫, 浦上 淳, 吉田 和弘, 中島 一毅, 森田 一郎, 猶本 良夫

    日本外科学会雑誌   114 ( 臨増2 )   614 - 614   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 血清鉄コントロールを用いた新たな肝細胞癌治療戦略

    大原 利章, 白川 靖博, 浦野 真一, 前田 直見, 渡邊 伸一郎, 田辺 俊介, 野間 和広, 能祖 一裕, 貞森 裕, 八木 孝仁, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   634 - 634   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 血清鉄コントロールによる食道癌細胞の浸潤・転移能制御の可能性

    浦野 真一, 野間 和広, 大原 利章, 西谷 正史, 前田 直見, 渡邉 伸一郎, 田辺 俊介, 櫻間 教文, 友野 靖子, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   747 - 747   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 高リスクGIST症例の検討 無作為化比較試験SSGXVIII/AIOの報告をうけて

    宇野 太, 永坂 岳司, 香川 俊輔, 西崎 正彦, 岸本 浩行, 黒田 新士, 石田 道拡, 青山 克幸, 稲田 涼, 前田 直見, 大原 利章, 近藤 喜太, 田辺 俊介, 野間 和広, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   114 ( 臨増2 )   891 - 891   2013.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 病期診断に難渋した早期食道癌の一例 術前PET-CT偽陽性症例の検討

    山辻 知樹, 平林 葉子, 高岡 宗徳, 深澤 拓也, 繁光 薫, 林 次郎, 浦上 淳, 吉田 和弘, 中島 一毅, 森田 一郎, 大原 利章, 田辺 俊介, 櫻間 教文, 野間 和広, 白川 靖博, 藤原 俊義, 河本 博文, 猶本 良夫

    Gastroenterological Endoscopy   55 ( Supplement 1 )   1160 - 1160   2013

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    J-GLOBAL

    researchmap

  • 予後および病態評価が可能な新規食道癌同所移植性モデル

    大原利章, 白川靖博, 野間和広, 浦野真一, 前田直見, 田辺俊介, 櫻間教文, 田澤大, 藤原俊義

    日本消化器癌発生学会総会プログラム・抄録集   24th   2013

  • 肝臓癌における除鉄併用ソラフェニブ療法の可能性

    浦野真一, 大原利章, 勝部亮一, 友野靖子, 木村文昭, 野間和広, 白川靖博, 藤原俊義

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   37th   2013

  • 鉄代謝を利用した新規分子標的薬併用療法

    浦野真一, 大原利章, 白川靖博, 野間和広, 前田直見, 田辺俊介, 櫻間教文, 田澤大, 藤原俊儀

    日本消化器癌発生学会総会プログラム・抄録集   24th   2013

  • Non-recurrent inferior laryngeal nerveを伴う胸部食道癌に対して胸腔鏡下食道亜全摘を施行した1例

    前田 直見, 白川 靖博, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本内視鏡外科学会雑誌   17 ( 7 )   696 - 696   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 内視鏡外科におけるチーム医療の在り方 食道癌鏡視下手術の周術期におけるチーム医療の関わり

    白川 靖博, 青山 克幸, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本内視鏡外科学会雑誌   17 ( 7 )   313 - 313   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 我々の目指すチーム内視鏡外科 当科における腹臥位胸腔鏡下食道亜全摘における術者助手のコラボレーション

    野間 和広, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 田辺 俊介, 香川 俊輔, 藤原 俊義

    日本内視鏡外科学会雑誌   17 ( 7 )   604 - 604   2012.12

     More details

    Language:Japanese   Publisher:(一社)日本内視鏡外科学会  

    researchmap

  • 出血性ショックをきたした回腸静脈瘤破裂に対しバルーン下逆行性経静脈的塞栓術(BRTO)が奏功した1例

    濱田 侑紀, 竹原 裕子, 竹原 清人, 大原 利章, 近藤 喜太, 永坂 岳司, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   1084 - 1084   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌手術における再建法の安全性とQOL 胃が使用できない食道癌症例におけるQOL向上を目指した腸管による食道再建法

    田辺 俊介, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   383 - 383   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • チームで乗り切る食道癌手術(当院での周術期管理センター:PERIOの取り組み)

    白川 靖博, 青山 克幸, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   481 - 481   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 当科における食道胃接合部癌に対する再建法の工夫 胸腔内観音開き法吻合の経験

    野間 和広, 白川 靖博, 青山 克幸, 前田 直見, 大原 利章, 田辺 俊介, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   525 - 525   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 低肺機能合併の胸部食道癌症例に対する腹臥位胸腔鏡下食道切除の経験

    前田 直見, 白川 靖博, 青山 克幸, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   706 - 706   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • Zenker憩室に合併した頸部食道表在癌の1例

    大原 利章, 白川 靖博, 青山 克幸, 前田 直見, 田辺 俊介, 櫻間 教文, 野間 和広, 藤原 俊義

    日本臨床外科学会雑誌   73 ( 増刊 )   945 - 945   2012.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 癌関連線維芽細胞が食道癌の増殖に寄与する(Cancer-associated fibroblasts contribute to progression of esophageal cancer)

    渡邉 伸一郎, 野間 和広, 浦野 真一, 大原 利章, 橋本 悠里, 田澤 大, 藤原 俊義

    日本癌学会総会記事   71回   143 - 143   2012.8

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 当科におけるBarrett食道癌手術症例の検討

    野間 和広, 白川 靖博, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   67回 ( Supplement1 )   1 - 1   2012.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 当科における胸部食道癌に対する鏡視下手術導入の成果についての検討

    白川 靖博, 前田 直見, 田辺 俊介, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   67回 ( Supplement1 )   1 - 1   2012.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 喫煙食道癌患者の治療マネジメント

    大原 利章, 白川 靖博, 前田 直見, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本消化器外科学会総会   67回 ( Supplement1 )   2 - 2   2012.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 耐術能を有する超高齢者は胃癌に対する手術の意義が示唆される

    香川 俊輔, 宇野 太, 岸本 浩行, 西崎 正彦, 白川 靖博, 永坂 岳司, 野間 和広, 田辺 俊介, 近藤 喜太, 大原 利章

    日本消化器外科学会総会   67回 ( Supplement1 )   3 - 3   2012.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 当科における高齢者食道癌症例の治療への取り組み

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 野間 和広, 櫻間 教文, 足羽 孝子, 伊藤 真理, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   66回   210 - 210   2012.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 食道疾患におけるチーム医療のあり方 食道癌手術患者への周術期管理チーム介入について

    足羽 孝子, 伊藤 真理, 江木 盛時, 坂本 八千代, 白川 靖博, 田辺 俊介, 野間 和広, 前田 直見, 大原 利章, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   66回   153 - 153   2012.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 胃が使用不能な食道癌症例における腸管による最良の再建術を目指した工夫

    白川 靖博, 前田 直見, 田辺 俊介, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   66回   187 - 187   2012.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 当科におけるBarrett食道癌手術症例の検討

    野間 和広, 白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   66回   191 - 191   2012.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • 鉄コントロールによる新しい食道癌治療法の開発

    大原 利章, 白川 靖博, 青山 克幸, 前田 直見, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集   66回   196 - 196   2012.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    J-GLOBAL

    researchmap

  • I期の上皮型悪性中皮腫に対し胸膜はく離術+温熱化学療法を施行し約5年間の長期生存をしている一症例

    木村 幸男, 大原 利章, 兵頭 剛, 西川 敏雄, 森 雅信, 井上 文之

    日本呼吸器外科学会雑誌   26 ( 3 )   P37 - 06   2012.4

     More details

    Language:Japanese   Publisher:(NPO)日本呼吸器外科学会  

    J-GLOBAL

    researchmap

  • Iron deficiency suppresses EMT through down-regulation of N-cadherin in esophageal cancer.

    Shinichiro Watanabe, Seishi Nishitani, Kazuhiro Noma, Toshiaki Ohara, Yasuko Tomono, Yuuri Hashimoto, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   72   2012.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2012-2421

    Web of Science

    researchmap

  • Iron chelator contributes to anti-angiogenic therapy via selective induction of VEGF-A

    Toshiaki Ohara, Kazuhiro Noma, Seishi Nishitani, Shinichiro Watanabe, Yasuko Tomono, Yuuri Hashimoto, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   72   2012.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2012-2323

    Web of Science

    researchmap

  • 当科における中下咽頭表在癌に対するESDの工夫

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    Gastroenterological Endoscopy   54 ( Suppl.1 )   1154 - 1154   2012.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    J-GLOBAL

    researchmap

  • 大学病院の特殊な疾患群に対する胃瘻造設の現況

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 櫻間 教文, 野間 和広, 藤原 俊義

    Gastroenterological Endoscopy   54 ( Suppl.1 )   1201 - 1201   2012.4

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    J-GLOBAL

    researchmap

  • 高齢者食道癌症例に対する手術術式と周術期管理

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本外科学会雑誌   113 ( 臨増2 )   362 - 362   2012.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 胆嚢軸捻転を来たし開腹胆嚢摘出術を施行した一例

    武田 正, 清田 正之, 藤原 裕子, 森廣 俊昭, 竹原 清人, 大原 利章, 荒田 尚, 中川 仁志, 田中屋 宏爾, 青木 秀樹, 竹内 仁司

    日本臨床外科学会雑誌   73 ( 3 )   744 - 744   2012.3

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 食道癌転移診断におけるPET-CT偽陽性症例の検討

    木下 真一郎, 山辻 知樹, 高岡 宗徳, 繁光 薫, 山田 貴子, 林 次郎, 深澤 拓也, 吉田 和弘, 田辺 俊介, 大原 利章, 野間 和広, 白川 靖博, 森田 一郎, 猶本 良夫

    日本外科学会雑誌   113 ( 臨増2 )   737 - 737   2012.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • ロボット支援下幽門側胃切除術の安全な導入

    西崎 正彦, 香川 俊輔, 宇野 太, 岸本 浩行, 近藤 喜太, 田邊 俊介, 大原 利章, 野間 和広, 永坂 岳志, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   113 ( 臨増2 )   490 - 490   2012.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 当科での胸部食道癌手術の低侵襲化の推移とその成果

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本外科学会雑誌   113 ( 臨増2 )   736 - 736   2012.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 胃管癌の治療 当科において経験した食道癌術後胃管癌18例の検討

    白川 靖博, 前田 直見, 田辺 俊介, 大原 利章, 野間 和広, 岸本 浩行, 宇野 太, 西崎 正彦, 香川 俊輔, 藤原 俊義

    日本胃癌学会総会記事   84回   175 - 175   2012.2

     More details

    Language:Japanese   Publisher:(一社)日本胃癌学会  

    researchmap

  • 乳房全摘後15年経過して発症した異時性同側乳癌の1例

    荒田 尚, 藤原 裕子, 森廣 俊昭, 竹原 清人, 清田 正之, 大原 利章, 中川 仁志, 田中屋 宏爾, 青木 秀樹, 竹内 仁司

    山口医学   61 ( 1/2 )   74 - 75   2012

     More details

    Language:Japanese   Publisher:山口大学医学会  

    J-GLOBAL

    researchmap

  • 当科における咽頭喉頭食道全摘症例の検討

    田辺俊介, 白川靖博, 青山克幸, 前田直見, 大原利章, 櫻間教文, 野間和広, 藤原俊義

    General Thoracic and Cardiovascular Surgery   60 ( Supplement )   2012

  • 当院でのPERIOによる胸部食道癌周術期管理の取り組みについての検討

    白川靖博, 青山克幸, 前田直見, 田辺俊介, 大原利章, 野間和広, 櫻間教文, 藤原俊義

    General Thoracic and Cardiovascular Surgery   60 ( Supplement )   2012

  • 腹部食道癌に対して左開胸開腹連続切開および観音開き法食道残胃吻合を行った1症例

    野間和広, 白川靖博, 青山克幸, 前田直見, 大原利章, 田辺俊介, 西崎正彦, 香川俊輔, 藤原俊義

    General Thoracic and Cardiovascular Surgery   60 ( Supplement )   2012

  • 食道癌における除鉄による遊走,浸潤能抑制作用の検討

    浦野真一, 大原利章, 前田直見, 渡辺伸一郎, 田辺俊介, 野間和広, 友野靖子, 白川康博, 木村文昭, 藤原俊義

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   36th   2012

  • 当科における食道癌頭頸部癌重複症例の検討

    前田 直見, 白川 靖博, 田辺 俊介, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   557 - 557   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 当科における食道胃接合部の食道癌についての検討

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   501 - 501   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 当科における胃管再建作成および吻合における工夫

    野間 和広, 白川 康博, 前田 直見, 大原 利章, 田辺 俊介, 永坂 岳司, 香川 俊輔, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   517 - 517   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 当科におけるT4食道癌に対する治療戦略についての検討

    大原 利章, 白川 靖博, 前田 直見, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   531 - 531   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 当科における高齢者食道癌手術症例の術式選択の工夫

    田辺 俊介, 白川 靖博, 前田 直見, 大原 利章, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   533 - 533   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 当科における食道及び中下咽頭表在癌に対するESDの工夫

    白川 靖博, 前田 直見, 大原 利章, 田辺 俊介, 野間 和広, 櫻間 教文, 藤原 俊義

    日本臨床外科学会雑誌   72 ( 増刊 )   593 - 593   2011.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 鉄欠乏状態は食道がんにおいてNカドヘリンを低下させることでEMTを抑制する(Iron deficiency suppress EMT through downregulation of N-cadherin in esophageal cancer)

    西谷 正史, 野間 和広, 大原 利章, 長谷井 嬢, 佐々木 剛, 渡邊 伸一郎, 大西 哲平, 吉田 亮介, 橋本 悠里, 田澤 大, 宇野 太, 香川 俊輔, 藤原 俊義

    日本癌学会総会記事   70回   467 - 468   2011.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 当院における頭頸部癌・食道癌領域におけるPEGの適応と現状

    田辺 俊介, 白川 靖博, 野間 和広, 前田 直見, 大原 利章, 櫻間 教文, 浅野 博昭, 岸本 浩行, 宇野 太, 西崎 正彦, 佃 和憲, 香川 俊輔, 藤原 俊義, 小野田 友男, 勝井 邦彰, 片山 敬久, 吉尾 浩太郎, 武本 充広

    Gastroenterological Endoscopy   53 ( Suppl.2 )   2784 - 2784   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本消化器内視鏡学会  

    J-GLOBAL

    researchmap

  • Lynch症候群関連がん発生の経時代変遷

    田中屋 宏爾, 藤原 裕子, 森廣 俊昭, 竹原 清人, 清田 正之, 大原 利章, 荒田 尚, 中川 仁志, 青木 秀樹, 竹内 仁司

    日本消化器外科学会総会   66回 ( Supplement1 )   916 - 916   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • FDG-PET陽性にて癌再発との鑑別に苦慮した大腸癌術後晩期腹腔内膿瘍の2例

    藤原 裕子, 竹原 清人, 荒田 尚, 森廣 俊昭, 清田 正之, 大原 利章, 中川 仁志, 田中屋 宏爾, 青木 秀樹, 竹内 仁司

    日本消化器外科学会総会   66回 ( Supplement1 )   596 - 596   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 巨大肝嚢胞による圧排が起因となった下大静脈血栓症の一手術例

    清田 正之, 大原 利章, 森廣 俊昭, 藤原 裕子, 竹原 清人, 荒田 尚, 中川 仁志, 田中屋 宏爾, 青木 秀樹, 竹内 仁司

    日本消化器外科学会総会   66回 ( Supplement1 )   645 - 645   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 直腸癌肝転移に同時合併した肝原発平滑筋肉腫の1切除例

    竹原 清人, 青木 秀樹, 藤原 裕子, 森廣 俊昭, 清田 正之, 大原 利章, 荒田 尚, 中川 仁志, 田中屋 宏爾, 竹内 仁司

    日本消化器外科学会総会   66回 ( Supplement1 )   651 - 651   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 原発不明神経内分泌癌肝転移の1切除例

    青木 秀樹, 森廣 俊昭, 藤原 裕子, 竹原 清人, 清田 正之, 大原 利章, 荒田 尚, 中川 仁志, 田中屋 宏爾, 竹内 仁司

    日本消化器外科学会総会   66回   652 - 652   2011.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • 体内鉄コントロールを利用したBevacizumabの新規治療法

    大原 利章, 野間 和広, 友野 靖子, 西谷 正史, 田辺 俊介, 田澤 大, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   112 ( 臨増1-2 )   771 - 771   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 体内鉄コントロールによるN-cadheinの発現低下が癌細胞の浸潤・転移能にどのような影響を与えるかについての検討

    西谷 正史, 野間 和広, 大原 利章, 友野 靖子, 田邊 俊介, 白川 靖博, 藤原 俊義

    日本外科学会雑誌   112 ( 臨増1-2 )   595 - 595   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 食道癌転移診断におけるPET-CT偽陽性症例の検討

    山辻 知樹, 関 亮太, 木下 真一郎, 深澤 拓也, 林 次郎, 繁光 薫, 吉田 和弘, 森田 一郎, 山田 英司, 西谷 正史, 大原 利章, 田邊 俊介, 藤原 康宏, 櫻間 教文, 野間 和広, 高岡 宗徳, 白川 靖博, 松岡 順治, 羽井佐 実, 藤原 俊義, 猶本 良夫

    日本外科学会雑誌   112 ( 臨増1-2 )   837 - 837   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • Inhibition of mammalian target of rapamycin (mTOR) signaling by Temsirolimus as a potential therapeutic strategy for esophageal cancer treatment

    Munenori Takaoka, Toshio Nishikawa, Toshiaki Ohara, Yasuko Tomono, Yasuhiro Fujiwara, Yasuhiro Shirakawa, Hitoshi Nagatsuka, Takuya Fukazawa, Tomoki Yamatsuji, Xiaohong Bao, Huifang Hao, Kaori Shigemitsu, Ichiro Morita, Toshiyoshi Fujiwara, Yoshio Naomoto

    CANCER RESEARCH   71   2011.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2011-4415

    Web of Science

    researchmap

  • Iron deficiency suppress EMT through downregulation of N-cadherin in esophageal cancer

    Seishi Nishitani, Kazuhiro Noma, Shinichiro Watanabe, Teppei Onishi, Toshiaki Ohara, Yasuko Tomono, Yuuri Hashimoto, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   71   2011.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2011-3363

    Web of Science

    researchmap

  • Iron controlled treatment can be novel therapeutic agent and biomarker of Bevacizumab

    Toshiaki Ohara, Kazuhiro Noma, Shinichiro Watanabe, Teppei Ohnishi, Seishi Nishitani, Yasuko Tomono, Yuuri Hashimoto, Hiroshi Tazawa, Toshiyoshi Fujiwara

    CANCER RESEARCH   71   2011.4

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    DOI: 10.1158/1538-7445.AM2011-4247

    Web of Science

    researchmap

  • ハイリスク(特に後期高齢者)食道癌症例に対する手術術式の工夫

    田辺俊介, 白川靖博, 前田直見, 大原利章, 野間和広, 櫻間教文, 藤原俊義

    General Thoracic and Cardiovascular Surgery   59 ( Supplement )   2011

  • 鉄欠乏マウスモデルを用いた血管新生阻害薬併用療法の基礎的検討

    大原利章, 野間和広, 木村文昭, 友野靖子, 西谷正史, 渡辺伸一郎, 藤原俊義

    日本鉄バイオサイエンス学会学術集会プログラム・抄録集   35th   2011

  • 禁煙指導の効率化 質を担保し、やりがいを高めるスキルミックス指導法

    大原 利章, 福武 奈津子

    日本禁煙学会学術総会プログラム・抄録集   5回   70 - 70   2010.9

     More details

    Language:Japanese   Publisher:(一社)日本禁煙学会  

    J-GLOBAL

    researchmap

  • 分子標的治療 FAKを標的とした大腸癌腹膜播種抑制の実験的検討(Molecular target therapy Experimental approach to control peritoneal dissemination of colon cancer by targeting FAK)

    はお 慧芳, 高岡 宗徳, 包 暁紅, 桜間 教文, 大原 利章, 友野 靖子, 白川 靖博, 山辻 知樹, 藤原 俊義, 猶本 良夫

    日本癌学会総会記事   69回   237 - 237   2010.8

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 食道狭窄を伴う新規食道癌同所性移植マウスモデル(Establishment of a novel orthotopic mouse model with obstructive human esophageal cancer)

    大原 利章, 高岡 宗徳, 櫻間 一史, 永石 香, 武田 晴郎, 白川 靖博, 山辻 知樹, 永坂 岳, 松岡 順治, 田中 紀章, 藤原 俊義, 猶本 良夫

    日本癌学会総会記事   69回   115 - 115   2010.8

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • Ras-MAPKパスウェイの活性化した食道癌細胞は新規IGF-IR阻害剤(NVP-AEW541)に対し抵抗性を示す(Esophageal cancer exhibits a resistance to a novel IGF-1R inhibitor NVP-AEW54 1 with a maintained Ras-MAPK activity)

    包 暁紅, 高岡 宗徳, はお 慧芳, 大原 利章, 桜間 教文, 友野 靖子, 白川 靖博, 山辻 知樹, 藤原 俊義, 猶本 良夫

    日本癌学会総会記事   69回   184 - 184   2010.8

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 新しいバスキュラーアクセス開存の指標 アクセス係数と平均無手術期間について

    宮崎 雅史, 岡 良成, 高津 成子, 松田 浩明, 丸山 昌伸, 宇野 太, 大原 利章, 近藤 喜太

    日本透析医学会雑誌   43 ( Suppl.1 )   546 - 546   2010.5

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    researchmap

  • 当科における食道憩室切除症例の検討

    山辻 知樹, 山田 英司, 西谷 正史, 大原 利章, 田辺 俊介, 藤原 康宏, 野間 和広, 櫻間 一史, 高岡 宗徳, 白川 靖博, 貞森 裕, 小林 直哉, 藤原 俊義, 八木 孝仁, 羽井佐 実, 松岡 順治, 猶本 良夫

    日本外科学会雑誌   111 ( 臨増2 )   582 - 582   2010

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • より良い禁煙講演を目指して 講演分析から個別化指導へ向けて

    大原 利章, 福武 奈津子

    日本禁煙学会学術総会プログラム・抄録集   4回   118 - 118   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本禁煙学会  

    J-GLOBAL

    researchmap

  • 糖質調整流動食MHN-01の食道癌術後高血糖抑制効果 ランダム化クロスオーバー試験

    山辻 知樹, 猶本 良夫, 田辺 俊介, 藤原 康宏, 野間 和広, 大原 利章, 元木 崇之, 高岡 宗徳, 白川 靖博, 羽井佐 実

    日本消化器外科学会雑誌   42 ( 7 )   1093 - 1093   2009.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • バスキュラーアクセス開存に関する新しい指標 平均無手術期間について

    宮崎 雅史, 岡 良成, 高津 成子, 宇野 太, 大原 利章, 戸田 桂介, 丸山 昌伸, 松田 浩明

    日本透析医学会雑誌   42 ( Suppl.1 )   593 - 593   2009.5

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    J-GLOBAL

    researchmap

  • Antiproliferative effects of a novel mTOR inhibitor (Temsirolimus) provide the prolonged survival in a pleural dissemination model using non-small cell lung cancer cells

    Toshiaki Ohara, Yoshio Naomoto, Yasuko Tomono, Shinichi Toyooka, Toshio Nishikawa, Kazufumi Sakurama, Seishi Nishitani, Huifang Hao, Xiaohong Bao, Shunsuke Tanabe, Yasuhiro Fujiwara, Takayuki Motoki, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Noriaki Tanaka

    CANCER RESEARCH   69   2009.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    Web of Science

    researchmap

  • The upregulation of FAK contributes to tumor progression and a resistance to Imatinib in gastrointestinal stromal tumor

    Xiaohong Bao, Nobuyuki Kamo, Huifang Hao, Kazufumi Sakurama, Kazuhiro Noma, Yasuhiro Shirakawa, Hitoshi Nagatsuka, Yasuko Tomono, Yasuhiro Fujiwara, Nobuyuki Watanabe, Seishi Nishitani, Toshiaki Ohara, Munenori Takaoka, Tomoki Yamatsuji, Junji Matsuoka, Seiichi Hirota, Shinji Hatakeyama, Osamu Omori, Zhigang Wang, Noriaki Tanaka, Yoshio Naomoto

    CANCER RESEARCH   69   2009.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    Web of Science

    researchmap

  • Targeting mTOR by temsirolimus as a potential therapeutic alternate in esophageal cancer

    Seishi Nishitani, Toshio Nishikawa, Toshiaki Ohara, Yasuko Tomono, Kazufumi Sakurama, Xiaohong Bao, Huifang Hao, Kazuhiro Noma, Takayuki Motoki, Yasuhiro Fujiwara, Shunsuke Tanabe, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Minoru Haisa, Junji Matsuoka, Noriaki Tanaka, Yoshio Naomoto

    CANCER RESEARCH   69   2009.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER ASSOC CANCER RESEARCH  

    Web of Science

    researchmap

  • 軟性気管支鏡およびラリンジアルマスクにて気管ステントを留置した1例

    西川 敏雄, 井上 文之, 石井 泰則, 高橋 健司, 高橋 正彦, 大原 利章

    日本臨床外科学会雑誌   70 ( 2 )   407 - 410   2009.2

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    症例は79歳,女性.2007年12月下旬より呼吸困難を自覚していた.他院にて甲状腺癌による気管狭窄と診断されたものの治療困難と言われたため加療目的にて2008年1月上旬当院初診となった.画像上甲状腺に腫瘍を認め,気管は腫瘍の浸潤により声帯下3cmの部位より末梢側に5cmにわたって狭窄していた.甲状腺癌に対する手術適応はないと考え気管ステント留置を行うこととした.自発呼吸下にてラリンジアルマスクを挿入,次いでこれより軟性気管支鏡を挿入した.気管内にガイドワイヤーを挿入し狭窄部の末梢側にガイドワイヤーの先端を留置した後に気管支鏡のみを抜去した.ガイドワイヤーに沿って透視下にてデバイスを気管内に挿入し金属ステントを留置した.日常使用し慣れている軟性気管支鏡と挿入の容易なラリンジアルマスクを用いての気管ステント留置は全身状態不良である症例や特に声帯近傍でのステント留置に有用であると考えられた.(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2009&ichushi_jid=J03156&link_issn=&doc_id=20090309100013&doc_link_id=10.3919%2Fjjsa.70.407&url=https%3A%2F%2Fdoi.org%2F10.3919%2Fjjsa.70.407&type=J-STAGE&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00007_3.gif

  • 新規mTOR阻害剤(テムシロリムス)の食道癌細胞における抗腫瘍効果の検討

    西川 敏雄, 猶本 良夫, 高岡 宗徳, 大原 利章, 櫻間 一史, 元木 崇之, 白川 靖博, 山辻 知樹, 羽井佐 実, 松岡 順治, 田中 紀章

    日本外科学会雑誌   110 ( 臨増2 )   564 - 564   2009

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 非小細胞肺癌におけるmTOR阻害薬(temsirolimus)による抗腫瘍効果の基礎的検討

    大原利章, 西川敏雄, 豊岡伸一

    肺癌   49 ( 5 )   2009

  • 食道癌細胞におけるテムシロリムスの抗腫瘍効果の検討

    西川 敏雄, 猶本 良夫, 高岡 宗徳, 大原 利章, 田邊 俊介, 藤原 康宏, 渡辺 信之, 櫻間 一史, 野間 和広, 元木 崇之, 白川 靖博, 山辻 知樹, 羽井佐 実, 松岡 順治, 田中 紀章

    日本癌治療学会誌   43 ( 2 )   694 - 694   2008.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    J-GLOBAL

    researchmap

  • 周術期の栄養管理 糖尿病合併食道癌の周術期管理における糖質調整流動食MHN-01の効果とその臨床応用

    大原 利章, 猶本 良夫, 田辺 俊介, 藤原 康宏, 西川 敏雄, 高岡 宗徳, 白川 靖博, 山辻 知樹, 羽井佐 実, 田中 紀章

    日本消化器外科学会雑誌   41 ( 7 )   1141 - 1141   2008.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    researchmap

  • A review article: Sevelamer hydrochloride and metabolic acidosis in dialysis patients

    Yoshinari Oka, Masashi Miyazaki, Shigeko Takatsu, Toshiaki Oohara, Keisuke Toda, Futoshi Uno, Hiroaki Matsuda

    Cardiovascular and Hematological Disorders - Drug Targets   8 ( 4 )   283 - 286   2008

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.  

    Sevelamer hydrochloride is a phosphate binder and its effectiveness to reduce the cardiovascular mortality of dialysis patients has been tested. Sevelamer hydrochloride also contains chlorine, so a decrease in bicarbonate due to chlorine load was anticipated and metabolic acidosis thought to associate with sevelamer hydrochloride has been reported in some papers. We reported that sevelamer hydrochloride exacerbated metabolic acidosis in hemodialysis patients, depending on the dosage. Also a Japanese nationwide survey suggested that sevelamer hydrochloride usage potentially aggravates acidosis in dialysis patients. A multi-institute research study by Edmung et al. has shown that metabolic acidosis, with serum CO2 below 17.5 mmol/L, is by itself associated with increased risk of death in dialysis patients. Furthermore, the Dialysis Outcomes and Practice Patterns Study (DOPPS) revealed that both high (&gt
    27 mmol/L) and low (&lt
    or = 17 mmol/L) serum bicarbonate (total CO2) levels were associated with increased risk for mortality and hospitalization. There has not been any significant evidence to show that sevelamer hydrochloride has reduced the cardiovascular mortality of dialysis patients compared with calcium-based binder. Clinicians should check not only the level of chlorine but also the level of total CO2 or bicarbonate during the treatment with sevelamer hydrochloride, and control metabolic acidosis. © 2008 Bentham Science Publishers Ltd.

    DOI: 10.2174/187152908786786197

    Scopus

    PubMed

    researchmap

  • 食道癌細胞におけるテムシロリムスの抗腫瘍効果の検討

    西川敏雄, 猶本良夫, 高岡宗徳, 大原利章, 田邊俊介, 藤原康宏, 渡辺信之, 櫻間一史, 野間和広, 元木崇之, 白川靖博, 山辻知樹, 羽井佐実, 松岡順治, 田中紀章

    日本癌治療学会誌   43 ( 2 )   2008

  • 肺リンパ脈管筋腫症による生体肺移植後の難治性胸腹水に対するSirolimusの投与経験

    大原 利章, 佐野 由文, 三好 健太郎, 田尾 裕之, 山根 正修, 豊岡 伸一, 大藤 剛宏, 岡崎 恵, 伊達 洋至

    移植   42 ( 総会臨時 )   240 - 240   2007.10

     More details

    Language:Japanese   Publisher:(一社)日本移植学会  

    J-GLOBAL

    researchmap

  • 進行食道癌(Mt領域)に対する当院の治療戦略

    木村 幸男, 大原 利章

    山口医学   56 ( 4 )   140 - 140   2007.9

  • 75歳以上の高齢者食道癌の治療戦略 手術症例

    木村 幸男, 大原 利章

    日本消化器外科学会雑誌   40 ( 7 )   1339 - 1339   2007.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 胸腔鏡下に生検をして診断したCastleman diseaseの一例

    木村 幸男, 大原 利章

    日本呼吸器外科学会雑誌   21 ( 3 )   483 - 483   2007.4

  • 集学的治療が奏功した原発性肺多形癌の1例

    大原 利章, 木村 幸男

    日本呼吸器外科学会雑誌   21 ( 3 )   458 - 458   2007.4

  • 胸腔内温熱療法を施行した2例

    大原 利章, 木村 幸男

    山口県医学会誌   ( 41 )   173 - 173   2007.3

     More details

    Language:Japanese   Publisher:(一社)山口県医師会  

    J-GLOBAL

    researchmap

  • 医師個人の技術評価におけるPOSSUM scoring systemの有用性

    竹内 仁司, 安井 義政, 金川 泰一朗, 田中屋 宏爾, 中川 仁志, 金澤 卓, 村田 宏, 荒田 尚, 大原 利章, 重安 邦俊, 愛洲 尚哉

    日本外科学会雑誌   108 ( 臨増2 )   715 - 715   2007.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 当院における肝癌治療の変遷

    竹内 仁司, 重安 邦俊, 大原 利章, 荒田 尚, 村田 宏, 金澤 卓, 中川 仁志, 田中屋 宏爾, 金川 泰一朗, 安井 義政, 大田 剛由, 詫間 義隆, 牧野 泰裕

    山口県医学会誌   ( 41 )   170 - 170   2007

     More details

    Language:Japanese   Publisher:(一社)山口県医師会  

    J-GLOBAL

    researchmap

  • 膿胸関連悪性リンパ腫の一例

    木村 幸男, 大原 利章

    日本臨床外科学会雑誌   67 ( 増刊 )   545 - 545   2006.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 多発性肺転移性腫瘍の治療戦略 外科的治療を中心に

    木村 幸男, 大原 利章

    日本呼吸器外科学会雑誌   20 ( 3 )   878 - 878   2006.5

  • 当院における過去20年間の肝癌の動向

    竹内 仁司, 荒田 尚, 大原 利章, 黒田 新士, 武田 晃, 田中屋 宏爾, 谷口 信將, 村田 年弘, 安井 義政

    日本外科学会雑誌   107 ( 臨増2 )   438 - 438   2006.3

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • Rubinstein-Taybi症候群に合併した小腸癌の1例

    中川 仁志, 金川 泰一朗, 田中屋 宏爾, 黒田 新士, 谷口 信将, 大原 利章, 荒田 尚, 村田 年弘, 安井 義政, 竹内 仁司

    日本消化器外科学会雑誌   39 ( 7 )   1247 - 1247   2006

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 手術不能進行性肺・食道癌に発生した気管支食道瘻に対しステントによるQOLの改善について

    木村幸男, 大原利章

    日本緩和医療学会総会プログラム・講演抄録集   11th   2006

  • 数ヵ月で約5cmの腫瘤として発育した肺の癌肉腫の1例

    大原 利章, 木村 幸男

    肺癌   45 ( 5 )   599 - 599   2005.11

  • 頸部からのアプローチで摘出を行った縦隔甲状腺腫の二例

    木村 幸男, 大原 利章

    日本臨床外科学会雑誌   66 ( 増刊 )   526 - 526   2005.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 虚血性腸疾患における治療法の新たな展開

    田中屋 宏爾, 竹内 仁司, 安井 義政, 武田 晃, 村田 年弘, 荒田 尚, 大原 利章, 黒田 新士, 谷口 信將, 小山 裕

    日本臨床外科学会雑誌   66 ( 増刊 )   274 - 274   2005.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 虫垂癌の早期診断と一期的根治手術を目指した治療戦略

    村田 年弘, 田中屋 宏爾, 谷口 信將, 大原 利章, 黒田 新士, 荒田 尚, 武田 晃, 安井 義政, 竹内 仁司

    日本臨床外科学会雑誌   66 ( 増刊 )   286 - 286   2005.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 腹腔鏡下肝切除術の手技と位置付

    竹内 仁司, 大原 利章, 黒田 信士, 谷口 信將, 荒田 尚, 村田 年弘, 田中屋 宏爾, 武田 晃, 安井 義政

    日本臨床外科学会雑誌   66 ( 増刊 )   326 - 326   2005.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • ハルトマン手術の功罪

    黒田 新士, 田中屋 宏爾, 大原 利章, 谷口 信将, 荒田 尚, 村田 年弘, 武田 晃, 安井 義政, 竹内 仁司

    日本臨床外科学会雑誌   66 ( 増刊 )   487 - 487   2005.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 進行性肺癌の気管支食道瘻に対しCovered Ultraflex stentにてQOLの改善を認めた1例

    大原 利章, 木村 幸男

    日本臨床外科学会雑誌   66 ( 8 )   2080 - 2080   2005.8

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 大腸癌術後の大腸フォローアップ:吻合部再発と多発癌に対する監視法の個別化

    田中屋 宏爾, 竹内 仁司, 安井 義政, 武田 晃, 荒田 尚, 大橋 勝久, 大原 利章, 黒田 新士, 谷口 信將, 小山 裕

    日本消化器外科学会雑誌   38 ( 7 )   998 - 998   2005.7

     More details

    Language:Japanese   Publisher:(一社)日本消化器外科学会  

    J-GLOBAL

    researchmap

  • 遺伝性非ポリポーシス大腸癌におけるサーベイランスのありかた

    田中屋 宏爾, 竹内 仁司, 安井 義政, 武田 晃, 荒田 尚, 大橋 勝久, 大原 利章, 黒田 新士, 谷口 信将, 小山 裕

    日本外科学会雑誌   106 ( 臨増 )   619 - 619   2005.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    researchmap

  • 遺伝性非ポリポーシス大腸癌における発症前遺伝子変異保有者診断

    田中屋 宏爾, 竹内 仁司, 安井 義政, 武田 晃, 荒田 尚, 大橋 勝久, 大原 利章, 黒田 新士, 谷口 信將, 小山 裕, 石川 秀樹, 古川 洋一, 大腸癌研究会HN, の登録と遺伝子解析プロジェクト

    日本遺伝カウンセリング学会誌   26 ( 1 )   53 - 53   2005.4

     More details

    Language:Japanese   Publisher:日本遺伝カウンセリング学会  

    J-GLOBAL

    researchmap

  • リスク指標を用いた高齢者手術リスク対策

    竹内 仁司, 小山 裕, 徳田 貴則, 大原 利章, 黒田 新士, 谷口 信将, 大橋 勝久, 荒田 尚, 田中屋 宏爾, 武田 晃, 安井 義政

    日本外科学会雑誌   106 ( 臨増 )   145 - 145   2005.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

    J-GLOBAL

    researchmap

  • 当院における家族性乳癌症例の検討

    荒田 尚, 小山 裕, 徳田 貴則, 大原 利章, 黒田 新士, 谷口 信将, 大橋 勝久, 田中屋 宏爾, 武田 晃, 安井 義政, 竹内 仁司, 小長 英二

    山口医学   54 ( 1 )   47 - 47   2005.2

     More details

    Language:Japanese   Publisher:山口大学医学会  

    J-GLOBAL

    researchmap

  • 特異な陰影の変化を示し術前診断に苦慮した肺癌の一例

    大原利章, 木村幸男

    国立病院総合医学会   59th   2005

  • 腸ぼうこうろうの臨床病理学的検討

    大原利章, 田中屋宏爾, 小山裕, 黒田新士, 谷口信将, 大橋勝久, 荒田尚, 武田晃, 安井義政, 竹内仁司

    日本消化器外科学会雑誌   38 ( 7 )   2005

  • チームで取り組む家族性大腸癌の拾い上げ

    田中屋宏爾, 竹内仁司, 安井義政, 武田晃, 村田年弘, 荒田尚, 黒田新士, 谷口信将, 大原利章, 市川かよ子, 知利川鋭子, 松岡利恵

    国立病院総合医学会   59th   2005

  • 肝細胞癌に対し胸腔鏡下経横隔膜的ラジオ波焼灼療法を施行した1例

    小山 裕, 竹内 仁司, 安井 義政, 武田 晃, 田中屋 宏爾, 荒田 尚, 伊藤 充矢, 大橋 勝久, 大原 利章, 黒田 新士, 徳田 貴則

    日本臨床外科学会雑誌   65 ( 10 )   2807 - 2807   2004.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    researchmap

  • 胸腺腫に重複した大腸癌の2例

    小山 裕, 田中屋 宏爾, 竹内 仁司, 安井 義政, 武田 晃, 荒田 尚, 伊藤 充矢, 大橋 勝久, 大原 利章, 黒田 新士, 徳田 貴則

    日本臨床外科学会雑誌   65 ( 増刊 )   772 - 772   2004.9

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 胃癌集積家系の臨床的特徴

    黒田 新士, 田中屋 宏爾, 徳田 貴則, 小山 裕, 大原 利章, 大橋 勝久, 荒田 尚, 伊藤 充矢, 武田 晃, 安井 義政, 竹内 仁司

    日本臨床外科学会雑誌   65 ( 増刊 )   494 - 494   2004.9

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 脈絡膜転移をきたした乳癌の1例

    徳田 貴則, 田中屋 宏爾, 竹内 仁司, 安井 義政, 武田 晃, 荒田 尚, 伊藤 充矢, 大橋 勝久, 大原 利章, 黒田 新士, 小山 裕

    日本臨床外科学会雑誌   65 ( 増刊 )   536 - 536   2004.9

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 多発肝転移を伴った径18mm大の直腸カルチノイドの1例

    大橋 勝久, 武田 晃, 竹内 仁司, 安井 義政, 田中屋 宏爾, 荒田 尚, 伊藤 充矢, 黒田 新士, 大原 利章, 小山 裕, 徳田 貴則

    日本臨床外科学会雑誌   65 ( 増刊 )   599 - 599   2004.9

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

  • 膵奇形を伴った胃重複症の1例

    大原 利章, 村岡 篤

    香川県内科医会誌   40   81 - 81   2004.6

     More details

    Language:Japanese   Publisher:香川県内科医会  

    researchmap

  • 食道癌術後の再建胃管(胸壁前)に発生した難治性穿孔性潰ようの1治験例

    大原利章, 津村真, 内海方嗣, 山崎泰源, 国土泰孝, 村岡篤, 曽根良幸, 香川茂雄, 鶴野正基

    日本消化器外科学会雑誌   37 ( 7 )   2004

  • 大量の小腸出血をきたした成人Henoch-Schonlein紫斑病の一手術例

    内海 方嗣, 村岡 篤, 大原 利章, 渡辺 信之, 國土 泰孝, 立本 昭彦, 曽根 良幸, 香川 茂雄, 津村 眞, 鶴野 正基

    香川県医師会誌   56 ( 特別 )   62 - 62   2003.11

     More details

    Language:Japanese   Publisher:(一社)香川県医師会  

    J-GLOBAL

    researchmap

  • 回結腸憩室炎による上腸間膜静脈血栓症の一手術例

    渡辺 信之, 津村 眞, 内海 方嗣, 大原 利章, 池田 義博, 国土 泰孝, 村岡 篤, 立本 昭彦, 香川 茂雄, 鶴野 正基

    日本臨床外科学会雑誌   64 ( 増刊 )   834 - 834   2003

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

    J-GLOBAL

    researchmap

▼display all

Industrial property rights

  • Vascular-Access Intervention Assistance Plate

    Toshiaki Ohara, Masatoki Yoshida

     More details

    Applicant:Okayama university

    Application no:2021-01879  Date applied:2021.8.31

    Patent/Registration no:1713126  Date registered:2022.4.12  Date issued:2022.4.12

    researchmap

  • 木質燃料製造システム及び方法

     More details

    Application no:特願2020-140265号  Date applied:2020.8.21

    researchmap

  • ショウガまたはタケの精製物を含む植物病害の防除剤および抗動物ウイルス剤

    鳴坂 義弘, 畑中 唯史, 鳴坂 真理, 大原 利章

     More details

    Applicant:岡山県

    Application no:特願2019-054641  Date applied:2019.3.22

    Announcement no:特開2020-152695  Date announced:2020.9.24

    J-GLOBAL

    researchmap

  • DOSAGE MANAGEMENT ASSISTANCE SYSTEM

    Ohara Toshiaki, Suito Hiroshi, Sugitani Yoshiki

     More details

    Applicant:JAPAN SCIENCE AND TECHNOLOGY AGENCY

    Application no:特願2019-009333  Date applied:2019.1.23

    Publication no:WO2020153423  Date published:2020730

    researchmap

  • リグニン抽出物を有効成分とする薬剤

    古藤田, 香代子, 大原 利章

     More details

    Applicant:株式会社カスケード資源研究所

    Application no:特願2018-223506  Date applied:2018.11.29

    Announcement no:特開2019-059754  Date announced:2019.4.18

    J-GLOBAL

    researchmap

  • 抗腫瘍活性、抗菌活性、および/または抗ウイルス活性を有し、副作用が低減された鉄キレート剤を含む医薬組成物

    西田 雄三, 大原 利章, 大森 一弘, 友野 靖子

     More details

    Applicant:株式会社ダステック, 国立大学法人 岡山大学, 医療法人創和会

    Application no:特願2018-010757  Date applied:2018.1.25

    Announcement no:特開2018-188419  Date announced:2018.11.29

    J-GLOBAL

    researchmap

  • リン酸吸着剤及びその製造方法並びに下水処理剤

    加来田 博喜, 大原 利章

     More details

    Applicant:大原 利章

    Application no:特願2017-175207  Date applied:2017.8.26

    Announcement no:特開2019-037970  Date announced:2019.3.14

    J-GLOBAL

    researchmap

  • 多能性幹細胞の腫瘍化抑制剤及び腫瘍化抑制方法

    大原 利章, 桂 佑貴

     More details

    Applicant:大原 利章

    Application no:特願2017-074187  Date applied:2017.4.4

    Announcement no:特開2018-177648  Date announced:2018.11.15

    J-GLOBAL

    researchmap

  • カテーテルの留置位置の事前確認具の製造方法

    大原 利章, 櫻間 教文, 唐井 利昌

     More details

    Applicant:有限会社ケイ・テクノ

    Application no:特願2017-046795  Date applied:2017.3.10

    Announcement no:特開2018-149038  Date announced:2018.9.27

    Patent/Registration no:特許6829804  Date registered:2021.1.27 

    J-GLOBAL

    researchmap

  • 癌幹細胞抑制剤、癌の転移又は再発の抑制剤並びに癌細胞の未分化マーカー発現抑制剤

    大原 利章, 二宮 卓之, 友野 靖子

     More details

    Applicant:国立大学法人 岡山大学, 医療法人創和会

    Application no:特願2016-078614  Date applied:2016.4.11

    Announcement no:特開2017-071592  Date announced:2017.4.13

    J-GLOBAL

    researchmap

  • がんの非ヒトモデル動物及びその作製方法、がん幹細胞及びその製造方法

    妹尾 昌治, 笠井 智成, 岩崎良章, 大原 利章, 廣畑 聡, 加来田 博貴

     More details

    Applicant:国立大学法人 岡山大学

    Application no:特願2016-546537  Date applied:2016.3.30

    Announcement no:WO2016-170938  Date announced:2016.10.27

    Patent/Registration no:特許第6161828号  Date registered:2021.9.30 

    J-GLOBAL

    researchmap

  • リグニン抽出物を有効成分とする植物病害防除剤

    大原 利章, 鳴坂 義弘, 鳴坂 真理, 山次 康幸, 古藤田 香代子

     More details

    Applicant:国立大学法人 岡山大学, 株式会社カスケード資源研究所

    Application no:JP2016051216  Date applied:2016.1.18

    Announcement no:WO2017-125993  Date announced:2017.7.27

    J-GLOBAL

    researchmap

  • リグニン抽出物を有効成分とする薬剤

    古藤田, 香代子, 大原 利章

     More details

    Applicant:株式会社カスケード資源研究所

    Application no:JP2014071498  Date applied:2014.8.15

    Announcement no:WO2016-024359  Date announced:2016.2.18

    J-GLOBAL

    researchmap

  • カテーテルの留置位置の事前確認具

    大原 利章, 櫻間 一史

     More details

    Applicant:国立大学法人 岡山大学

    Application no:特願2013-226369  Date applied:2013.10.31

    Announcement no:特開2015-084971  Date announced:2015.5.7

    Patent/Registration no:特許第6179859号  Date issued:2017.7.28

    J-GLOBAL

    researchmap

  • バルーンダイレーター

    田邊 俊介, 白川 靖博, 野間 和広, 大原 利章, 前田 直見

     More details

    Applicant:国立大学法人 岡山大学

    Application no:特願2012-004501  Date applied:2012.1.12

    Announcement no:特開2013-141588  Date announced:2013.7.22

    Patent/Registration no:特許第6048946号  Date issued:2016.12.2

    J-GLOBAL

    researchmap

  • 抗腫瘍剤

    大原 利章, 高岡 宗徳, 猶本 良夫, 友野 靖子

     More details

    Applicant:国立大学法人 岡山大学, 医療法人創和会

    Application no:特願2012-505674  Date applied:2011.3.14

    Patent/Registration no:特許第5882889号  Date issued:2016.2.12

    J-GLOBAL

    researchmap

  • 食道癌同所性移植モデル動物

    大原 利章, 高岡 宗徳, 猶本 良夫

     More details

    Applicant:国立大学法人 岡山大学

    Application no:特願2009-125089  Date applied:2009.5.25

    Announcement no:特開2010-268759  Date announced:2010.12.2

    Patent/Registration no:特許第5595675号  Date issued:2014.8.15

    J-GLOBAL

    researchmap

▼display all

Awards

  • 生物学研究奨励賞

    2020.10   両備檉園記念財団  

    大原 利章

     More details

  • 研究奨励賞

    2014.11   日本消化器癌発生学会  

    大原 利章

     More details

  • がん研究奨励賞

    2014.6   岡山医学会  

    大原 利章

     More details

  • 研究助成金

    2014.2   高松宮妃がん研究基金  

    大原 利章

     More details

Research Projects

  • 鉄キレート剤のHIF誘導効果を活用した新規がん免疫療法の開発

    Grant number:22K08712  2022.04 - 2025.03

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    大原 利章

      More details

    Authorship:Principal investigator 

    Grant amount:\4290000 ( Direct expense: \3300000 、 Indirect expense:\990000 )

    researchmap

  • Analysis of tumor vessels by artificial intelligence

    2022.01 - 2023.03

    HighTec SISTEMS Co., Ltd. 

      More details

    Authorship:Principal investigator 

    researchmap

  • AIを活用した腫瘍血管の新規構造解析

    2021.09 - 2022.03

    岡山大学研究推進産学官連携機構 プレ共同研究支援事業 

      More details

    Authorship:Principal investigator 

    researchmap

  • Development of water-soluble lignin

    2021

    Okayama University  Industry-academia collaboration 

      More details

    Authorship:Principal investigator 

    researchmap

  • Micro grid technolog by novel plant compression

    2020

    Okayama University  A grant for Startup venture challenge 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • AIの学習と数理から解き明かす熟練者の技

    2019.11 - 2022.03

    科学技術振興機構(JST)  未来社会創造事業 

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

    researchmap

  • 思考を学習させたAIを用いた高効率機械学習の医療応用

    2019.09 - 2022.03

    Okayama University  A grand for developing research group of next generation 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\1500000

    researchmap

  • リグニン抽出によるタールフリー 木質ガス化システムの開発および 抽出したリグニン由来製品の研究開発

    2019.04 - 2022.03

    高砂熱学工業株式会社 

      More details

    Authorship:Principal investigator  Grant type:Collaborative (industry/university)

    researchmap

  • 非ビッグデータ用の高効率的機械学習法を応用した腎性貧血に対するESA製剤の投薬管理システムの開発

    2019.04 - 2020.03

    文部科学省  補助事業「特別電源所在県科学技術振興事業」 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 緊急検査時の安全性を確保するX線透過性検査板の開発

    Grant number:JPMJTM1812  2018.12 - 2019.03

    Japan Science and Technology Agency  Adaptable and Seamless Technology Transfer Program through Target-driven R&D 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\2990000

    researchmap

  • プラスチック材料を用いた患者転落防止機能付きX線透視下手術板の開発

    2018.06 - 2019.02

    Ministry of Education, Culture, Sports, Science and Technology  A grant for the Promotion of Science and Technology in Okayama Prefecture by MEXT  プラスチック材料を用いた患者転落防止機能付きX線透視下手術板の開発

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\1500000

    researchmap

  • 除鉄による幹細胞性喪失のメカニズムの解明と癌幹細胞治療への新展開

    Grant number:18K08539  2018.04 - 2021.03

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    大原 利章

      More details

    Authorship:Principal investigator 

    Grant amount:\4420000 ( Direct expense: \3400000 、 Indirect expense:\1020000 )

    1)幹細胞性維持に関わる未知の鉄代謝経路の解明
    幹細胞性マーカー(Nanog等)を発現している食道癌細胞株TE-8を用いて、鉄キレート剤(DFX, DFO, SP-10)を投与すると、これまで確認したHSC-2細胞、OE33細胞と同様に幹細胞マーカーの発現が抑制される事を確認した。次に食道癌の既存の標準治療薬であるCDDPを対照薬としてマイクロアレイを行い、鉄キレート剤と幹細胞性に関係するシグナルについて検討を行った。その結果、IL-6の発現がCDDPと鉄キレート剤で大きく誘導性が異なる事を見い出し、PCRおよびELISAで、CDDPは食道癌細胞株(TE-8、OE33)に対してDFXと比較してTE8は100倍、OE33は20倍以上誘導する事が判明した。しかし、IL-6の自己分泌のみによる幹細胞性の保持は確認できず、IL-6は癌微小環境維持の主なサイトカインのひとつであるため、癌微小環境を介した幹細胞性維持機構を低下させている可能性が示唆された。
    <BR>
    2)新しい着想に基づく癌幹細胞治療法の新機軸への挑戦
    幹細胞マーカーNanogが本当に臨床手的に予後不良因子であるか明らかにするために食道癌の134例の切除検体を用いてNanogの免疫染色を行い、予後との相関について検討を行った。既報に習いスコアリングを行うと、Nanogの高発現群は98例、低発現群は36例であった。全生存期間、無病生存期間共にNanog高発現は有意に悪く、予後不良因子である事が明らかになった。鉄キレート剤はNanogの発現を強く抑制できるため、食道癌の予後を改善できる可能性が示唆された。

    researchmap

  • 磁性粒子ポリマーを用いた革新的迅速免疫染色法

    2017.04 - 2018.03

    AMED  A grand for translational research 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 血液透析用カフ型カテーテル留置位置の事前設定器具の開発

    2017.01 - 2019.12

    (有)ケイテクノ 

      More details

    Authorship:Principal investigator  Grant type:Collaborative (industry/university)

    researchmap

  • 磁性粒子ポリマーを用いた新規迅速免疫染色法の開発

    2017 - 2018

    Kurozumi Medical Foudation  25th research grant 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 鉄制御を用いた癌幹細胞治療法の開発

    2017 - 2018

    岡山大学  大学機能強化促進補助金 若手研究者育成支援事業 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • バイオマスリグニンを活用した植物ウイルス及び鳥インフルエンザウイルス防除の革新的防除技術の研究開発

    2016 - 2017

    岡山県  外部知見活用型・産学官連携研究事業 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Development of new nontoxic iron chelator

    2015.03 - 2020.03

    株式会社 ダステック 

      More details

    Authorship:Principal investigator  Grant type:Collaborative (industry/university)

    researchmap

  • 理学・工学との連携による革新的ウイルス対策技術の開発

    2014.11 - 2017.03

    農林水産省  革新的技術創造促進事業(異分野融合共同研究) 

      More details

    Authorship:Coinvestigator(s)  Grant type:Competitive

    researchmap

  • 血液透析用カフ型カテーテル留置位置の事前設定器具の開発

    2014.09 - 2015.02

    岡山大学研究推進産学官連携機構  プレ共同研究支援事業 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • がん幹細胞に対する除鉄治療法の開発

    2014.09

    岡山大学  若手研究者スタートアップ研究支援 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Development of iron control cancer therapy

    Grant number:26861048  2014.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    TOSHIAKI OHARA

      More details

    Authorship:Principal investigator 

    Grant amount:\3770000 ( Direct expense: \2900000 、 Indirect expense:\870000 )

    Iron overload is known to cause cancer. We previously reported that iron depletion inhibited cancer cell proliferation and conversely induced angiogenesis. Since sorafenib has an anti-angiogenic effect by its inhibitory targeting VEGFR, we hypothesized that sorafenib could complement the anti-cancer effect of iron depletion. Human hepatocarcinoma HepG2 and HLE cells were used in this study. Deferasirox, iron chelator, enhanced the inhibitory effect of sorafenib on cell viability. Sorafenib combined with deferasirox synergistically inhibited the cell cycle and induced apoptosis. We retrospectively investigated HCC patients that were treated with sorafenib (n=58). Low iron conditions (high TIBC and low ferritin groups) prolonged overall survival. These results suggested that ron depletion by deferasirox has the potential to be a novel combination chemotherapy with sorafenib in clinical study.

    researchmap

  • Novel targeting therapy to cancer-associated fibroblasts for treatment-resistant carcinomas

    Grant number:26861077  2014.04 - 2016.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    Noma Kazuhiro, KATSUBE Ryoichi, SHIRAKAWA Yasuhiro, OHARA Toshiaki, FUJIWARA Toshiyoshi, TAZAWA Hiroshi

      More details

    Grant amount:\3770000 ( Direct expense: \2900000 、 Indirect expense:\870000 )

    CAF of fibroblast cells by esophageal cancer and the promoted malignancy of cancer cells by the CAF were verified. Fibroblasts turned into CAF in the interaction of the cancer cells, the cancer cells by stimulation of the CAF enhanced the malignancy. In addition, cancer cells which are stimulated by CAF had acquired a treatment-resistant phenotype to chemotherapy and radiation therapy. In animal studies it was observed a decreased anti-tumor effect of 5-FU in the group inoculated with CAF, showing treatment-resistant as well as in vitro. It has been predicted that controlling the CAF can suppress the acquisition of growth and therapy-resistant cancers. Subsequently, we have succeeded in developing selectively Photoimmunotherapy that target the CAF.

    researchmap

  • 肝臓癌における除鉄誘導療法の確立

    2014.02

    高松宮妃がん研究基金 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Iron controlled cancer therapy

    Grant number:24791424  2012.04 - 2014.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    OHARA Toshiaki

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    Iron is an essential element for both normal and cancer cells in humans. Iron overload is known to induce some kinds of cancer, which suggests that prevention of iron overload may become a therapeutic strategy for cancer prevention. However, iron depletion mono-therapy by iron decreased treatment has not been thought to be superior to ordinary chemotherapy and is not part of the standard therapeutic strategy for the treatment of cancer. We revealed that iron depletion inhibited the cancer cell proliferation and reciprocally induced angiogenesis in vitro and in vivo. Treatment to deplete iron levels combined with anti-angiogenic therapy could induce a novel therapeutic effect in the treatment of cancer.

    researchmap

▼display all

 

Class subject in charge

  • Pathology (1) (2021academic year) special  - その他

  • Practice in Pathology (1) (2021academic year) special  - その他

  • Research Projects and Practicals: Pathology and Experimental Medicine I (2021academic year) special  - その他

  • Lecture and Research Projects: Pathology and Experimental Medicine I (2021academic year) special  - その他

  • Research Projects and Practicals: Pathology and Experimental Medicine II (2021academic year) special  - その他

  • Lecture and Research Projects: Pathology and Experimental Medicine II (2021academic year) special  - その他

  • Pathology (2021academic year) Concentration  - その他

  • Pathology (1) (2020academic year) special  - その他

  • Practice in Pathology (1) (2020academic year) special  - その他

  • Research Projects and Practicals: Pathology and Experimental Medicine I (2020academic year) special  - その他

  • Lecture and Research Projects: Pathology and Experimental Medicine I (2020academic year) special  - その他

  • Research Projects and Practicals: Pathology and Experimental Medicine II (2020academic year) special  - その他

  • Lecture and Research Projects: Pathology and Experimental Medicine II (2020academic year) special  - その他

  • Pathology (2020academic year) Concentration  - その他

▼display all

 

Media Coverage

  • AIが最適な投薬量を判断 岡山大などグループ システム開発 Newspaper, magazine

    山陽新聞  2021.4

     More details

  • AIが最適な投薬量を判断 岡山大などグループ システム開発 Internet

    時事通信社  時事メディカル  2021.3

     More details

  • カテーテル挿入正確に 高齢透析患者用補助具を開発 Newspaper, magazine

    山陽新聞  朝刊 1面  2019.2

     More details

  • がん幹細胞再現 iPS使い創薬 Newspaper, magazine

    日本経済新聞  朝刊 11面  2018.3

     More details

  • がん幹細胞の除鉄治療の可能性 TV or radio program

    NHK岡山放送局 ニュース  2017.12

     More details

  • 人工透析手術の器具開発へ ケイ・テクノ、精度向上狙う Newspaper, magazine

    山陽新聞  2016.3

     More details

  • 「がんの親玉」鉄分除去で抑える…根本的治療法、開発の可能性 Newspaper, magazine

    読売新聞  朝刊 37面  2015.10

     More details

  • カテーテル正確位置決め事前設定器具を試作 Newspaper, magazine

    日本工業新聞  2015.5

     More details

  • 体内の鉄分減らす肝がん治療の治験 Newspaper, magazine

    日本経済新聞  2014.1

     More details

  • 分子標的薬と鉄分減併用で腫瘍増殖を大幅抑制 Newspaper, magazine

    山陽新聞  朝刊 36面  2012.11

     More details

▼display all